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Abstract
Aluminum (Al) is a ubiquitous substance encountered both naturally (as the third most abundant 
element) and intentionally (used in water, foods, pharmaceuticals, and vaccines); it is also present 
in ambient and occupational airborne particulates. Existing data underscore the importance of Al 
physical and chemical forms in relation to its uptake, accumulation, and systemic bioavailability. 
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The present review represents a systematic examination of the peer-reviewed literature on the 
adverse health effects of Al materials published since a previous critical evaluation compiled by 
Krewski et al. (2007).
Challenges encountered in carrying out the present review reflected the experimental use of 
different physical and chemical Al forms, different routes of administration, and different target 
organs in relation to the magnitude, frequency, and duration of exposure. Wide variations in diet 
can result in Al intakes that are often higher than the World Health Organization provisional 
tolerable weekly intake (PTWI), which is based on studies with Al citrate. Comparing daily 
dietary Al exposures on the basis of “total Al” assumes that gastrointestinal bioavailability for all 
dietary Al forms is equivalent to that for Al citrate, an approach that requires validation. Current 
occupational exposure limits (OELs) for identical Al substances vary as much as 15-fold.
The toxicity of different Al forms depends in large measure on their physical behavior and relative 
solubility in water. The toxicity of soluble Al forms depends upon the delivered dose of Al+3 to 
target tissues. Trivalent Al reacts with water to produce bidentate superoxide coordination spheres 
[Al(O2)(H2O4)+2 and Al(H2O)6+3] that after complexation with O2•−, generate Al superoxides 
[Al(O2•)](H2O5)]+2. Semireduced AlO2• radicals deplete mitochondrial Fe and promote generation 
of H2O2, O2•− and OH•. Thus, it is the Al+3-induced formation of oxygen radicals that accounts 
for the oxidative damage that leads to intrinsic apoptosis. In contrast, the toxicity of the insoluble 
Al oxides depends primarily on their behavior as particulates.
Aluminum has been held responsible for human morbidity and mortality, but there is no consistent 
and convincing evidence to associate the Al found in food and drinking water at the doses and 
chemical forms presently consumed by people living in North America and Western Europe with 
increased risk for Alzheimer’s disease (AD). Neither is there clear evidence to show use of Al-
containing underarm antiperspirants or cosmetics increases the risk of AD or breast cancer. 
Metallic Al, its oxides, and common Al salts have not been shown to be either genotoxic or 
carcinogenic. Aluminum exposures during neonatal and pediatric parenteral nutrition (PN) can 
impair bone mineralization and delay neurological development. Adverse effects to vaccines with 
Al adjuvants have occurred; however, recent controlled trials found that the immunologic response 
to certain vaccines with Al adjuvants was no greater, and in some cases less than, that after 
identical vaccination without Al adjuvants.
The scientific literature on the adverse health effects of Al is extensive. Health risk assessments for 
Al must take into account individual co-factors (e.g., age, renal function, diet, gastric pH). 
Conclusions from the current review point to the need for refinement of the PTWI, reduction of Al 
contamination in PN solutions, justification for routine addition of Al to vaccines, and 
harmonization of OELs for Al substances.
Keywords
Alzheimer’s disease; antiperspirants; aluminum nanoparticles; breast cancer; encephalopathy; 
microcytic anemia; minimal risk level; osteomalacia; parenteral nutrition; reactive oxygen; 
threshold limit value; tolerable weekly intake; vaccine adjuvants
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Introduction
The adverse neurologic, hematopoietic, skeletal, respiratory, immunologic, and other effects 
associated with excessive aluminum (Al) exposures are well known (reviewed in ATSDR 
2008, Nordic Expert Group 2011, Willhite et al. 2012). Controversy over what constitutes 
“safe” Al exposure began at least 100 years ago (Gies 1911) and questions persist 
concerning the role of Al in AD (Campdelacreu 2012, Exley et al. 2012, Tomljenovic 2011, 
Solfrizzi et al. 2011, Walton 2012a) and other disease states (AFSSAPS 2011). Over the past 
two decades, a number of regulatory guidelines and limits on Al have been adopted and 
revised. To appreciate these changes in Al guidance and regulation, it is important to keep in 
mind that the physical and chemical nature of the particular Al form can be far more 
important to health outcomes than exposure to Al per se.
Krewski et al. (2007) summarized exposure and toxicity data for approximately 100 
different Al forms and found that health risks to humans related to excessive Al exposure 
include:
• Osteomalacia and microcytic anemia after exposure from dialysate and/or 
gastric antacids or Al phosphate binders in people with compromised 
kidney function;
• Encephalopathy/dementia after exposure from dialysate and/or Al 
phosphate binders in patients with impaired renal function;
• Contact allergy and local irritation/adverse reations to vaccines with Al 
adjuvants;
• Pneumoconiosis after long-term inhalation of Al dusts or powders.
Krewski et al. (2007), like Sorenson et al. (1974), observed that most healthy adults tolerate 
comparatively large repeated daily oral Al exposures (up to 3500–7200 mg/day from 
antacids and buffered aspirin) without any adverse effect, but that other people (notably pre-
term infants, young children, and those with reduced kidney function) can be at serious risk 
for systemic Al intoxication even at much lower daily doses. Because Al gastrointestinal 
uptake varies from essentially non-detectable for hydrated Al silicates (Afriyie-Gyawu et al. 
2005, Wiles et al. 2004), to 0.1–0.3% for sodium Al phosphates in foods, to 0.2% for AlCl3 
to much higher values (> 2.0%) after ingestion of organic Al (EFSA 2011, Krewski et al. 
2007), exposures expressed as “total Al” are problematic for human health risk assessments.
The present review compiles recent environmental and occupational Al exposures, evaluates 
recent Al health effects data, and compares those outcomes with existing Al exposure 
standards and guidelines.
Sources of information
A systematic approach was undertaken to update the evidence for adverse health effects in 
humans of metallic Al, Al oxides, and Al hydroxide considered by Krewski et al. (2007). 
The search strategy was designed to identify recently published studies that examined acute 
toxicity, irritation/corrosion, sensitization, mutagenicity/genotoxicity, carcinogenicity, 
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repeated dose toxicity including neurotoxicity, reproduction and developmental toxicity 
associated with oral, inhalation, dermal, and intramuscular exposures to these Al substances. 
The Ovid MEDLINE, Ovid EMBASE and Toxline databases were searched to ensure that 
the database remained current during the conduct of the hazard assessments. The search 
strategy was first developed to cover the Ovid MEDLINE and the Ovid EMBASE and then 
adapted to cover the Toxline database. Search terms were grouped according to the Boolean 
operators OR and AND to develop the search profile. The titles and abstracts of all articles 
identified in the primary search were independently examined by two reviewers to determine 
the potential eligibility of each study for inclusion. No language exclusion criteria were 
applied at the screening stage in an effort to compensate for potential publication bias. 
Following the primary screening, the full articles were obtained and the inclusion/exclusion 
criteria applied. Only publications appearing in peer-reviewed sources (including book 
chapters and regulatory evaluations) were included; conference proceedings and abstracts 
were excluded. Where only abstracts of full studies could be located, or further details were 
required particularly relating to data reporting, the corresponding author was contacted to 
ascertain the particulars of the study. Where multiple publications on the same issue or data 
were identified, only the most relevant study was retained.
After all of the relevant studies were identified, the same two reviewers independently 
extracted data and entered the study results into a standard data abstraction form. The 
collected data related to referencing, Al compound(s) tested, subject selection/animal 
species/test system, study design, and results. The same two reviewers then independently 
assessed the methodological quality of all included studies. The quality of individual in vivo 
and in vitro studies was assessed using criteria developed by Klimisch et al. (1997) and 
Schneider et al. (2009). The overall methodological quality of individual epidemiological 
studies was assessed using a set of relevant check points used in the EU risk assessment of 
metals (EC 2005) and the Wells et al. (2003) and Bradford-Hill (1965) guidance. Differences 
in quality assessment of individual studies were resolved by consensus. No attempt was 
made to blind the reviewers to the authorship of the original publications. Consistency/
concordance or lack of concordance between results of comparable human studies, between 
results in studies of different genders, species and strains in comparable animal studies and 
between results of different in vitro assays designed to measure similar endpoints were taken 
into account.
Using our search algorithm, 3820 studies were identified since publication of the Krewski et 
al. (2007) monograph and of those 469 are included here. Publications dated prior to 2007 
are cited where they contribute to understanding the more recent data. The more informative 
studies are discussed below whereas others deemed less so are summarized in tables.
Environmental and occupational exposure
Krewski et al. (2007) tabulated the major sources of Al exposure in humans. Daily exposures 
range from as little as less than 0.06 mg/day as a result of inhaling PM10 particulates in 
ambient air with 0.6–7.0 μg Al/m3 to as high as 3500–5200 mg Al/day as a result of 
consuming Al antacids.
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Dietary
Yokel (2012) found that daily dietary Al contributed only a fraction (0.07–0.2%) of that 
received from gastric antacids. Depending upon regional preferences, beverages can 
constitute a major source of ingested Al. Cao et al. (2010) measured Al in 17 fermented and 
19 raw teas grown near Puerh City, China; the Al concentration in fermented tea (794 ± 140 
mg/kg) was somewhat higher than that in raw tea (594 ± 129 mg/kg) and based on the tea 
consumption rates among 110 Puerh City and 109 Kumming City residents, mean daily Al 
doses from tea were 99 and 60 μg/kg-day, respectively. Consumption of tea infusions can 
account for up to 50% of one’s daily Al exposure (Yokel 2013).
Aluminum concentrations in eight different infant formulas purchased in the United 
Kingdom ranged from 176 to 700 μg/L and the Al content in eight different reconstituted 
formulas ranged from 333 to 629 μg/L. For a (50th percentile) five-month-old boy weighing 
7.63 kg or a (50th percentile) 12 -and-a half- month-old 10.46 kg boy (CDC 2000), these 
concentrations correspond to daily Al consumption between 27–78 and 19–57 μg/kg-day, 
respectively (Burrell and Exley 2010). Those values are consistent with or generally less 
than those reported for Australian, Canadian, and French children (FSANZ 2011, Health 
Canada 2007, Rose et al. 2010).
Aluminum concentrations present in formula can vary by location, over time and with 
product type. Dabeka et al. (2011) calculated current mean total Al concentrations in 
Canadian ready-to-use milk- and soy-based formulas as 440 and 730 mg/L, respectively. 
Compared to their previous study (Dabeka and McKenzie 1990) that found 130 and 1980 μg 
Al/L in similar products, mean Al levels in formula ranged from 72 μg/L in fat supplements 
to 510 μg/L in a whey-based formula. Lactose-free formula had a somewhat higher Al 
content than the standard milk-based formula, but the highest concentration (3442 μg/L) was 
found in a milk-based iron-fortified ready-to-use formula.
Dabeka et al. (2011) collected levels of Al in formula measured in Britain, the European 
continent, Nigeria, Spain, Saudi Arabia, and the United States. Aluminum concentrations as 
low as 6 μg/L to as high as 1152 μg/L (particularly for soy-based, lactose-free, and 
hypoallergenic formula) have been reported. However, the contemporary data all show Al 
levels far lower than the highest recorded (5900 mg/kg) for a dry formula purchased in the 
United Kingdom (Ministry of Agriculture, Fisheries and Food 1999). Assuming an infant 
consumed only commercial formula, Dabeka and McKenzie (1990) calculated that daily 
ingestion of a soy-based (high Al) formula by a 1- to 3 month-old baby corresponded to 363 
μg/kg-day amounting to ~700 times the daily Al dose received by an infant consuming only 
cow’s milk (0.5–2.0 μg/kg-day).
As with infant formula, the Al concentrations in milk vary by source, location, and local 
practice. Al-Ashmawy (2011) found differences in Al concentrations in raw cow’s milk 
(0.004 ± 0.001 mg/L), ‘small market’ milk (0.081 ± 0.010 mg/L), powdered milk (0.732 
± 0.270 mg/L) and processed cheese (0.027–5.7 mg/kg). The differences in Al 
concentrations between raw milk and “small market” milk were attributed to boiling raw 
milk in Al pans. Processed Egyptian cheese wrapped in Al foil had higher Al concentrations 
(1.62 ± 0.32 mg/kg) than processed cheese packed in glass containers (1.14 ± 0.55 mg/kg). 
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Based on those results, Al-Ashmawy (2011) calculated maximum estimated daily intakes 
(MEDI) for consumption of 200 ml Egyptian bulk farm milk or market milk per day or 45 g 
(~1.5 ounces) processed cheese per day provided 0.029, 0.612, and 4.282 mg Al/kg-day, 
respectively. For a 60-kg Egyptian adult, the milk MEDI contributed 6 μg/kg-day and 
consumption of processed Egyptian cheese (mean Al = 1.1–1.6 mg Al/kg) contributed 2.2–
4.28 mg Al/kg-day or 15–30 mg Al/kg-week, equivalent to 15 times the 2 mg/kg-week 
PTWI (Benford et al. 2012). Assuming a 60-kg adult consumes 200 ml of cow’s milk per 
day, the daily Al dose varied from 0.23 to 13.1 μg/kg-day (Arnich et al. 2012, Fernandez-
Lorenzo et al. 1999, Franzmann et al. 1976, Garcia et al. 1999, González-Weller et al. 2010: 
Hermansen et al. 2005). The Al concentrations in processed cheese reported by Al-
Ashmawy (2011) are less than those reported in American cheese (411–695 mg/kg), in 
Swiss, cheddar, and bleu cheese (3.83–14.1 mg/kg) and in processed cheese (297 mg/kg) by 
Pennington (1987), Schenk et al. (1989) and Greger et al. (1985). The Al in processed 
cheese is related to the addition of anti-caking additives including sodium aluminosilicate 
(Saiyed and Yokel 2005, Schenk et al. 1989, Stahl et al. 2011).
A number of Al dietary exposure assessments considered fish and shellfish. As part of the 
2006–2007 French national dietary survey, Arnich et al. (2012) found the highest Al 
concentrations in molluscs and crustaceans (21.09 mg/kg). Fish and its products had the 
highest Al levels of all French foods sampled, with mean levels in shrimp (25.5 mg/kg) and 
mussels (42.9 mg/kg) that were 7–10 times those found in salmon (4.57 mg/kg) and other 
smoked or fried fish. Those results were generally consistent with those by Millour et al. 
(2011) who found Al at up to 116 mg/kg in shellfish. Employing microwave digestion and 
ICP-MS, Guerin et al. (2011) found a mean 1.35 mg Al/kg in the edible portions of 159 
species of saltwater organisms collected from four French coastal areas. The highest levels 
were present in sea urchin (88.4 mg/kg), gurnard (9.68 mg/kg), eel, anchovy and pollock 
(2.53–3.59 mg/kg). Those data were similar to the results for commercially important 
species from Agah et al. (2009), Erkan et al. (2009), Kelly et al. (2008), Leblanc et al. 
(2005), and Mahalakshmi et al. (2012). The levels reported by Agah et al. (2009), Kelly et 
al. (2008), and Leblanc et al. (2005) in fresh seafood do not account for the increased Al 
after baking or grilling in Al foil or other Al kitchenware (Ranau et al. 2001) or after 
addition of alum as a firming agent during canning (Wong et al. 2010).
Braganca et al. (2011) measured Al concentrations in commercial Brazilian grape, peach, 
mango, passion fruit, and guava juice. Depending upon the manufacturer, Al concentrations 
in grape juice ranged from less than 0.1 to 0.19 mg/L, peach ranged from 0.15 to 0.31 mg/L, 
mango varied from less than 0.1 to 0.25 mg/L, passion fruit from less than 0.11 to 0.37 mg/L 
and Al concentrations in guava juice ranged from less than 0.19 to 0.3 mg/L. Those levels 
were consistent with the mid-range Al concentrations (0.05–1.1 mg/L) in Spanish fruit juice 
(González-Weller et al. 2010) and taken together with the daily Al contributions from 
drinking water and soft drinks, the mean Spanish (non-alcoholic) beverage consumption 
amounted to 156 μg Al/person or 2.6 μg/kg-day for a 60-kg adult. Thus, the Al associated 
with consumption of fruit juice represented only a small fraction (1.5%) of the total daily Al 
intake by Spanish adults (González-Weller et al. 2010).
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Tariba (2011) tabulated the (total) Al concentrations in wines from Argentina (0.017–0.018 
mg/L), the Czech Republic (0.132–1.67 mg/L), Croatia (0.244–0.81 mg/L), Hungary (0.01–
1.5 mg/L) and Greece (0.36–9.5 mg/L). The major source of Al in wine is bentonite/
montmorillonite clay added during manufacture as a clarifying agent to reduce suspended 
proteins, polypeptides, and other particulates (McKinnon et al. 1992). Tariba (2011) pointed 
to the organic acids in wine as facilitating Al uptake from the gut, but neglected to note that 
the hydrated Al silicates (e.g., bentonite) in wine have no measurable oral bioavailability 
(Wiles et al. 2004).
Ohno et al. (2010) measured Al in Japanese rice, cereals and potatoes, sweets, oils and fats, 
legumes, fruit, green and yellow vegetables, seaweed, alcohol and other beverages, seafood, 
meat and poultry, dairy and seasonings. For most Japanese the highest Al daily exposure 
(1.1 g/person) was associated with drinking 550 g of alcoholic beverages. The mean total 
daily dietary Al consumed by a 50-kg Japanese adult was 3.6 ± 1.3 mg/day (25.2 mg/week 
or 70 μg/kg-day) or approximately 25% of the 285 μg/kg-day PTWI (Benford et al. 2012). 
Ogimoto et al. (2012) conducted a similar survey and found that scones (0.37 mg/g), pound 
cake (0.36 mg/g), and salted jellyfish (0.90 mg/g) had the highest Al concentrations. Sato et 
al. (2014) found the highest Al concentrations in processed Japanese confections (21.73 
mg/kg) and the lowest in rice (0.32–0.43 mg/kg).
The mean total daily Al dietary consumption (including alcoholic and non-alcoholic 
beverages, coffee, soups, and broth made with potable drinking water) by French adults and 
children (40 and 62.2 μg/kg-day; 95% UCl = 69 and 119 μg/kg-day, respectively) (Arnich et 
al. 2012) was somewhat less than Al consumed by Japanese. Of the foods included in the 
2011 French national dietary survey, pastries contained Al at up to 24 mg/kg, biscuits 
contained Al at up to 10 mg/kg and dark chocolate contained Al at up to 54 mg/kg (Millour 
et al. 2011). At customary French consumption rates, coffee and vegetables (excluding 
potatoes) accounted for 24% of total daily dietary Al for an adult and pasta, pastries, cakes, 
and dairy products accounted for 19% of a child’s daily Al consumption. For residents of the 
Canary Islands, the estimated total daily dietary Al intake was 10.2 mg/day (170 μg/kg-day 
for a 60 kg adult) where the naturally occurring levels of Al in fruit were a major source 
(González-Weller et al. 2010).
Rose et al. (2010) found UK consumers received their highest Al dietary dose from cereals 
and that the highest Al levels provided adults and toddlers with 144 and 345 μg/kg-day, 
respectively. Compared to the 2 mg/kg-week PTWI (Benford et al. 2012) [equivalent to 120 
mg/week for a 60-kg woman or 285 μg/kg-day], the average daily Al doses for UK residents 
aged 4–18 were less than the PTWI while those for residents 1.5–4.5 years consuming the 
highest Al levels were 20% greater than the PTWI.
Total dietary Al intakes vary with location
Country
Mean adult exposure (μg/kg-
day)
Mean child exposure (μg/kg-
day) References
Australia 36 44 FSANZ (2011)
Japan 70 NR* Ohno et al. (2010)
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43 64–123 Sato et al. (2014)
Hong Kong 86 NR Wong et al. (2010)
Canada 56 64 Health Canada (2007)
Western Europe 28.6–214 NR EFSA (2008)
France 40.3 62.2 Arnich et al. (2012)
Italy 60 NR Turconi et al. (2009)
United Kingdom 71 187 Rose et al. (2010)
Canary Islands 124–204 NR González-Weller et al. (2010)
*NR not reported
Stahl et al. (2011) calculated Al consumption by German adults (70 kg) and children (30 
kg). Of all German foods considered, cocoa powders consistently had the highest mean Al 
(165 mg/kg) and chocolate had a mean 48 mg Al/kg. Based on average yearly cocoa 
consumption, the German child received 4% and the adult received 2% of the PTWI; 
chocolate provided up to 12% of the adult and 30% of the child’s PTWI.
Yokel (2013) compiled typical median Al concentrations found in United States beer (0.16 
mg/L), coffee (0.24 mg/L), fruit juice (0.18–0.67 mg/L), wine (0.90 mg/L), soft drinks 
(0.25–0.41 mg/L) and distilled spirits (0.42 mg/L). The highest Al concentrations were 
present in powdered non-dairy creamers (38–170 mg/kg), in paprika (92 mg/kg) and in 
single-serving packets of table salt (180 mg/kg). In general, current total Al dietary 
exposures in the United States are somewhat less than those measured during the 1990s 
when mean total daily adult dietary intake was 7–9 mg/day (ATSDR 2008, Pennington and 
Schoen 1995), an intake equivalent to 116–128 μg Al/kg-day for a 60-kg adult. Thus, dietary 
Al exposures for most Americans represent about 50% of the PTWI. Assuming ingestion of 
five EU-approved Al food additives at their maximum permitted levels, the EFSA (2013) 
calculated Al doses for toddlers (11.3–156.2 mg/kg-week), children (26.9–286.8 mg/kg-
week) and adults (2.3–100.4 mg/kg-week). All of the calculated values were greater than the 
PTWI.
Consumer products
Two studies found that certain metallic and ceramic products can leach considerable 
quantities of Al. Bolle et al. (2011) found 0.07–3.5 mg Al/L in aqueous citric acid (1 g/L at 
pH 2.7 to simulate commercial lyophilized teas with lemon) extracts (30 min on a heated 
hotplate) from traditional Indian and Moroccan brass teapots. Demont and associates (2012) 
measured Al migration from glazed ceramic pots at up to 90 mg/L into pH 2.37–3.63 
aqueous citric, acetic or maleic acids at 22° C.
Aluminum migration from glass bottles into electrolyte and glucose solutions and into infant 
formula has been recognized for many years (Bohrer et al. 2001, 2003, Koo et al. 1988). 
Fekete et al. (2012) investigated Al leaching from glass, ceramic, and stainless steel utensils 
as well as from Al plates and foil. Aluminum migration from these articles depends on 
temperature (20–180° C), contact time (30–142 min), pH (2.2–7), and salt concentration (0–
9.6 g/L) of the extractant (cream, tomato sauce, black tea, or salted lemon juice). Extreme 
temperature, low pH and prolonged contact times caused complete disintegration of Al foil 
Willhite et al. Page 8
Crit Rev Toxicol. Author manuscript; available in PMC 2016 August 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and plates. When pH 4.5 tomato sauce with 5 g/L salt was used as the extractant, Al leaching 
from glass and stainless steel was less than the analytical limit of detection; daily Al doses 
depend not only on kitchenware and food type, but frequency of Al utensil use in food 
storage and preparation.
Verbeken et al. (2011) examined Al migration from the food-grade Al foil used in hospital 
cryo preservation of human skin. They found 1.4 mg Al/L in pooled cryo preservation media 
(30% v/v glycerol in physiological saline) for seven skin samples that had been frozen for 10 
years.
Aluminum is present at 0.37% in tobacco and at 0.4% in marijuana (Exley et al. 2006). 
Intentional inhalation of glue (Akay et al. 2008), cocaine, and/or heroin (‘Chasing the 
Dragon’) can lead to Al exposure when Al-bound drug vaporizes after heating on Al plates, 
cans, or foil (Boto de los Bueis et al. 2002, Pechansky et al. 2007), where Al can enter the 
brain via olfactory pathways (Perl and Good 1987, Divine et al. 1999, Exley et al. 1996, 
Yokel 2002). Aluminum concentrations in heroin (42–2280 ppm) increase as a result of its 
synthesis at elevated temperature in Al cookware (Bora et al. 2002). These exposures are 
such that elevated urinary Al can be measured after repeated heroin use either after it is 
inhaled off Al foil or after intravenous injection (Exley et al. 2007a). Intentional abuse of 
oral methadone delivered by intravenous injection has also been held responsible for Al 
intoxication (Friesen et al. 2006).
Da Silva et al. (2010) measured Al concentrations in 14 different calcium (Ca) dietary 
supplements and gastric antacid capsules or chewable tablets. These supplements were made 
of synthetic carbonate/phosphates, carbonate/citrate, carbonate malate/succinate/glutamate 
or crushed oyster shell, and the antacids were comprised of Ca carbonate compounded with 
MgO, Mg stearate, aspartame, sucrose, powdered cellulose, and/or Na hexametaphosphate. 
Aluminum concentrations generally ranged from 0.24 to 0.65 mg/g Ca, but one antacid (sold 
under the tradename AntSyn2 with H2MgO2, C36 H70MgO2, corn starch and dextrose) 
contained 1.22–1.25 mg Al/g Ca. All the chewable tablets had higher Al concentrations than 
any of the capsules; those chewable tablets provide 2–12 mg Al/day or 33–200 μg Al/kg-day 
for a 60-kg adult. Assuming consumption of a chewable daily Ca dietary supplement 
sufficient to provide 1500–3000 mg Ca/day represents 11–70% of the current 285 μg/kg-day 
PTWI (Benford et al. 2012).
Prescription of Al-based phosphate binders has been discontinued in large part in North 
America and in the United Kingdom due to cases of Al-induced microcytic anemia, seizures, 
and osteomalacia (National Kidney Foundation 2003), but it remains common in Australia, 
New Zealand, Germany, Italy, and Spain (Mudge et al. 2011). Except in rare cases of 
equipment failure (CDC 2008) or inadvertent introduction of Al into dialysate (Berend et al. 
2001), elevated serum Al and risk of dialysis encephalopathy have for all practical purposes 
been eliminated by controlling Al concentrations in dialysate to less than 10 μg/L (ANSI/
AAMI 2004, CAN/CSA-ISO 2011) and substituting Al phosphate binders with Ca acetate, 
Ca carbonate, sevelamer, or lanthanum. Abnormally high plasma and serum Al levels can 
result after daily consumption of the customary approximately 4 g of Al-based phosphate 
chelators even with regular clinical monitoring (Arenas et al. 2008, Cárdenas et al. 2010, 
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Gault et al. 2006). Those observations contrast with Jimenez et al. (2011) and Mudge et al. 
(2011) who concluded Al-based phosphate chelators are not only economical and effective, 
but they have a high rate of patient compliance without undue health risk. In this regard, 
Mudge et al. (2011) presented Australian patient costs for Al(OH)3 (currently A72¢/day) 
compared to A$10.80/day for sevelamer and A$13.20/day for lanthanum (equivalent to an 
annual A$262, A$3942, and A$4818, respectively).
Cárdenas and associates (2010) compared serum Al in 63 patients on renal dialysis (21–89 
years of age) with that of 20 healthy referents (24–73 years of age). The dialysis water had 
less than 2 μg Al/L and the mean serum Al in healthy people (8.05 ± 4.3 μg/L) was less than 
the serum Al in those with kidney disease (26.5 ± 8.0 μg/L). Given the very low Al 
concentration in dialysis water, Cárdenas et al. (2010) concluded that consumption of 
Al(OH)3 to mitigate hyperphosphatemia was the primary source of elevated serum Al.
Kan et al. (2010) confirmed the on-going problem with elevated Al among HD patients. 
Pepper et al. (2011) evaluated serum Al using ICP-MS and measured Al body burdens using 
the 48-h low-dose (500 mg) DFO challenge test in 39 HD patients with a history of chronic 
(1–73 months) Al(OH)3 ingestion. Those patients were 56.5 ± 2.4 years of age, consumed 
on average a total of 1.2 kg (0.07–7.15 kg) of Al(OH)3 over 23 months and the mean time 
since Al(OH)3 dosing ceased until evaluation was 12.9 months. Serum Al concentrations for 
37 of the 39 subjects were less than 1.0 μmol/L (27 μg/L) and the remaining two (who 
consumed 1.36–1.85 kg of Al(OH)3) had serum Al less than 3.0 μmol/L (80 μg/L). Although 
serum Al increased significantly after DFO challenge, none of these patients experienced an 
increase higher than 3 μmol/L. No confirmatory bone biopsy data were presented to support 
the contention that these doses of Al(OH)3 represent low risk. As there was no significant 
correlation (p = 0.10) between cumulative Al dose and post-DFO serum Al concentration, 
Pepper et al. (2011) suggested that Al exposure from phosphate binders “is likely to be 
dwarfed by other sources such as drinking water and foods.” Pepper et al. (2011) offered no 
empirical comparisons to support that interpretation whereas Krewski et al. (2007) noted 
mean daily Al intake from food (7.2–8.6 mg) and drinking water (0.16 mg) were 
substantially less than the customary 4000 mg Al/day used by patients on kidney dialysis.
Evaluations of Al(OH)3 or other Al-based phosphate binders in routine management of 
patients with compromised kidney function are problematic (Jimenez et al. 2011). Hou et al. 
(2010) measured serum Al in 319 patients on chronic (41.5 ± 34.9 months) HD (166 men 
and 153 women aged 21–89 years) compared to 62 young (23.9 ± 3.7 years) healthy 
students and 81 patients (57.9 ± 15.2 years) with renal failure who were not on dialysis. 
Those on HD had significantly higher serum Al (3–443 μg/L) than renal patients not on 
dialysis (2–237 μg/L) or the healthy students (1–14 μg/L). There was no indication of 
gender-related differences at any age, but serum creatinine levels were inversely correlated 
(p < 0.0001) with serum Al. Older dialysis patients (67–89 years) had significantly higher 
serum Al than younger (21–43 years) dialysis patients. Out of the 319 HD patients, 14 
patients used oral Al(OH)3 to control serum phosphate and three had serum Al higher than 
250 μg/L. Ingested Al(OH)3 is not the only source of Al that Bohrer et al. (2009) found for 
patients with kidney disease, because injectable drugs (notably insulin, EPO, and Fe) were 
also significant Al sources. Jimenez et al. (2011) concluded that Al-based phosphate binders 
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could be used but in light of the risks for adynamic bone disease other measures (reduced 
dietary phosphate and increased dialysis duration) should be exhausted prior to considering 
use of Al-based phosphate binders.
After reviewing the history of Al(OH)3 to control serum phosphate in patients with kidney 
disease, Mudge et al. (2011) calculated that at customary doses, Al(OH)3 reduced serum 
phosphate 0.3 mmol/L and that reduction is equivalent to a 10–15% reduction in 
cardiovascular mortality for these patients. Mudge et al. (2011) reported success with 
Al(OH)3 (as compared with Ca carbonate) and pointed out that there are no controlled 
prospective randomized clinical trials that have examined the safety and efficacy of different 
phosphate binders. Mudge et al. (2011) made no mention of restrictions to control dietary 
acids (e.g., ascorbate, citrate, and lactate) that enhance Al uptake from ingested Al(OH)3 
(Coburn et al. 1991, Priest et al. 1996, Weberg and Berstad 1986). The experience described 
by Mudge et al. (2011) contrasts with the dose-dependent increase in serum Al and/or Al-
induced bone disease after oral Al(OH)3 among renal patients with no history of dialysis 
(Andreoli et al. 1984, Felsenfeld et al. 1982), who either all received identical Al exposures 
during dialysis (Cannata et al. 1983) or who were never exposed to excessive Al in dialysis 
fluid, but who used Al-based phosphate binders (Andress et al. 1986, Jenkins et al. 1989, 
Salusky et al. 1991).
Drinking water
Health Canada (2010) reported mean Al concentrations of 20–174 μg/L in finished 
municipal tap water. Frankowski et al. (2011) measured Al in potable water using three 
analytical techniques (GFAAS, ICP-MS, and ICP-AES) and found the chemical forms 
depended upon water source pH, temperature and the concentrations of organic carbon and 
the nature of the suspended particulates. At lower Al concentrations and at pH 5.5–6.5, the 
fluorides (AlF2+, AlF2+, AlF30, and AlF4−) and sulfates (AlSO4+, and Al(SO4)2−) 
predominated, but at higher Al concentrations and at neutral pH, the hydroxides (AlOH2+, 
Al(OH)2+, and Al(OH)4−) and Al organics (e.g., fulvic and humic acids) were the major 
species.
Al-Ashmawy (2011) considered drinking water contributed approximately 1.2% of a typical 
Egyptian’s daily Al intake, a conclusion that was consistent with Ohno et al. (2010) who 
found that adults living in six Japanese cities who consumed 2 liters of water each day 
received 80 ± 7 μg Al/day or 2.2% of their total mean daily Al dietary intake (3600 ± 1370 
μg/day). Assuming a 50-kg Japanese adult consumes 2 liters of drinking water per day, water 
accounts for 1.6 μg Al/kg-day or 0.6% of the 285 μg Al/kg-day PTWI (Benford et al. 2012). 
Those concentrations are consistent with historical data from the United States where a 
median Al concentration in finished municipal drinking water (0.112 mg/L) corresponded to 
a daily ingested dose (assuming consumption of 1.4 l/day) of 160 μg Al/kg or about 1% of 
the amount contributed by food for a 70-kg adult (ATSDR 2008, Krewski et al. 2007). Those 
estimates are lower than the 4% value put forward by WHO (2010) after assuming drinking 
water contained 0.1 mg Al/L.
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Workplace air
The air inside Al smelters, foundries, and remelting plants can contain appreciable 
concentrations of Al oxides and Na3AlF6 (Nordic Expert Group 2011, Westberg et al. 2001).
Weinbruch et al. (2010) used SEM and energy-dispersive X-ray microanalysis (EDX) to 
define the size, morphology, and composition of 543 Søderberg and 176 Prebake potroom 
aerosol particles (> 500 nm); particles smaller than 500 nm were composed primarily of 
sodium Al fluorides. The highest mean inhalable particle mass concentration (6800 μg/m3) 
was found in Prebake potrooms. Total and respirable Al dust concentrations in workers’ 
breathing zones during routine operations were 0.08–2.1 mg/m3 and 0.03 mg/m3, 
respectively. The Al oxides present in these dusts generally constitute approximately 25–
44% of the total Al. On average, the Søderberg particles were composed of 60% soot, 7.2% 
Al oxides, and cryolite (NaAlF6) mixtures, 0.7% pure oxides, 12% silicates, 14% Ca sulfates 
and lesser amounts (3%) of Ca fluorides. The Prebake particles were primarily (56%) 
mixtures of Al oxides and cryolite, 36% soot, 1% silicates, 0.6% Ca fluorides, and 2.8% 
other materials. No pure cryolite particles were seen in either process. Under humid 
conditions (as in the respiratory tract) all these aerosols developed thin films of water over 
their surfaces and the Al oxides/cryolite particles agglomerated into larger water droplets. 
These observations are important because up to 10% of the airborne HF and 1% of the 
airborne SO2 dissolved into those liquid aerosols and their physical properties facilitated 
transfer of these acids into the deeper (alveolar) regions of the lung than when workers are 
exposed to the airborne acid alone. At the present time, however, it is not known if these 
factors increase the risk of local pulmonary irritation, edema, and hemorrhage or contribute 
to occupational respiratory disease (Weinbruch et al. 2010).
Lewis et al. (2011) compiled workplace area (> 120 min) and breathing zone (> 30–543 
min) measurements of Al2O3 and Al2S3 in dust generated during handling of a powdered 
catalyst (zeolite with trace elements) used in crude oil fractionation. No efforts were 
expended to determine particle size distributions, but the literature sources suggested the 
mean diameter was 70–80 mm. Personal and workplace area samples found the highest total 
dust (540 mg/m3) and Al oxide (2.1 mg/m3) concentrations during catalyst loading, but 
airborne Al2S3 concentrations were always less than the analytical limit of detection.
Alumina and Al silicate nanoparticles (2–3 nm diameter) are used in pigments and 
cosmetics, fine polishing powders, and in microelectronics production. Al nanoparticles are 
generated during friction stir, flame, and solid-state welding on Al (Curwin and Bertke 2011, 
Dash and D’Arcy 2008, Gomes et al. 2012a, 2012b, Pfefferkorn et al. 2010), sanding painted 
surfaces (Koponen et al. 2010) and in electric arc thermal sprays (Bémer et al. 2010). The 
extent of Al nanoparticle exposure during welding depends on work practices, the 
temperature of the weld (as a function of electrical current) and operator distance to the 
welding front (Gomes et al. 2012). While concerns have been expressed over carcinogenic 
potential and other aspects of toxicity associated with occupational and environmental 
exposures to engineered nanospheres or nanodots, short- and long nanobelts, nanorods, 
nanowires, or nanotubes (Borm et al. 2006, Byrne and Baugh 2008, Nel et al. 2006, NIOSH 
2011), it has proven complicated to assess health risks of nanoscale materials because the 
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physiochemical properties and particle behavior can differ from those of ultrafine or bulk 
materials of the same chemical composition.
Ambient air
Boullemant (2011) compared collection methods used to capture total particulate matter 
(PMtotal = PM > 0.3 mm plus condensables), PM10 and PM2.5 in Al smelter emissions (e.g., 
anode baking furnace exhaust, potroom scrubber stacks, and potroom roof vents). Two 
primary Al smelters (both using prebake technologies) with different production rates (190 
and 420 kt/year) were studied. The uncontrolled roof vents were responsible for 85% of all 
smelter emissions and accounted for 71% of all smelter PM2.5. Aluminum comprised the 
majority of the PM2.5 mass fraction regardless of whether the sample was from ambient air 
(1.74–4.05%) or from stacks at the gas treatment center (13%). Scanning electron 
microscopy/energy dispersive X-ray analyses confirmed these Al particles were related to 
those generated in the electyrolytic bath (chiolite, cryolite, NaAlF4, and fluorinated 
alumina).
Naturally occurring Al nanoforms are prominent in volcanic ash (Wada 1987) and in the fine 
fractions of clay soils (Li et al. 2012a, Theng and Yuan 2008). 1–100 nm Al nanoplatelets, 
nanowires/nanotubes and/or nanodots are abundant in allophane (where nanotubes exist as 
individual 3.5–5.0 nm particles 30–50 Ǻ in diameter), halloysite, hectorite, kaolinite and 
montmorillonite (Childs et al. 1990, Floody et al. 2009, Hall et al. 1985, Karube et al. 1996, 
Theng et al. 1982) and these materials are present in the dust suspended in ambient air.
Absorption, distribution, and elimination
Ingestion
Krewski et al. (2007) described the influence of Al chemical form and the influence of 
citrate and other carboxylic acids on oral absorption of Al. Ingested Al is absorbed primarily 
from the duodenum and small intestine via passive diffusion, pinocytosis, and transferrin/
vitamin D-dependent active transport (summarized in Crisponi et al. 2012). Parathyroid 
hormone (PTH) increases intestinal Al uptake by stimulating renal synthesis of 1, 25-
dihydroxycholecalciferol (1, 25-DHC) (Azik et al. 2011, Malluche and Faugere 1985). 
Dietary constituents that reduce Al uptake from the gut include phosphates that combine 
with Al to yield insoluble dialuminum triphosphate and Fe that competes for transferrin; 
dietary factors that enhance Al uptake include citric and other organic acids. Following 
absorption, Al+3 in serum is bound primarily (~90%) to transferrin and the remaining 
fraction is bound to low molecular weight molecules including citrate, phosphate, and 
citrate-phosphate complexes of which Al-citrate predominates (7–8%) (Yokel and 
McNamara 2001).
Mujika et al. (2011b) studied the interaction between Al3+ and Fe3+ with serum transferrin. 
Iron bound to serum transferrin is normally released from the protein’s closed conformation 
N-lobe to the transferrin receptor 1 in peripheral (e.g., neurons, glial and blood-brain barrier) 
cells where it is internalized by endocytosis. The process is pH-dependent in that the 
endosomal pH 5.5 is significantly less than serum pH (7.4). Trivalent Al does not compete 
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effectively with ferric iron for serum Fe-binding sites. The successive stability constants for 
Fe3+ binding to transferrin (log K1 = 22.7 and log K2 = 22.1) are much higher than those for 
Al3+ (log K1 = 12.9 and log K2 = 12.3). As 70% of serum metal binding sites are normally 
unoccupied by Fe+3, the transferrin protein can accommodate two Al+3 ions—first one 
binding at the C-lobe and the second at the N-lobe. Additional studies of serum transferrin 
Al+3 binding and release by Mujika et al. (2012a) revealed that only under conditions where 
Tyr188 is protonated do transferrin’s conformational hinge-bending and hinge-twisting 
changes permit Al+3 release (Mujika et al. 2012a).
Citrate is important not only because it increases gastrointestinal Al bioavailability (Krewski 
et al. 2007, Priest 2004, 2010a, 2010b, Wu et al. 2012b) and 7–8% of the Al in plasma is 
bound to citrate (Chen et al. 2010b, Krewski et al. 2007), but it has been suggested that Al-
citrate is also taken up by the monocarbonate transporter (MCT) and that it might serve as a 
substrate for the organic anion-transporting polypeptide (OATP) enabling brain brain influx 
(Crisponi et al. 2012, Yokel 2006), where it constitutes approximately 90% of the Al in 
cerebrospinal fluid (Yokel and McNamara 2001). Based on Al citrate uptake into 
immortalized rat cells in the presence of ligands for the sodium-independent L-glutamate/L-
cysteine exchanger system Xc−, Nagasawa et al. (2005) suggested that system may also 
mediate Al citrate uptake into the brain.
The EFSA (2011) reviewed the Al gastrointestinal bioavailability results by Priest (2010a). 
This study examined Sprague-Dawley rats given a single oral 50-mg intubation of 26Al 
citrate (1.47 ng 26Al), AlCl3, Al(NO3)3, or Al2(SO4)3 in water or 17 mg of Al(OH)3 or 23 
mg of Al2O3 in carboxymethycellulose or 6.9 mg metallic Al particles in honey. At 7 days 
after intubation, whole body (WB)26Al retention (following removal of the pelt, gut, paws, 
tail and head in an effort to reduce external contamination) after an oral dose was compared 
to that after iv injection of 0.19 ng 26Al citrate. The mean 26Al fraction remaining at 7 days 
after iv Al citrate (0.079 ± 0.006%) was substantially less than the 0.3–1.49% 
gastrointestinal uptake reported previously for rats (Froment et al. 1989, Schönholzer et al. 
1997, Yokel et al. 2001). It is possible this difference is due to Al elimination during the 7 
days after administration. Among the salts Al2(SO4)3 had the highest oral absorbed fraction 
(0.21 ± 0.079%) and Al(OH)3 had the lowest (0.025 ± 0.041%). Retention of 26Al after an 
oral dose of metallic Al (< 0.015%) was less than the analytical limit of detection.
Yokel and associates (2008) measured gastrointestinal uptake of 26Al by fasted male F344 
rats from 1 g of processed cheese containing 1.5% or 3% basic sodium aluminum phosphate 
(SALP). Comparing the area under the serum concentration: time curve after 60-h 
intravenous infusion with 100 μg Al/kg-h (as AlK(SO4)2) to the serum 26Al concentrations 
after feeding cheese, peak circulating Al was achieved at 8.0–8.6 h and the highest 
concentration was seen in rats that consumed the lower (1.5%) SALP cheese. Total oral Al 
bioavailability was 3 times greater in rats consuming cheese with the higher Al content than 
in those consuming the lower Al level cheese. Yokel and Florence (2008) then compared 
oral bioavailability (to 60 h) of 26Al in F344 rats using serum concentration: time profiles 
after an intravenous infusion of AlK(SO4)2 at 100 μg Al/kg-hr over 14 h. Total 
gastrointestinal uptake of Al from tea was 0.37% (Flaten 2002, Yokel and Florence 2008), a 
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value higher than the Al uptake measured in rats fed cheese containing SALP (0.10–0.29%) 
or after rats were fed acidic SALP in baked goods (0.12%) (Yokel and Florence 2006).
Poirier et al. (2011) compared the relative oral Al uptake and distribution after repeated 7 or 
14 days oral gavage with 30 mg/kg-day of either Al citrate, Al2(SO4)3, AlCl3, Al(OH)3, or 
Al(NO3)3 dissolved in deionized water (< 2 μg Al/L) in rats. Whole blood Al concentrations 
were similar at Day 7 for all Al forms. Whole blood Al concentrations declined on Day 14 
compared to those measured on Day 7 despite the continued daily oral dosing. The highest 
Al concentrations were present in liver, kidney, and bone.
The Poirier et al. (2011) conclusions with Al2(SO4)3 and Al(OH)3 contrast with the relative 
WB Al bioavailability (0.025–0.21%) after a single oral 50-mg intubation in groups of six 
adult female Sprague-Dawley rats with 26Al labeled Al2(SO4)3 > Al citrate > AlCl3 > 
Al(NO3)3 > Al(OH)3 (EFSA 2011). The comparatively low value (0.025 ± 0.041%) listed by 
EFSA (2011) for Al(OH)3 is perhaps due to the smaller 17 mg dose given as a suspension in 
carboxymethylcellulose which may alter uptake compared to the aqueous vehicle used for 
the other congeners.
The factors relating to bioavailability and tissue accumulation of Al citrate are complicated. 
Mujika et al. (2012b) examined Al+3 binding with citrate and determined four pKa values 
(2.9, 4.3, 5.6, and 11.6/14.4). Citrate binds Al+3 at three coordination sites and three labile 
water molecules occupy the remaining positions in an octahedron. Depending on pH, 
unprotonated citrate binds Al+3 at two terminal carboxylic and one alkoxy group; as pH 
increases, a second then a third ionization of carboxyl then alkoxy groups commences and 
Al+3 binding shifts the citrate pKa values. This binding and deprotonation of the trivalent 
Al-citrate coordination complex contributes to its high uptake from the gut. Binding and 
deprotonation also contribute to Al interaction with MCT and OATP transporters, Al 
sequestration in different intracellular compartments and to Al efflux from the central 
nervous system (Crisponi and Nurchi 2011, Yokel 2002).
The bioavailability of ingested Al depends in large measure on the aqueous solubility of the 
particular physical and chemical form. Krewski et al. (2007) concluded that gastrointestinal 
bioavailability of Al(OH)3 is 0.1% or less and that Al uptake from foods ranges between 0.1 
and 0.3%. The data from Poirier et al. (2011) and Priest (2010a) support the conclusion that 
ingested citrate enhances Al uptake from the gut.
Percutaneous
Krewski et al. (2007) concluded that topical Al penetration into intact skin “is very shallow”. 
This conclusion was based in part on the data by Flarend et al. (2001), who found 0.012% of 
a single topical 26Al-labeled ACH dose applied to the underarm of two volunteers was 
absorbed.
Mayeux et al. (2012) inspected Al deposition patterns in the stratum corneum following 1 or 
7 days repeated application of aqueous 5% AlCl3 on the forearms of volunteers. A total of 
37 volunteers of both genders (aged, 21–59 years) participated. The AlCl3 solution was 
applied on skin of the volar aspect of the forearm and after air drying, biometrological 
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measurements were performed at rest and after a moderate 10-min physical exercise on a 
cycloergometer. The AlCl3-treated skin was documented using two ultraviolet light-emitting 
cameras to record subtle variations or changes related to AlCl3 deposition and/or local 
effects. After a single application of AlCl3, Al deposits on skin were observed 
predominantly inside the microrelief lines and at their crossings. After daily applications of 
AlCl3 for 1 week, Al deposits were evident within the plateaus delimited by the microrelief 
lines. No information regarding local irritation following single or repeated applications of 
AlCl3 or after physical exercise compared with the resting condition was provided.
The Mayeux protocol also included corneoxenometry to predict local AlCl3 irritation 
(Goffin et al. 2000, Piérard-Franchimont et al. 2010). Briefly, CSSS were dipped into AlCl3 
solutions at 5, 20, and 40% for 2 h and these samples were then dried and stained with 
toluidine blue and basic fuchsin for 3 min. After rinsing, the color of the samples was 
measured and the staining intensity of the stratum corneum was calculated. No significant 
differences in the median or range of staining intensity were detected at any concentration 
compared to the concurrent water control. Mayeux et al. (2012) suggested these data were 
indicative of low irritant potential for AlCl3 under the conditions of their study. Among the 
limitations of this study are: little information was available on the study participants, test 
compound (chemical characteristics and purity), no information regarding pH of the 
administered AlCl3 solutions, or the pH of the skin after exposure and the report provided no 
details on the application technique (e.g. duration of contact, occlusion condition).
Yanagishita et al. (2012) studied localization of Al in palm skin after topical 20% AlCl3 
treatment for palmar hyperhidrosis. The study included 127 patients (no other details 
available) who received a daily solution without occlusion (once each day) for one month. 
No mention was made of the pH of the solution or whether any of the participants 
complained of local irritation or other clinical signs. The mean rate of sweat production after 
30 days of AlCl3 applications was reduced significantly. Hematoxylin-eosin staining of the 
stratum corneum found that prior to AlCl3 treatment the eccrine sweat ducts were intact, but 
after treatment those ducts were filled with an amorphous polysaccharide/cytokeratin-
containing cast. Histologic study of 5 μm sections of treated palm skin found that an Al 
complex was present on the surface of the stratum corneum and in casts that accumulated in 
the sweat duct. There was no evidence of Al accumulation in either the eccrine sweat duct or 
in the sweat gland.
In a report that measured Al retention beneath the epidermis, Guillard et al. (2012) measured 
Al in a dermatofibrosarcoma taken from a 45-year-old woman at 5–12 years after im 
injection of an Al(OH)3 adjuvant-containing vaccine. Skin Al (768 mg/kg dry weight) was 
elevated compared to that in the skin of two untreated volunteers (40–44 mg/kg dry weight). 
However, the high Al concentration was traced to the Al-containing tattoo paste (35 mg 
Al/kg) used to mark the biopsy site.
Pineau et al. (2012) used Franz® diffusion cells to measure Al transdermal movement from 
topical ACH at 37°C for 6–24 h. Abdominal skin biopsies (513 μm thick) from five healthy 
Caucasian (29–52 years) volunteers were treated with either a 14.5% ACH emulsion (8 mg), 
a 21.2% ACH “stick” (4.5 mg) or a 38.5% ACH aerosol base (2.6 mg). The mean thickness 
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of the materials applied to the skin was 1402 ± 348 μm. Blanks applied to tape-stripped skin 
were of similar thickness. Because of its high viscosity, a higher dose of the aerosol base 
could not be applied to the test cells. After incubation, the superficial horny layer was 
removed and the skin was dissected to separate epidermis and dermis. Regardless of the 
ACH formulation, the highest mean Al concentration (2.24–4.43 μg/cm2) was present in the 
horny layer. The epidermis had the highest mean Al concentration (9.42 ± 7.82 mg/cm2) 
after it was in treated with the 21.2% “stick”. The most salient observation was the fact that 
the Al concentrations in the Franz® receptor fluid were less than 0.1 μg/cm2 and 
corresponded to only 0.012% (1/10,000) of the applied Al. The Pineau et al. (2012) in vitro 
assays used abdominal skin and the experimental conditions were such that personal habits 
and conditions (e.g., frequent repeated underarm shaving) and individual rates of Al 
application (e.g., diaper rash, prickly heat, insect stings, Tinea pedis) (reviewed in Krewski 
et al. 2007) could not be taken into account.
One case of systemic hyperaluminemia (plasma Al = 104.7 μg/L) presenting with 
complaints of bone pain after 4 years of daily ACH deodorant application has been 
described (Guillard et al. 2004). In light of that report, Yokel (2012) calculated the highest 
systemic Al uptake after routine topical application of a commercial 20% Al zirconium 
glycine or a 25% ACH deodorant was no more than 0.1 mg/kg-day.
Inhalation
Aluminum workers can encounter a mixture of Al fumes and inhalable (aerodynamic 
diameter ≤ 100 μm), thoracic (< 28 μm), and respirable (< 10 μm) Al particulates in the 
occupational environment. These materials can be deposited in the respiratory tract where a 
fraction is absorbed from the lung and above 95% is eliminated in urine (reviewed in 
ATSDR 2008, Krewski et al. 2007). The magnitude of these exposures and their associated 
Al urinary concentrations depend upon the particular industrial operations (such as bauxite 
mining, Al refining, reduction, casting, fettling, slagging, welding, and AlF3 production) and 
the Al forms encountered. Krewski et al. (2007) estimated that inhalation of Al dust and 
fume by refinery workers and welders yields a daily intake on the order of 6 × 10−3 mg/kg-
day.
Intramuscular injection
Systemic uptake of Al from a vaccine depot in skeletal muscle depends upon the chemical 
form of the Al adjuvant (Flarend et al. 1997, Verdier et al. 2005). Krewski et al. (2007) 
examined Al absorption and distribution profiles of Al(OH)3 (present as poorly crystallized 
AlO(OH)) and AlPO4 (present as HAlO5P) (Hem and White 1995, Shirodkar et al. 1990) 
and concluded that 100% of the injected Al is eventually absorbed. This conclusion was 
based in part on results by Verdier et al. (2005) who found that Al concentrations in muscle 
at 3–6 months after a single im injection of AlO(OH) in macaques were 4-fold higher than 
after equivalent injection of AlPO4. Muscle Al concentrations declined to less than the 
analytical limit of detection (≤ 25 μg/g) within 12 months.
Intramuscular AlO(OH) is more rapidly taken up into rabbit blood than AlPO4. Within 1 h 
of a single im injection of 0.85 mg Al as 26Al(OH)3 plasma 26Al peaked at 2 ng/ml (Flarend 
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et al. 1997). The maximum Al concentration represented approximately 7% of the normal Al 
level in rabbit plasma (30 ng/ml). Total 26Al uptake from the injection ranged from 13 to 
22% and was distributed to all organs examined (kidney> spleen> liver > heart> lymph 
nodes > brain). The initial plasma 26Al concentrations after AlO(OH) injection were thrice 
those after equivalent injection of AlPO4, but by 28 days mean peripheral tissue 26Al 
concentrations were 3-fold greater in rabbits given AlPO4 compared to those in rabbits given 
AlO(OH). Aluminum uptake from the depot continued for more than 28 days at which time 
only 6% of the injected 26AlO(OH) had been eliminated in urine compared to 22% of the 
injected 26AlPO4. Flarend et al. (1997) extrapolated the rabbit plasma concentration:time 
profile to humans and concluded that the Al dose associated with a single im adjuvant 
injection represented 0.8% or lesser increase above the normal (2.7–6.2 μg Al/L) range 
(Krewski et al. 2007).
Mechanisms of action
Understanding mechanism of action and compound-specific bioavailability is key to the 
evaluation and interpretation of the health risks posed by exposure to the many different 
physical and chemical forms of Al. Mechanistic studies with the soluble Al salts point to 
Al+3 as the entity responsible for tissue damage whereas studies with the non-reactive Al 
oxides demonstrate adverse effects of particulates that are separate and distinct from the 
actions of ionized Al. Under some conditions (e.g., Al welding, fettling, refining) mixed 
exposures to soluble, sparingly soluble, and insoluble Al forms occur.
Fraga et al. (1990), Gutteridge et al. (1985), Savory et al. (1999), Tomljenovic (2011) and 
Zatta et al. (2002) concluded that elevated Al+3 concentrations induce cytotoxicity as a result 
of oxidative damage. Mailloux et al. (2011) traced the biochemical events contributing to 
(soluble) Al-induced toxicity in cultured HepG2 cells and advanced the hypothesis that 
disruption of “mitochondrial metabolism is the main site of the toxicological action of Al” 
due to interference with “Fe-dependent redox sensitive enzymes in the tricarboxylic acid 
(TCA) cycle and oxidative phosphorylation”. Initial changes (apparently initiated via Al+3 
binding with protein and competition for Fe-binding sites) include depletion of 
mitochondrial Fe and generation of H2O2, O•2− and OH•. These changes result in a cellular 
metabolic shift from oxidative ATP production to anaerobic glycolysis (seen with the 
increased activity of LDH, pyruvate kinase, and glyceraldehyde-3-phosphate 
dehydrogenase) resulting in increased α-ketoglutarate and succinate and reduced L-carnitine 
due to diversion of α-ketoglutarate to scavenging ROS. These changes are reflected in 
reduced fatty acid β-oxidation that further facilitates increased peroxidation.
Data from cultured murine primary cortical astrocytes treated with Al glycinate do not 
necessarily support the hypothesis that mitochondrial membranes are the primary Al+3 
target. Aremu et al. (2011) found no indication of mitochondrial-mediated apoptosis after 
astrocyte incubation with 0.1 mM Al glycinate for 12–24 h (followed by maintenance in 
fresh media for 7 days) or after culture with 0.1 or 1.0 mM Al glycinate for 48 h. Not only 
were there no detectable alterations in Bcl2, Bax, or Bcl2 binding component 3/p53 (3bc3/
PUMA) expression, but there was no influence on cytochrome c release. Aluminum 
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treatment up-regulated Ire1β, a response that was considered indicative of stress within the 
endoplasmic reticulum (Aremu et al. 2011).
Trivalent Al is a promoter of Fe-mediated (Gutteridge et al. 1985, Lemire and Appanna 
2011) and non-Fe superoxide radical anion-mediated biological oxidation (Exley 2004, 
Kong et al. 1992, Mendez-Alvarez et al. 2002). Several theories advanced the concept that 
Al+3 binding with phospholipids leads to peroxidation and altered membrane fluid dynamics 
as responsible for Al toxicity. Ghribi et al. (2001a, 2001b, 2002) suggested the primary site 
of Al damage was within the endoplasmic reticulum leading to cytochrome c release from 
mitochondria and activation of apoptotic demise. Free energy calculations and the physical 
chemistry of trivalent Al in water and its complex with O2•− demonstrate displacement of a 
water molecule [Al(H2O)6+3 + O2•− → [Al(O2•) (H2O5)]+2 + H2O] to produce bidentate 
superoxides (Mujika et al. 2011a). Thus, reaction of Al+3 with its first microsolvation shell 
generates an Al+3 superoxide semireduced radical [AlO2•]+2 via [Al(H2O)6]+3. Formation of 
these radicals, together with Al+3 potentiation of Fe+2/Fe+3 redox and non-heme-mediated 
OH• formation, appear to account for the oxidant activity of Al+3 in biological systems.
Some the earliest genomic changes induced by Al+3 appear to involve increased p53 
(Johnson et al. 2005) followed by Bax translocation, increased Bax reactivity in the 
endoplasmic reticulum (Ghribi et al. 2001a), reduced endoplasmic reticulum (Ghribi et al. 
2001a, 2001b), and mitochondrial (Ghribi et al. 2001c) Bcl-2 and perturbation of the 
Bcl-2/Bax ratio (Savory et al. 1999). These events are followed by activation of caspase-3 
(Ghribi et al. 2001a) and caspase-12 (Ghribi et al. 2001b). The intrinsic apoptotic pathway 
responds to oxidative stress and this is apparent in the Al+3—induced release of 
mitochondrial cytochrome c (Ghribi et al. 2001a, 2001c) into the cytosol. The initial 
oxidative changes that lead to DNA fragmentation (Ghribi et al. 2001c) and the genomic 
response that occur at the lowest Al+3 concentration and at the earliest key metabolic 
juncture responsible for cytotoxicity remain to be confirmed (Crisponi et al. 2012).
Unlike the soluble salts, insoluble Al materials elicit dose-dependent pulmonary damage as a 
consequence of accumulation of nonreactive particles. At neutral pH the Al oxides and 
oxyhydroxides are chemically stable. After 60 days incubation of 565 mg/L Al2O3 in pH 
5.3–8.2 deionized or saline water at room temperature, Batten and Lafayette (undated) found 
the concentration of soluble Al+3 undetectable. Pauluhn (2009a) reported pulmonary 
inflammation after rats inhaled γ-AlO(OH) for 4 weeks. There was no evidence for either Al 
translocation from the lung or increased urinary Al. Those data are consistent with the 
observations by de Kom et al. (1997) who found no significant difference in serum Al 
among bauxite (gibbsite [Al(OH)3], boehmite [γ-AlO(OH)], and diaspora [α-AlO(OH)]) 
miners compared to wood workers. Prolonged inhalation of bauxite dust increased the risk 
of simple and complex pneumoconiosis (Shaver’s disease) (Beach et al. 2001, Donoghue et 
al. 2014, Friesen et al. 2009, Gartner 1952, Taiwo 2014). These conditions are related to 
inert particle accumulation and lung overload (Oberdörster 1995).
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Organ systems and function
Nervous system
The AD and Al literatures remain linked in reports from some researchers (Bondy 2010, 
Campdelacreu 2012, Tomljenovic 2011, Walton 2012b) yet others conclude factors distinct 
from Al are responsible for AD (reviewed in Lidsky 2014, Willhite et al. 2012). A primary 
feature of AD pathogenesis is β-amyloid precursor protein (APP) catabolism by the actions 
of α-and β-secretase that yield the amyloid β-peptides (Aβ). While Aβ is constitutively 
produced from APP, normally it is degraded immediately; failing that, Aβ polypeptides can 
mis-fold and self-aggregate in the brain leading to insoluble ‘senile’ plaques.
Aβ1–40 is the major form present in biological fluids and Aβ1–42 is the major insoluble form 
present in neuronal plaques. These plaques consist of an amorphous core surrounded by 
amyloid adjacent to degenerating neurons and glial cells. The plaques accumulate, 
neurofibrillary tangles develop, intraneuronal (argyrophilic) granulovacuolar lesions appear 
and progressive atrophy (shrinkage) of the brain follows. The amyloid cascade hypothesis 
seeks to explain the excessive Aβ accumulation and it is believed the relative rates of Aβ 
generation and degradation are key to AD. The Al/AD hypothesis has three distinct aspects: 
Al participation in Aβ aggregation (perhaps via cross-linking hyperphosphorylated protein); 
Al induction of Aβ integration into β-sheet proteins found in the cores of senile plaques and 
Al-mediation of abnormal Fe-catalyzed oxidation, increased free radical generation, 
increased lipid peroxidation (LPO), inflammation and neuronal apoptosis.
At least four physiological factors contribute to the increased susceptibility of the brain to 
oxidative insult: its high rate of O2 consumption, the abundance of polyunsaturated fatty 
acids, its elevated Fe content and its relatively low antioxidant capabilities. Aluminum binds 
to phospholipids (Verstraeten et al. 1997a), stimulates Fe-initiated LPO (Toda and Yase 
1998, Xie and Yokel 1996) and it reacts with O2− to form Al-O2− that increases oxidation of 
amino acids leading to generation of protein carbonyls (Exley 2004, Sánchez-Iglesias et al. 
2009, Yokel 2000). These reactions reduce the activity of antioxidant enzymes (e.g., 
glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase) (Chaitanya et al. 
2012, Shrivastava 2012, Verstraeten et al. 1997b, Yuan et al. 2012).
It is well known that Al+3 and other metal ions (notably Cu+2, Fe+3 and Zn+2) can bind 
proteins including Aβ and that those reactions (at least in vitro) can lead to conformation 
changes, reduced Aβ solubility and can promote spontaneous Aβ (1–42) Al+3 
oligomerization, aggregation, and precipitation. Zinc+2 and Cu+2 accelerate amorphous Aβ 
aggregation whereas Al+3 and Fe+3 tend to promote Aβ fibril and oligomer formation 
(Kawahara 2005, Kawahara and Kato-Negishi 2011, Ricchelli et al. 2005). SanMartín et al. 
(2012) interpreted the elevated concentrations of Al, Cu, Fe, and Zn in human 
neurofibrillary tangles and senile plaques along with their in vitro acceleration of Aβ fibril 
and amyloid β oligomer formation as consequences of oxidative stress.
Data on the presence and accumulation of Al in amyloid fibers and AD plaques vary. A 
number of reports (e.g., Bjertness et al. 1996, Landsberg et al. 1992, Makjanic et al. 1998) 
failed to find Al accumulation in either whole AD brain or neuritic cores and neurofibrillary 
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tangles. Strozyk et al. (2009) found no correlation between Al and Aβ42 in the cerebrospinal 
fluid of AD patients. In contrast, Yumoto et al. (2009) used EDX spectroscopy to measure 
Al in amyloid fibers of senile AD plaques in the human hippocampus and temporal lobe. 
Identification of senile plaque cores by TEM found Aβ peptides in senile plaque cores where 
Al, P and Ca co-located. The Yumoto et al. (2009) findings are consistent with earlier data 
by Good et al. (1992) and Perl and Moalem (2006) who found Al in tangle-bearing neurons 
of the AD hippocampus, but none of those data defined whether the presence of Al occurs as 
a result of the AD pathophysiological process or whether elevated Al concentrations initiate 
or accelerate Aβ fibril and/or amyloid β oligomer formation.
Kawahara and Kato-Negishi (2011) collated data on Aβ structural alterations and 
Thinakaran and Koo (2008) reviewed the human APP3 gene and intracellular proteolytic 
APP processing. These authors listed 25 + APP mutations considered causal in early onset 
familial AD (EOFAD) and hereditary cerebral angiopathy. EOFAD is associated with 
mutations in the presenilin one (PS1) or two (PS2) genes found on chromosomes 14 and 1, 
respectively. More than 230 APP/Ps1/PS2 mutations have been associated with EOFAD; 
however, EOFAD accounts for less than 1% of all AD cases (Wu et al. 2012d).
For the more common late onset AD (LOAD) the major genetic risk factor identified thus far 
is the inheritance of the apolipoprotein E4 gene (apoE4) (Verghese et al. 2011). Inheritance 
of the apoE4 allele has been linked to enhanced aggregation of Aβ and to reduced Aβ 
clearance from the brain (Potter and Wisniewski 2012). From studies with more than 16,000 
subjects, four new Aβ genetic determinants for sporadic late onset AD have been identified 
and these include the PICALM (phosphatidyl inositol binding clathrin assembly protein), 
CLU (clusterin), CR1 (complement component receptor 1) and BIN1 (bridging integrator 1) 
genes (Harold et al. 2009, Lambert and Amouyel 2011). Results of functional assays suggest 
that LOAD is associated with impaired clearance of the Aβ peptide where CR1 participates 
in Aβ clearance, PICALM apparently alters synaptic vesicle cycling, BIN1 appears to alter 
neuronal membranes and formation of synaptic vesicles and CLU enhances amyloid plaque 
formation. Together with apoE, CLU influences the structure and accumulation of Aβ. Of 
the many recent reports concerning Al neurotoxicity, those judged more informative are 
described below.
Neurotoxicity in humans—Exley and House (2011) tabulated literature reports on the Al 
content of human brain. In general the normal range is between 0.1 and 4.5 μg/g dry wt. with 
the higher values (> 2 μg/g dry wt.) measured in brains of non-demented elderly, AD 
patients (up to 11.5 μg/g dry wt.), dialysis encephalopathy (up to 14.1 mg μg/g dry wt.), 
congophilic amyloid angiopathy (CAA) (up to 23.0 μg/g dry wt.) and other encephalopathies 
(up to 47.4 μg/g dry wt.).
House et al. (2012) measured Al in the temporal, frontal, occipital, and parietal lobes of 
brains from older donors (n = 60, aged 70–103 years) (described in Wharton et al. 2011). 
The Al content ranged from 0 (after subtraction of method blank values) to 33 μg/g dry wt (n 
= 713 tissue digests). The median Al value was 1.02 μg/g dry wt. and 75% of all values were 
less than 2.01 μg/g dry wt. All these Al concentrations were within the “normal” range (0.1–
4.5 μg/g; Exley and House 2011) for aged brain.
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Akatsu et al. (2011) studied Al concentrations in the hippocampus and amygdala from 
people with AD (15 and 18 patients, respectively) or dementia with Lewy bodies (DLB) (11 
and 11 patients, respectively) and compared those values to samples from brains of people 
with no history of dementia. The average Al concentrations in the hippocampus (n = 12) and 
amygdala (n = 16) of non-demented people were 2.8 ± 2.0 and 6.0 ± 6.5 μM wet tissue, 
respectively. The average Al concentrations in the hippocampus (n = 15) and amygdala (n = 
18) from AD patients were 4.4 ± 3.8 and 6.4 ± 5.5 μM wet weight, respectively. The average 
Al concentrations in the hippocampus (n = 11) and amygdala (n = 11) from people with 
DLB were 5.6 ± 6.1 and 6.9 ± 5.9 μM wet weight, respectively. Akatsu et al. (2011) found 
no significant differences in total Al concentrations in the hippocampus and amygdala 
between demented and non-demented individuals.
Rusina et al. (2011) measured Al in brains from 29 deceased patients (mean age 79 years, 
women to men ratio 20:9) with neuropathologically confirmed AD. All these samples 
fulfilled the National Institute of Aging (Hyman et al. 2012, McKhann et al. 2011) and 
Reagan Institute (Newell et al. 1999) AD diagnostic criteria. The 27 subjects (12 women and 
15 men, mean age 76 years) in the referent group had no signs of AD or other degenerative 
dementias on autopsy. Different statistical approaches used by Rusina et al. (2011) provided 
somewhat different results: higher mean Al concentrations in the hippocampus were found 
in AD patients compared with the healthy individuals (0.357 vs 0.090 μg/g; p = 0.039) after 
Box-Cox data transformation, but not after standard logarithmic transformation to correct 
deviations from normality.
Walton (2010) examined Al in corticolimbic tissue from brains of five deceased older AD 
patients (4 males and 1 female) compared to five non-demented referents (4 males and 1 
female). Autopsy confirmed diagnoses were made according to criteria established by the 
Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer’s 
Disease (Mirra et al. 1991). Ten-micron paraffin sections from the corticolimbic region were 
examined after histological staining for Al (using the modified Walton (2004) method) and 
immunostaining with anti-PHF1 antibody for hyperphosphorylated tau. Nine of the 10 
subjects exhibited pre-tangle cells. The remaining AD subject had extensive CA1 cell loss. 
The pre-tangle granules did not stain positively for Al; one referent and one AD case had 
CA1 pyramidal cells with distinctive cytoplasmic pools that stained for both Al and 
hyperphosphorylated tau. Walton (2010) reported a few NFT development pre-tangle stage 1 
(early 1a and late 1b), mature NFT stage 2 and extracellular NFT stage 3 in AD and non-
demented subjects. Early pre-tangle (stage 1a) cells contained small cytoplasmic granules 
that were distributed throughout the cytoplasm that immunostained for hyperphosphorylated 
tau. These cells were observed frequently in both aged demented and non-demented humans. 
Late pre-tangle (stage 1b) cells had grainy-textured cytoplasmic pools that stained for Al and 
hyperphosphorylated tau and these were visible as cytoplasmic filaments. There was no 
evidence for Al accumulation in cells at the early pre-tangle stage. The presence of early 
pre-tangle cells was observed in four of the AD cases and in one referent. Walton (2010) 
suggested that the lack of Al staining during the early stage could indicate either an absence 
of Al or that Al levels were below the staining threshold. Mature (stage 2) NFTs were 
observed as densely packed filaments that stained for both Al and hyperphosphorylated tau; 
in these cases, the nuclei of affected cells were displaced to the cell periphery and in some of 
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these cells no cytoplasm at all could be seen given the extent of the large NFTs. Mature 
NFTs were observed in all AD cases and in three of the five referents. Extracellular (stage 3) 
NFTs stained for both Al and hyperphosphorylated tau; in most of these cases, the glial cells 
were associated with extracellular NFTs. Stage 3 NFTs were commonly observed in AD 
cases and less often in the referents. After Al de-staining and re-staining for 
hyperphosphorylated tau, the Al/hyperphosphorylated tau complexes were evident in the 
cytoplasm during the late pre-tangle stage, mature and extracellular stages. Overall the 
Walton (2010) report provides indications of colocalization of Al with hyperphosphorylated 
tau during NFT formation in the late pre-tangle stage, mature, and extracellular stages. 
While these observations could be taken as evidence for Al contributions to NFT formation, 
neither Al levels nor NFT presence show clear relations with AD clinical pathology or 
pathogenesis (Armstrong 2013, De-Paula et al. 2012, Hamdy 1990, Mizoroki et al. 2007). In 
spite of the reported sensitivity and specificity of the Walton (2004) method for identifying 
Al and NFTs in brain, there has been no independent validation of the Walton staining 
technique.
Ionized Al and other ionized inorganics bind protein and it is not inconsistent that metals 
(including Cu, non-heme Fe, Zn and Al) are colocated with Aβ40/42 in cerebral amyloid 
angiopathy (reviewed in Kawahara and Kato-Negishi 2011). As such, Al is not the only 
inorganic element implicated in AD (Bolognin et al. 2011, Grasso et al. 2011) and recent 
studies point to reduced Cu status and elevated AD risk (Schrag et al. 2011). Baum et al. 
(2010) measured Al and 11 other inorganic elements by ICP-MS in the serum of 44 AD and 
41 healthy referent subjects who lacked symptoms of neurologic disease. All AD patients 
had NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders 
and Stroke-Alzheimer’s Disease and Related Disorders Association) diagnosis of probable 
or possible AD (McKhann et al. 1984). These individuals were recruited from geriatric 
outpatient clinics (n = 35) and long-term care facilities (n = 9). The authors administered the 
Cantonese Mini-Mental Status Examination (MMSE, maximum score 30; Chiu et al. 1994) 
to 43 AD and one healthy subject (rationale was not given for lack of MMSE assessment for 
the remaining 40 referents). Three statistical models were tested: (1) one metal at a time 
with age and sex as additional control covariates; (2) all metals in one model along with age 
and sex; and (3) a model with variables selected from model (2) by forward stepwise 
selection (p = 0.05, likelihood ratio test). Using the unadjusted comparisons, the AD patients 
had significantly higher serum Al (905 ± 630 nmol/L or 24 ± 17 μg/L) (median ± 
interquartile range) than healthy referents (580 ± 620 nmol/L or 15 ± 16 μg/L). Using the 
unadjusted comparisons, the AD patients had lower (p = 0.0001) serum Zn (10,900 ± 1600 
nmol/L) than healthy referents (12,300 ± 1600 nmol/L). After adjustment for age and gender 
(model 1), serum Al was increased (p = 0.002) and serum Zn was reduced (p = 0.0007) in 
AD patients compared to their healthy referents. These conclusions depended on statistical 
procedures; in the simultaneous model adjusted for all metals (Al, As, Be, Cr, Co, Cu, I, Fe, 
Mn, Ni, Se, and Zn) (model 2), only Cr, Se and Zn were significantly different with only Se 
and Zn differing after Bonferroni adjustment. In a forward stepwise regression (model 3), 
only Zn was reduced (p = 0.005). Since serum Zn was reduced significantly in all models, 
Baum et al. (2010) suggested that Zn induced Aß aggregation (Bush and Tanzi 2002). The 
Cantonese MMSE results correlated significantly with serum Al and As concentrations. The 
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serum Al data show marked variability and those values are elevated for the healthy 
participants (perhaps associated with Al antacid consumption) compared to the normal 
median (0.12 μM or 3.2 μg/L with an upper limit of 6 μg/L) concentration (reviewed in 
Krewski et al. 2007). Those observations and the fact that only one healthy referent was 
subject to MMSE scoring reduce the confidence that can be placed in the authors’ 
conclusions.
Baum et al. (2010) also suggested that the increased serum Al in AD patients might be 
associated with more efficient uptake of dietary Al in patients with AD, but that the 
reason(s) for this difference in Al uptake were unknown (Miu et al. 2004, Roberts et al. 
1998). The Baum et al. (2010) suggestion that Al gastrointestinal uptake is greater among 
people with AD than in otherwise healthy people is consistent with Moore et al. (2000), but 
it is at odds with the results presented by Molloy et al. (2007) who found there was no 
difference in Al (consumed as Al(OH)3 with citrate) uptake by AD patients and/or healthy 
people with apoE alleles compared to that by those who did not carry the apoE ɛ4 allele. 
Rather, the differences in serum Al might reflect reduced renal Al clearance as a 
consequence of declines in kidney function with age.
Following a similar line of inquiry, Exley et al. (2012) compared Al, Fe, and Cu 
concentrations to the Aβ content in senile plaques and in areas of amyloid angiopathy in 
brains from 38 women and 22 men (ages 70–103 years). There was no significant 
correlation between Al or Fe and senile plaques or amyloid angiopathy. The Exley et al. 
(2012) data do not support the hypothesis that elevated brain Al is associated with enhanced 
Aβ42 in senile plaques and/or focal CAA.
A pan-Canadian outbreak of hyperaluminemia occurred during 2005 among patients on 
peritoneal dialysis (PD). This was traced to a high Al content in dialysate solutions (1.3 
μmol/L, current maximum recommended < 0.742 μmol/L). Yue et al. (2011) examined 83 of 
those patients exposed to Al-contaminated dialysate and found the mean serum Al was 1.77 
± 0.74 μmol/L (47 μg/L) compared to a normal upper limit of 6 μg/L (reviewed in Krewski 
et al. 2007).
Sandhu et al. (2011) carried out retrospective analyses of quarterly serum Al determinations 
for 589 HD patients with end-stage renal disease. A total of 5,674 Al measurements for 589 
patients were made and of those 32 (0.5%) had Al concentrations 20 μg/L or higher. The 
overall mean Al concentration was 10 μg/L (range: 2–28 μg/L). Out of 589 (4.2%) patients, 
25 patients experienced increased serum Al at some point in the study. The reason for 
increased serum Al was identified for only two of the participants (Al-containing antacids).
In a small clinical study, Elshamaa and associates (2010) found a significant (p = 0.0001) 
correlation between serum Al and EPO dose among 22 boys and 21 girls (11 ± 3.3 years) 
with end-stage renal disease. These children were on long-term HD and renal dialysate was 
eliminated as a source of excess Al inasmuch as the filtered deionized water contained 10 μg 
Al/L or lesser. None were given Al-containing phosphate binders. The HD patients were 
moderately anemic and weekly subcutaneous EPO injections were given to maintain a 28–
31% hematocrit. Serum Al (≤ 30 μg/L) was significantly higher among HD patients than in 
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healthy referents, but there were no significant differences between HD boys and HD girls 
and HD duration had no influence on serum Al. There was a significant (p = 0.0001) linear 
correlation (r = 0.77) between serum Al and EPO dose. While the data suggest EPO was the 
source of the elevated Al, Elshamaa et al. (2010) did not quantify Al in the EPO given to 
these patients. This failure and the facts that the study was relatively small and confined to a 
single institution detract from the conclusions reached.
Albizzati et al. (2012) compared Al concentrations in blood, urine, and hair for 17 autistic 
children (ages 6–16 years; mean 11.5 ± 3.2 years; 15 males and 2 females) to those for non-
autistic subjects (ages 6–16 years; mean: 10.4 ± 3.2 years; 15 males and 2 females). There 
were no significant differences in Al between the two groups.
Bakar et al. (2010) evaluated drinking water Al concentrations in relation to cognitive 
function among residents of the Kirazli region of the Biga Peninsula, northwest Turkey. The 
Kirazli region was included in the study as it has acidic drinking water and its Al 
concentration exceeds the WHO (1984, 2004) recommended maximum (0.2 mg Al/L). Of 
201 Kirazli inhabitants 73 agreed to participate; the referent group included 164 selected 
from 921 residents of a Ciplak-Halileli village in the same province. A neurologist 
administered the MMSE using face-to-face interviews and performed clinical examinations. 
All subjects obtained their drinking water from groundwater networks in their regions and a 
total of 237 people from both regions participated in the study. Drinking water collected in 
both regions revealed higher Al concentrations in Kirazli (13–16 mg/L) than in the referent 
region (0.005–0.010 mg/L). Despite the differences in Al levels in their drinking water, no 
significant differences were detected between serum Al levels, the MMSE scores or the 
incidence of clinical neuropathy between the two regions.
Studies of Akila et al. (1999), Bowler et al. (2003), Flaten et al. (1996), Hanninen et al. 
(1994), and Riihimaki et al. (2000) described subtle deficits in cognition associated with 
chronic occupational exposure to Al fume. It is those observations that apparently prompted 
the reduction in the TLV® for Al welding fume (ACGIH 2008). Those observations contrast 
with Kiesswetter et al. (2007, 2009) who found no changes in neurobehavioral parameters or 
motor performance compared to production or construction workers of similar average age.
Giorgianni et al. (2012) measured serum Al and performance on the Wechsler Memory 
Scale, attention matrix test and the color-word (Stroop) test for 86 non-smoking (apparently 
healthy) male Al welders (38.45 ± 6.34 years). Those results were compared to the results 
for 90 (38.29 ± 7.14 years) male clerical workers who had no history of occupational Al 
exposure. Study participants had similar years of formal education and all were employed at 
the same shipyard for similar durations (mean = 15.5–15.8 years). Employees who used Al-
containing antacids, experienced occupational Mn exposure or who had a history of 
diabetes, kidney disease, or cerebrovascular conditions were excluded. Work station 
(presumably area sampling) concentrations of airborne Al fume averaged 19.5 mg/m3 and 
this was attributed to “soldering operations performed inside large and medium-size hulls 
with double-bottoms and limited air circulation”. Serum Al among the welders (24.2 ± 9.9 
μg/L) was four times that in the clerical workers (6.93 ± 1.95 μg/L). Performance of welders 
on the Wechler and Stroop tests was reduced and older welders displayed reduced attention 
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spans compared to the office staff; welders with longer employment generally had poorer 
scores. Giorgianni et al. (2012) concluded that chronic exposure (e.g., ≥ 16 years) to Al 
welding fume not only resulted in markedly elevated circulating Al, but that those 
concentrations over many years were associated with impaired cognition. The Giorgianni et 
al. (2012) data were qualitatively consistent with observations made by Akila et al. (1999), 
Bast-Petterson et al. (1994, 2000), Bowler et al. (2003), Hanninen et al. (1994), Riihimäki et 
al. (2000), and Sjogren et al. (1990). However, the confined space welding operations, 
apparent lack of fume control, absence of comprehensive exposure data (including 
frequency, duration and peak concentrations) taken together with the very high mean 
airborne Al levels do not permit quantitative comparisons among the different studies.
Kiesswetter et al. (2007) conducted a 4-year longitudinal repeated measures study of 20 Al 
welders exposed to 5–8 mg/m3 total dust in their breathing zone. There was no relation 
between symptoms, verbal intelligence, logic, psychomotor performance, memory or 
attention, and urinary (88–140 μg/g creatinine) or plasma (13–16 μg/L) Al. Kiesswetter et al. 
(2009) conducted a similar study in a second plant of 92 welders with an average of 11 years 
Al fume exposure. Personal samples found these men were exposed to 0.5–0.8 mg/m3 total 
dust and that their urinary Al (23–43 μg/g creatinine) and plasma Al (5–9 μg/L) 
concentrations were somewhat lower than those measured in the first cohort. There were no 
differences on neurobehavioral or motor performance tests by these welders compared to 
those by 50 construction workers of similar age not employed in Al welding. Kiesswetter et 
al. (2009) concluded, “The repeated measurement models of both studies show no adverse 
effects of Al welding.”
The review by Riihimäki and Aitio (2012) concluded that workers exposed to fine or 
ultrafine Al particulates while engaged in MIG/MAG Al welding, production and use of Al 
powders, plasma cutting, grinding, polishing, and thermal spraying were at risk for Al-
induced cognitive deficit. Riihimäki and Aitio (2012) found “The mainstream of studies over 
the past two decades on workers exposed to fine particles of sparsely soluble aluminum have 
revealed exposure-related subclinical disturbances of cognitive functions and associated 
subjective symptoms”. These are mixed exposures in that Al accounted for approximately 
30% of the fume generated from AlMg 4.5 Mn welding wire, Mg accounted for 3% and Cu, 
Mn, Pb, and Zn each represented 0.2% (Riihimaki and Aitio 2012). Results by Buchta et al. 
(2005), Meyer-Baron et al. (2007), Polizzi et al. (2002), and Riihimäki et al. (2000) differ. 
Buchta et al. (2005) concluded that their neurobehavioral results with 44 welders who had a 
mean 11 years exposure to Al fume were no different from those of 37 production workers 
of similar age who had no opportunity for exposure to Al welding fume. Meyer-Baron et al. 
(2007) examined 9 studies of 449 workers employed in Al welding, smelting and 
electrolysis compared to 315 control workers. Although Meyer-Baron et al. (2007) 
concluded that urinary Al less than 135 μg/L “might have an effect on cognitive 
performance” measured using six different neuropsychological tests with 10 variables 
(including the symbol-digit and digit span forward/backward tests), when one of the nine 
studies with uncertain Al exposure was omitted from their meta-analysis there was no 
statistically significant difference between the Al-exposed and control workers. These 
studies are difficult to reconcile because of differences in worker age, Al exposure history, 
education, native intelligence and life style (including ethanol consumption). In addition, use 
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of Al-containing over-the-counter pharmaceuticals results in urinary Al levels that are equal 
to or greater than those associated with routine occupational Al exposures. Riihimäki and 
Aitio (2012) opined that in spite of the preliminary, variable and incomplete evidence for 
changes in cognition among welders exposed to poorly soluble Al particulate, those reports 
could not be discounted.
Neurotoxicity in laboratory animals—Table 1 summarizes recent observations 
concerning Al-induced neurotoxicity in rodents and rabbits; many of these studies examined 
Al exposures that are much higher than those experienced by humans. Data considered more 
relevant to published guidance and regulatory limits are described below.
Shati et al. (2011) studied Al-induced biochemical and molecular changes in the brain of 
adult Balb/c and C57BL/6 mice given AlCl3 by repeated ip injections over 45 days. Li et al. 
(2012a) compared APP expression in the brain and selected internal organs of rats after ip 
injection of AlCl3 at 1 mg Al/kg once every other day over 60 days. Abdel-Aal et al. (2011a) 
gave daily ip injections of AlCl3 at 100 mg/kg-day for 60 days to male Wistar albino rats. 
Common limitations include only a single Al dose level, no details on clinical signs, food or 
drinking water consumption or the chemical purity of the test material and the pH of the 
administered AlCl3 solution or the Al content in the laboratory stock diet and drinking water 
were not reported. No controls given equimolar doses of HCl were included in any of these 
repeated ip AlCl3 injection studies. No neurobehavioral assessment (Shati et al. 2011) or 
only limited details of the conditions during the behavioral and neuromotor assays (e.g., 
blind examination) detract from these reports. Results from the Abdel-Aal et al. (2011a) 
study suggest that high-dose AlCl3 injections over a prolonged period can reduce locomotor 
and cognitive functions in rats, but the reductions in cognitive function and physical activity 
occurred at doses that also reduced body weight gain suggesting that repeated AlCl3 
injections induced systemic toxicity.
Three recent studies examined the potential toxicity of ingested Al in novel protocols that 
gave mice AlCl3 or Al lactate for at least 90 days (Akiyama et al. 2011, Ribes et al. 2010, 
2011). These assays are unique in that transgenic mice with increased amyloid β-protein 
(Aβ) deposition as a result of human Aβ precursor protein (AβPP) mutations (Tg2576) and 
(P301L) at the tau protein (Tg2576tau) were examined. The Tg2576 mouse carries the 
Lys670→Asn,Met671→Leu mutation and by six months of age they develop a 5-fold 
increase in Aβ(1–40) and a 14-fold increase in Aβ(1–42/43). The Ribes et al. (2010, 2011) 
protocols compared the responses seen in the Tg2576 mouse with those seen in wild-type 
mice. None of these studies examined more than one Al dose level.
Akiyama et al. (2011) followed the development of AD-like pathology in female AβPPsw 
(Tg2576) transgenic mice and in AβPPsw/tau (P301L, Tg2576/tau) doubly transgenic mice 
after long-term ingestion of Al. Akiyama et al. (2011) gave 5- to 8-month-old single 
transgenic Tg2576 mice or double AβPPsw/tau (P301L) (Tg2576/tau) transgenic mice 400 
mg Al/L in their drinking water as AlCl3 ad libitum for 4–10 months. Assuming a body 
weight of 20 g and consumption of 5 ml drinking water/day (http://www.informatics.jax.org/
mgi-home/other/mouse_facts1.shtml), the authors estimated the daily Al dose was 100 mg 
Al/kg bw. The first groups (six mice per group) of heterozygote AβPPsw transgenic mice 
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were given deionized water or AlCl3-treated drinking water for a total of 4 months (from 
ages 8–12 months) and subsequent groups were given identical treatments from age 8 
months for ten months. The doubly transgenic (Tg2576/tau) mice were maintained on the 
AlCl3–treated drinking water beginning at 5 months of age until 14 months. Histopathology 
was examined in serial sections from whole brains of two or three mice per group. Amyloid-
β (Aβ) in all of the surviving mice and tau in the Tg2576/tau mice were determined using 
immunohistochemistry and quantitative image analyses. The Aβ was present as diffuse and 
consolidated deposits in the cerebral cortex and hippocampus. Variability between 
hemispheres and also within age groups was evident, but there was a consistent increase in 
Aβ deposition in the 18-month-old mice compared with the 12-month-old Tg2576 and 14-
month-old Tg2576/tau mice. In the 18-month-old mice, Aβ deposition was widespread and 
the frontal and temporal cortices had the highest accumulations. The differences in Aβ 
deposition between the different treatment groups were not significant for the AlCl3-treated 
group and the distilled water controls. Deposition of Aβ was not significantly different 
between treatment groups in the 14-month-old Tg2576/tau mice given AlCl3 versus those 
given distilled water. Abnormally phosphorylated tau in the brains of the 14-month-old 
Tg2576/tau mice was assessed using AT8 immunostaining; quantitative comparisons 
between sections with the highest tau accumulation found no significant differences between 
groups. Concentrations of soluble Aβ increased with age, but no significant differences were 
observed between the different groups.
In sum, Akiyama et al. (2011) described brain pathology and Aβ deposition in transgenic 
mice and found an absence of excess tau in genetically susceptible mice given 100 mg 
Al/kg-day for nine months. Akiyama et al. (2011) concluded that Al ingestion failed to 
influence the amount of soluble Aβ or Aβ oligomer (Aβ*56) or accelerate or potentiate the 
pathogenesis of AD-type lesions in mouse brain. The authors also concluded that their 
results “did not show any significant effect of long-term intake of Al on the amount of Aβ 
accumulation in Tg2576 or of Aβ and tau accumulation in Tg2576/tau mice” and that “our 
results failed to demonstrate that excess Al in drinking water, a form which is considered to 
be more bioavailable than Al in food, increases AD pathology in transgenic mouse models.” 
While Akiyama et al. (2011) did not measure Al in the different brain areas, the authors 
cited the work of Gómez et al. (2008) who found feeding Al (as the lactate) at 1 mg/g in 
rodent chow for six months (equivalent to 1.3 mg Al/kg-day) to female Tg2576 mice 
increased Al concentrations in the hippocampus, cortex and cerebellum. It is noteworthy that 
Gómez et al. (2008) found no differences in the Al content of these brain regions between 
wild-type and Tg2576 mice.
In related protocols, Ribes et al. (2010) fed Al lactate in a stock rodent chow to male wild-
type and Tg2576 transgenic mice for 210 days. Ribes et al. (2011) followed those studies by 
feeding dietary Al lactate to 15 male wild-type and 17 Tg2576 transgenic mice for 3 months. 
Ribes et al. (2011) measured Al in the cerebellum and frontal cortex and counted the 
numbers of amyloid plaques (double immunofluorescence staining for Aβ and glial fibrillary 
protein) in the hippocampus and in the parietal and temporal cortex. These results were then 
correlated with results of behavioral assessments using a functional observational battery 
(FOB) along with measures of habituation, training, and memory retention.
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Ribes et al. (2010) evaluated learning, memory, and neurogenesis in 40 male wild-type and 
transgenic Tg2576 mice. Until 5 months of age, the animals had free access to laboratory 
chow containing 27 mg Al/kg and tap water containing 14 μg Al/L. Starting from 5 months 
of age, 10 wild-type and 10 Tg2576 transgenic mice were fed the stock diet supplemented 
with Al (1.1 mg Al lactate/g) for 210 days. Ten wild-type and ten transgenic mice (control) 
were fed the stock diet. Body weight, food intake, and water consumption were measured 
monthly during treatment, but the daily Al dose was not defined. After 7 months learning 
and memory were evaluated in a Morris Water Maze without habituation. Neurogenesis 
(proliferation, survival and differentiation of hippocampal cells) was assessed two days after 
behavioral testing. Primary bromo-2-deoxyuridine (BrdU) antibodies, NeuN and GFAP were 
used for immunochemistry. Optic microscopy was used to count BrdU, BRdU-NeuN, and 
BrdU-GFAP positive cells in the granular cell layer and hilus of the right and left 
hippocampus and dentate gyrus of coronal sections of six mice from each group. No 
significant effects of genotype or Al treatment were observed in relation to long-term 
retention (one week after the acquisition) and there were no differences between genotype/
treatment groups in proliferation, survival, and differentiation of hippocampal cells. The 
authors concluded “we were unable to observe a clear effect from the Al factor” and that 
there was no effect of dietary Al or genotype on cell proliferation in the hippocampus. The 
authors measured body weight and food consumption once in every month, but the results 
were not given in the publication. Assuming average food consumption of 4.4 g/day by a 30-
g adult male mouse (Bachmanov et al. 2002), the daily Al consumption may have been on 
the order of approximately 160 mg Al/kg-day. Verification of the dietary Al concentration 
was not mentioned and this is of concern due to an error in the amount of Al in the diet 
reported in an earlier publication by this same group (Gomez et al. 2008).
Ribes et al. (2011) fed 15 wild-type and 17 Tg2576 transgenic female mice (7–8 per group) 
dietary Al lactate (1 mg Al/g) ad libitum from six until nine months of age. Control mice 
received a stock chow (Hanlan, Barcelona). No data on body weight, or food and drinking 
water consumption were provided. The dietary concentrations correspond to 3.4 mg Al/kg 
bw/day in mice given the stock diet and 54 mg Al/kg-day in the treated mice (Gomez et al. 
2008). After treatment a number of behavioral endpoints were evaluated in a FOB and the 
results were scored on a scale from 1 (normal) to 4 (severely abnormal). A novel object 
recognition test examined the numbers of rearings, distance traveled, and total time spent 
exploring. After behavioral testing, Al levels in cerebellum and frontal cortex were measured 
using a computer-controlled ICP-AES (detection limit = 1.0 μg/kg) and serum corticosterone 
was measured. Because Tg2576 mice develop amyloid plaques, ß-amyloid plaques were 
determined in Tg2576 mice only: the total number of Aß deposits was counted in the 
parietal and temporal cortex surrounding the hippocampus and in the hippocampus of both 
Al-treated and control Tg2576 mice. Two-way ANOVA revealed a significant Al effect 
(diminished) on climbing in both Al-treated wild-type and Tg2576 mice [F(1,32) = 8.724, p 
= 0.006)] with lower activity in the Al-exposed Tg2576 group (p < 0.05, Mann-Whitney 
test). There was a significant Al effect [F(1,32) = 10.702, p = 0.003] on piloerection 
(increase) in both of the Al-exposed groups compared to the controls. No effect of genotype 
or Al × genotype interaction was found. There were no significant effects of Al ingestion on 
corticosterone levels or Al concentrations in frontal cortex and cerebellum of the wild-type 
Willhite et al. Page 29
Crit Rev Toxicol. Author manuscript; available in PMC 2016 August 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and Tg2576 mice. ß-amyloid plaque depositions were observed in both the Al-fed and 
control Tg2576 animals with a higher number of plaques in the controls compared to the Al-
treated Tg2576 mice, but there were no significant differences between these groups. Ribes 
et al. (2011) found that subchronic ingestion of Al lactate was associated with increased 
piloerection and diminished home cage activity in both Al-treated wild-type and Tg2576 
mice. The Al-treated Tg2576 mice spent less time exploring new objects and this was taken 
as evidence for impaired long-term memory in the Tg2576 mice. Ribes et al. (2011) also 
concluded that increased ß-amyloid plaques in Tg2576 transgenic mice had no correlation 
with deficits in recognition memory. Perhaps the most important conclusions were that 
“neither Al treatment nor genotype had any noticeable effect on Al concentrations in frontal 
cortex and cerebellum of mice” and that “Al did not alter the recognition memory and b-
amyloid plaque loads in Tg2576 mice.”
The Akiyama et al. (2011) and Ribes (2010, 2011) data demonstrate that repeated high-dose 
Al ingestion increased brain Al concentrations, but increased brain Al failed to potentiate 
abnormal accumulation of Aβ, tau, or neuritic β-amyloid plaques in transgenic mouse 
models of AD. Since Al-induced pathology in rodent brain is different from that seen in AD 
(Wisniewski 1997, Klatzo et al. 1965), extrapolation of studies in transgenic rodents to 
assessment of human health risks posed by Al is limited.
Neurobehavioral studies in humans—Olabanji et al. (2011) measured Al in hair and 
whole blood from 43 healthy adults compared to 60 adults of whom 43 were diagnosed with 
schizophrenia, 8 who were bipolar, 7 who were diagnosed with non-specific mental illness, 
and 2 who suffered from post-partum depression. The authors suggested that the Al 
concentrations were higher in patients with behavioral disorders than in the referent group, 
but the authors admitted the higher values “may be due to considerable contamination during 
sample preparation”. The investigators were not blinded to the patient and referent samples 
and the admitted contamination is such that no useful information can be gained from the 
Olabanji et al. (2011) publication.
In a retrospective evaluation of 8 men and 22 women who had histologically confirmed focal 
Al accumulation on skeletal muscle biopsy and who were diagnosed with vaccine-induced 
macrophagic myofasciitis (MMF), Passeri et al. (2011) assessed visual memory, left ear 
extinction for interhemispheric connection using dichotic listening and signs of dysexecutive 
syndrome (characterized by generalized loss of autonomy, impaired planning ability, 
impaired abstract thinking, impaired social skills, repetitive actions, and poor impulse 
control). Participant emotional status was measured using the Montgomery/Asberg 
Depression Rating Scale and the Centre for Epidemiologic Studies Depression (CES-D) 
self-reporting system. Participants were evaluated using the Wechsler Adult Intelligence 
Scale, Digit Span test, the California Verbal Learning test, Grober & Buschke test, Benton 
Visual Retention test, Rey-Ostereith Complex Figure Recall, Verbal Fluency and Trail 
Making tests, Zazzo’s Cancellation Test for attention, and the Picture Naming DO 80 test.
Seventeen subjects were considered non-amnestic and ten were considered amnestic, but 
none were classified as demented. Depression tended to increase in 13 (72%) who had 
“severe” signs of “mild cognitive impairment” (MCI) compared to those classified as pre-
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MCI (11%) or with clear MCI (17%). When these 30 patients were given MRI scans, five 
had cortical atrophy and three had callosal atrophy, but the imaging results found no 
correlation between brain anomalies and performance on any of these cognitive tests. 
Despite the authors’ contention that “most people with MCI progress to dementia, mostly 
AD”, no assessment of patient apoE ε4 allele (Mui et al. 1996, Rao et al. 1996) or PICALM, 
ClU, CR1 and BIN1 (Harold et al. 2009, Lambert and Amouyel 2011) was undertaken. The 
Passeri et al. (2011) study is biased in subject selection, failure to include age-matched 
referents, and lack of investigator blinding to subject history.
Neurobehavioral studies in laboratory animals—Recent neurobehavioral studies in 
rodents with Al are presented in Table 2 and the more informative reports are discussed 
below. Common problems with these studies include: failure to justify the dose, frequency 
and duration of exposure and only a single concentration was examined (so there is no 
opportunity to determine dose-response); there were limited or no details on clinical signs, 
food and drinking water consumption, body weight, the chemical purity of the test material, 
verification of administered dose, and the pH of the injected, oral gavage, or drinking water 
solutions. Most of these reports had no information on the Al content in the laboratory stock 
diet or drinking water. No concurrent controls treated with equimolar doses of HCl were 
included in any of these studies (e.g., Ali et al. 2008). Providing extraordinarily high AlCl3 
concentrations results in acidic water of low palatability and this can lead to dehydration, 
reduced food consumption and reduced body weight gain. There was no report of 
evaluations of plasma urea or creatinine concentrations or other indicators of kidney 
function. Those parameters are important given the variable findings of renal toxicity 
reported in some intermediate and chronic duration Al exposure studies (ATSDR 2008). 
Most of the recent publications provide limited details on conduct of the behavioral and 
neuromotor assays and only a few include circulating or peripheral tissue Al concentrations.
Liu et al. (2010) evaluated memory, cerebral cortex, and hippocampus excitatory amino 
acids (glutamate and aspartate) and brain acetylcholinesterase (AChE) activity in male 
Kunming mice. Intraperitoneal AlCl3 was given at 100 mg/kg once every other day for 60 
days. Control mice received the same ip volume of water once every other day for 60 days. 
Learning and memory were assessed using a single trial passive avoidance task. Reduced 
performance on tests for memory, reduced glutamate, and aspartate levels and increased 
AChE activity in the Al-treated mice were reported. A related study by Kakkar and Kaur 
(2011) investigated subchronic oral gavage with 100 mg AlCl3/kg-day AlCl3 in relation to 
escape latency, hippocampus and cortex histology, brain LPO, SOC, GSH, catalase, and 
AChE activity in mice. Kumar et al. (2011) gave male rats AlCl3 by oral gavage at 100 
mg/kg-day for 42 weeks. It is not clear to what extent the reported changes in behavior, brain 
chemistry, edema, and neuron degeneration in the hippocampus and cortex may be due to 
the acidic properties of high-dose AlCl3 and the influence of HCl on peritoneal tissues, 
drinking water consumption, hydration, and health of the animals.
Other recent studies suffer from similar limitations. Abu-Taweel et al. (2011b) gave adult 
male Swiss mice daily treatment “by oral route” with AlCl3 at 0, 300, or 600 mg/kg-day in 
distilled water over 20 days. Dose-dependent reductions in social investigations, numbers of 
attacks, and numbers of fights were seen along with significant increases in latency to threat, 
Willhite et al. Page 31
Crit Rev Toxicol. Author manuscript; available in PMC 2016 August 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
latency to attack, rears, and non-social investigations. The authors reported significant 
reductions in circulating T in both Al-treated groups. Significant declines in serotonin (5-
HT) were seen at the high dose and declines in dopamine (DA) were reported at 300 and 600 
mg/kg-day. Whole brain acetylcholine (Ach) was reduced at the low dose, but Ach was 
increased at the high dose. The authors concluded that daily AlCl3 ingestion resulted in 
neurobehavioral impairment associated with reduced brain 5-HT and DA. There were no 
details on the purity or pH of the dosing solution; the numbers of mice per group was not 
identified and clinical observations, food and water consumption and body weight gain data 
were not provided. Neither pair-fed controls nor concurrent controls given equimolar doses 
of HCl were included in the study design.
Thirunavukkarasu et al. (2012) gave groups of eight rats 100 mg/kg-day of AlCl3 in drinking 
water for 90 days and evaluated anxiety and memory. Aluminum concentrations in the 
cerebral cortex and hippocampus increased 13- and 6-fold, respectively, compared to the 
controls. Rats given AlCl3 had an 8.5-fold increase in the number of escape trials and 
significant reductions in cortex and hippocampus AChE activity. Ingestion of AlCl3 was 
associated with behavioural alterations, significant reductions in brain SOD, catalase, 
glutathione peroxidase (GPx) and, reduced GSH compared to the controls.”Shrunken” 
neuronal cells with vacuolated cytoplasm and massive cellular depletion along with severe 
necrosis were noted in the cerebral cortex and hippocampus. The changes in brain histology 
might reflect the increased Al levels in the cerebral cortex and hippocampus and behavioral 
changes; however, as no histologic evaluation of the gut and no data on food or water 
consumption were provided, it is difficult to determine whether the changes in behaviour and 
oxidative stress reflect direct consequences of Al or whether the changes were secondary to 
the acidic water.
Wang et al. (2010a) described the consequences of high-dose Al on memory in rats given 0, 
2000, 4000, or 6000 mg/L AlCl3 in distilled drinking water for 90 days. Body weights and 
drinking water consumption were monitored, but no results were provided. Assessments of 
memory and learning ability were measured using the step-down test, synaptic plasticity in 
the hippocampus was evaluated using long-term potentiation (LTP), expression of protein 
kinase C, assays of mitogen-activated protein kinase (MAPK), and measures of extracellular 
signal-regulated kinases (ERK1/2) and Ca +2 calmodulin-dependent protein kinase II 
(CaMKII)) expression. Absolute and relative brain weights and Al levels in whole brain and 
blood were measured. The average daily water intake declined as the AlCl3 concentration 
increased; animals given 2000, 4000, or 6000 mg/L AlCl3 consumed 25 ± 2, 20 ± 2, and 15 
± 2 ml per rat per day, respectively. By comparison, the control rats consumed 50 ± 2 ml of 
distilled water per day. These AlCl3 concentrations in drinking water were associated with 
4–16% reductions in body weight.
A significant concentration-dependent increase in the numbers of mistakes and reduced 
latency (indicators of memory) in the AlCl3-treated rats were observed. Absolute (8–16%) 
and relative brain weights (6–11%) were reduced in the AlCl3-treated groups. Wang et al. 
(2010a) concluded that ingestion of AlCl3 reduced memory, impaired hippocampal synaptic 
plasticity, and decreased LTP induction-related kinases MAPK, ERK1/2, and CAMKII. As 
in studies by Erazi et al. (2011) and Thirunavukkarasu et al. (2012), the pH of the drinking 
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water was not reported and no concurrent controls given equimolar concentrations of HCl 
were included.
In a study similar to Wang et al. (2010a), Cui et al. (2012) investigated the influence of 
prolonged Al ingestion on learning and memory of rats by studying changes in the 
Ras/Raf/ERK signal transduction pathway. Young Wistar rats given 2000, 4000, or 6000 
mg/L AlCl3 in drinking water for 90 days had increased brain Al, reduced brain weight, and 
reduced LTP amplitude in the hippocampus. Ras protein and mRNA expression increased 
and Raf1, ERK2, and CREB declined. The authors concluded that subchronic Al exposure 
during early life may affect learning and memory as a result of Al-induced changes in the 
Ras/ERK signal pathway.
Xiao et al. (2011) gave AlCl3 in distilled water to female Kunming mice at 0 or 20 mg/kg-
day by gavage for 10 weeks. Learning and memory were measured using the Morris water 
maze. Whole brain Ach and choline acetyltransferase (ChAT) and AChE activities along 
with amyloid ß (Aß) and hyperphosphorylated tau (HFT) were determined at 8 and 10 
weeks of exposure and after six weeks of recovery (i.e., 16 weeks from the beginning of the 
study). Histologic examination of senile plaque (SP)-like and neurofibrillary tangle (NFT)-
like structures was conducted and Aß was measured using mouse anti- Aß1–42 antibody. 
After eight weeks there were no significant differences in escape latency, probing time in the 
target quadrant, or in brain Ach, ChAT and AChE activities. There were no detectable SP-
like or NFT-like structures in the cortex or in the hippocampus. After 10 weeks there was a 
significant increase in escape latency among the AlCl3-treated rats compared to the controls, 
but there were no significant differences in Ach, AChT, and AChE activities and no SP-like 
or NFT-like structures in the cortex or hippocampus. At 16 weeks (10 weeks of treatment 
+ 6 weeks withdrawal) there were no significant differences in escape latency, probing time, 
brain Ach, AChT, and AChE activities or SP-like and NFT-like structures in the cortex or 
hippocampus. Similar to the Cui et al. (2012), Thirunavukkarasu et al. (2012), Wang et al. 
(2010a) reports, Xiao et al. (2011) provided no rationale for dose selection, examined only a 
single Al dose level and the pH of the AlCl3 solution was not reported. Xiao et al. (2011) 
made no mention of Al concentrations in blood or brain or changes in body weight, food and 
drinking water consumption or clinical signs.
By and large the most recent laboratory reports (Tables 1 and 2) concerned with Al-induced 
neurotoxicity and neurobehavioral disorders have not identified exposures or outcomes that 
alter previous conclusions (ATSDR 2008, Krewski et al. 2007, Willhite et al. 2012). Some of 
the recently published studies support the plausibility that prolonged high-dose Al exposure 
can induce neurobehavioral disorders in rodents, but most of the recent studies that 
employed oral administration and high doses of Al (administered as AlCl3) were such that 
increased mortality (Kakkar and Kaur 2011) and/or systemic toxicity (e.g., reduced body 
weight) (Cui et al. 2012, Wang et al. 2010a) complicate interpretation of the results. The 
majority of the recent reports in rats used different strains, doses, routes, durations and 
frequency of exposure, and make no mention of clinical signs, body weight change and 
drinking water or food consumption. Given the lack of consistency in experimental design 
and protocols, comparisons between results are problematic. Based on studies with Sprague- 
Dawley rats injected with AlCl3 at 100 mg/kg-day for 16 weeks, Elsaid et al. (2011) 
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suggested that increased brain LPO and reduced brain AChE were “a major factor 
responsible for the memory deficit in AD”. Kaizer et al. (2008) found increased 
hypothalamus and striatum AChE and reduced cerebellar, hippocampus and cortex AChE 
after chronic Al exposures in mice, but reported reduced hypothalamus AChE activity in the 
Kaizer et al. (2005) publication. Reduced rat brain AChE activity was also reported by 
Bhadauria (2012), Chakrabarty et al. (2012), Shrivastava (2012), Stevanović et al. (2011), 
and Thirunavukkarasu et al. (2012); however, Ahmed et al. (2011), Bihaqi et al. (2009), 
Kakkar and Kaur (2011), Kumar et al. (2011), Liu et al. (2010), and Sharma et al. (2009) all 
reported increased brain AChE activity, but Xiao et al. (2011) found no significant effect of 
prolonged oral AlCl3 on mouse brain AChE. Since there are no signs of cholinergic 
stimulation or inhibition seen after high acute doses of any Al form, the clinical significance 
of changes in AChE activity (if any) are not clear. Whether these differences are due to dose, 
duration or strain or species cannot be determined given the absence of brain Al 
concentration: time profiles. Similar discrepancies between the results of other rodent 
neurobehavioral assays after Al exposures were noted previously (Willhite et al. 2012).
Several studies were identified that examined exposure of laboratory animals to water-
soluble Al materials with durations that spanned from 1 to nearly 6 months (Tables 1 and 2). 
Some of these studies used parenteral injections and others examined changes after Al 
(primarily AlCl3) by repeated oral (gavage) administration or via drinking water. The 
objective of some of these studies was to investigate the neuroprotective effects of various 
drugs or plant extracts (Kumar et al. 2011, Thirunavukkarasu et al. 2011, 2012) on Al-
induced toxicity or to investigate mechanisms of Al neurotoxicity (Cui et al. 2012, Wang et 
al. 2010a, Xiao et al. 2011) following prolonged Al administration. Only Akiyama et al. 
(2011) and Ribes et al. (2010, 2011) provided a rationale for duration of exposure and some 
(González-Muñoz et al. 2008a, 2008b) lacked concurrent vehicle controls. Many of these 
studies used a single level of Al (administered as the chloride or lactate) and examined 
sexually mature male or female rats (Erazi et al. 2011, Kumar et al. 2011, Thirunavukkarasu 
et al. 2012) or mice (Kakkar and Kaur 2011, Xiao et al. 2011). Cui et al. (2012) and Wang et 
al. (2010a) studied young rodents; Abu-Taweel et al. (2011a, 2011b), Abd El-Rahman et al. 
(2011), Kakkar and Kaur (2011), and Xiao et al. (2011) studied mature mice. The majority 
of these studies gave Al via gavage (Abu-Taweel et al. 2011, Ahmed et al. 2011, Belaid-
Nouria et al. 2012, Bihaqi et al. 2009, Kakkar and Kaur 2011, Kumar et al. 2011, 
Thirunavukkarasu et al. 2012, Xiao et al. 2011) and others employed drinking water (Abd-
Elghaffar et al. 2007, Cui et al. 2012, Wang et al. 2010a); only two of the studies examined 
more than a single dose level (Cui et al. 2012, Wang et al. 2010a). Six of the recent studies 
presented measurements of Al in the brain and blood and included brain histology along 
with results of neurobehavioral testing (Chakrabarty et al. 2012, Cui et al. 2012, Erazi et al. 
2011, Kakkar and Kaur 2011, Kumar et al. 2011, Wang et al. 2010a).
Data showing increased brain LPO in rodents (Ahmed et al. 2011, Belaid-Nouria et al. 2012) 
and rabbits (Abd-Elghaffar et al. 2007) after repeated oral dose Al are abundant. In addition 
to alterations in the activity of brain antioxidant enzymes (Table 3), Wu et al. (2012a) listed 
consistent features of the Al neurotoxic mode of action: disturbances in Fe and other metal 
homeostasis, impaired mitochondrial function as a result of increased mitochondrial O2•− 
and •OH/H2O2 and alterations in NF-κB, p53, and JNK pathways that promote apoptosis. 
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The cerebral atrophy and neuronal necrosis in rabbits described by Abd-Elghaffar et al. 
(2007) were consistent with previous reports by Rabe et al. (1982) and Yokel (1989) who 
found Al-induced neurodegeneration and neurofibrillary changes in rabbits, but the Ahmed 
et al. (2011) report of neurofibrillary tangles in Sprague-Dawley rat brain after 4 months of 
daily AlCl3 intubation and the Sun et al. (2009) report of increased cortex and hippocampus 
Aβ in Kunming mice after three months of daily AlCl3 injections are novel and unlike the 
neurofibrillary damage described by Shrivastava (2012). Nevertheless, recent 
histopathological observations in the brain of laboratory animals after Al administration via 
oral or parenteral routes have not confirmed the neuritic plaques seen in human AD and the 
recent results are not sufficient to conclude that the damage seen in animals treated with high 
Al doses Al is equivalent to that seen in AD (Klatzo et al. 1965, Wisniewski and Wen 1992; 
reviewed in Kawahara and Kato-Negishi 2011).
None of the laboratory studies reviewed here met the current international test guidelines 
and most failed to specify the source and chemical purity of the test material. The 
experimental designs of the majority were limited to only one dose level and observations 
were performed at a single time point. Given the paucity of details and the absence of 
clinical chemistry parameters and urine analyses, it is difficult to determine the health of the 
animals and their renal function. In most of these recent publications blood and tissue Al 
levels were not measured; therefore, the absorbed and distributed doses cannot be identified 
and compared to those of other animal and human studies. Overall, none of the recent 
animal studies that examined Al oral administration provided clear indications of neurologic 
damage in the absence of systemic toxicity. While several studies on Al-induced 
neurotoxicity in laboratory animals have appeared, none of the recently published studies in 
animals are adequate upon which to base oral RfD or DNEl values for metallic Al, its oxides 
or the common Al salts.
Neurotoxicity in vitro—A number of in vitro studies focused on mechanisms of Al-
induced neurotoxicity (Table 3). A brief overview of the laboratory data considered most 
relevant to Al hazard identification is provided below.
Niedowicz et al. (2011) described assembly of amyloid-β (Aβ) and the hyperphosphorylated 
pathologically folded microtubule tau polymers of the neurofibrillary tangles that together 
make up the neuritic plaques. In an effort to understand the self-aggregation of soluble 
amyloid β-peptide (Aß) responsible for the protein mis-folding that leads to development of 
insoluble “senile” plaques, Atwood et al. (1998) incubated 10 μM synthetic human Aβ1–40 
with 0.6 or 30 μM Al3+ at pH 6.6, 6.8, or 7.4. No detectable Ab1–40 aggregation was 
observed over the pH range tested in the absence of Al3+ or other metal ions. Incubation of 
Aβ1–40 with 0.6 μM Al3+ increased protein sedimentation as pH declined; incubation of 
synthetic human Aβ1–40 with 30 μM Al3+ induced partial aggregation at pH 6.6, but there 
was no significant aggregation at pH 7.4. Atwood et al. (1998) interpreted their data as 
reflecting subtle changes in Aβ1–40 conformation that account for metal ion-induced Aβ 
assembly mediated by [H+].
The Atwood et al. (1998) observations were consistent with previous reports (Barrow and 
Zagorski 1991, Burdick et al. 1992, Fraser et al. 1991, Kirshenbaum and Daggett 1995, 
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Wood et al. 1996, Zagorski and Barrow 1992) on Al concentration, pH and Aβ aggregation; 
as Al concentrations increased, there was an increase in Al+3-induced Aβ conformational 
change. Atwood et al. (1998) found that addition of Cu2+ and Zn2+ also induced Aß1–40 
aggregation at pH 6.8–7.4 and that the reaction was completely reversible with chelation or 
at higher pH. The Atwood et al. (1998) data could be taken as support for the suggestion that 
metabolic acidosis (Yates et al. 1990) associated with inflammation (Akiyama et al. 2000), 
impaired energy metabolism (Small et al. 2000) or increased oxidative stress coupled with 
the actions of ionized metals might contribute to the pathogenesis of AD and/or other 
neurologic disorders.
Many mechanistic studies (Table 3) are not directly relevant to Al hazard identification, but 
some offer (curious and/or conflicting) insights into Aβ and its interactions with Al. For 
example, Nday et al. (2010) cultured Sprague-Dawly rat hippocampal cells with 0, 10, 100, 
or 500 μM Al+3 (as AlCl3). Neuronal dendrite skrinkage and lethality increased with 
concentration and duration of exposure and neurons were far more susceptible than glial 
cells. In a companion effort, cultured mouse neuroblastoma N2a cells expressing the 
amyloid precursor protein APP695 were used to produce a supernatant that contained 8.2 pg 
Aβ1–40/ml. Addition of 750 μl of that supernatant to 96 h cultures of rat neuronal and glial 
cells reduced their survival 26 and 14%, respectively. However, when 500 μM Al+3 was 
incubated along with the same concentration of Aβ-bearing N2a supernatant, neuronal and 
glial cell survival was no different from that in cultures treated with the Aβ supernatant 
alone. When Aβ alone was added (4 days) to cultured neurons there was a significant 
reduction in polymerized tubulin, yet when 50 μM Al+3 was added to neurons cultured under 
identical conditions there was no change in polymerized tubulin compared to cultures treated 
with Al+3 alone. The most important conclusion was that there was no significant interaction 
between Aβ1–40 and Al+3 in cultured rat neurons and glial cells.
The Nday et al. (2010) conclusion appears to conflict with that by Drago et al. (2007) who 
reported reduced survival of cultured rat endothelial cells after treatment with rat or human 
Aβ1–42 and that cytotoxicity was enhanced after exposure to human Aβ-Al. The Nday 
(2010a) conclusion is also at odds with that by Drago et al. (2008) who compared the 
viability and morphology of cultured human neuroblastoma cells treated with synthetic 
Aβ1–42 or Aβ-Al, Aβ-Cu, Aβ-Fe or Aβ-Zn conjugates (prepared via Aβ-binding with bare 
ions to yield monometalated molecules). Unlike Nday et al. (2010) who found native Aβ1–40 
was cytotoxic for rat primary hippocampal neurons after 96 h incubation, Drago and 
associates (2008) found no significant toxicity of synthetic Aβ1–42 in transformed human 
neuroblastoma cells after 24 h in culture. Notably, of the Aβ1–42 metal conjugates only the 
Aβ-Al reduced cell survival. It is not clear whether the differences between the results from 
Nday et al. (2010) and Drago et al. (2008) are due to the specific nature of the N2a-produced 
Aβ1–40 compared to the synthetic Aβ1–42, to different culture conditions and durations of 
exposure, or to differential uptake of Aβ1–40 and Aβ1–42 by primary and transformed cells. 
While Aβ1–40 incubation with rat neurons and glial cells was prolonged (4 days) and 
fluorescent stains were used to measure polymerized tubulin, Nday et al. (2010) made no 
confirmation by ElISA or other means to determine the extent of mouse N2a-generated 
Aβ1–40 uptake into cultured rat hippocampal cells.
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Bolognin et al. (2011) expanded on the Drago et al. (2007, 2008) efforts and found both Aβ-
Al and Aβ-Fe induced annular protofibrils and fibrillar oligomers in cultured human 
neuroblastoma cells, yet only Aβ-Al triggered production of the amyloid precursor protein 
and tau 181 (Table 3). The latter observations were not consistent with the in vivo results 
presented by Ribes et al. (2011) and Akiyama et al. (2011) who found not only that 
prolonged ingestion of 54 or 100 mg Al/kg-day failed to increase the numbers of β-amyloid 
plaques or influence the amount of soluble Aβ or Aβ*56 oligomer, but also failed to 
influence the levels of abnormally phosphorylated tau in the brains of susceptible transgenic 
mice. In follow-up studies with cultured human neuroblastoma cells to ascertain Aβ, 
Bolognin et al. (2011) measured aggregated Aβ and Aβ-metal conjugates with 
conformation-specific antibodies to aggregated Aβ, but no direct immunoreactivity for 
monomeric Aβ was included in that protocol. Given the notable activity of small oligomeric 
Aβ species that readily diffuse through cell membranes, Bolognin et al. (2011) suggested 
that in contrast to the historical specific focus on Aβ it may be that prefibrillar and/or 
fibrillar Aβ oligomers are the primary targets of concern.
In another example, Gatta et al. (2011) examined the influence of Aβ1–42 or the Aß1–42 -Al 
complex on gene expression in cultured human SHSY5Y neuroblastoma cells and compared 
those results to gene expression profiles in cultures with Aß1–42 or Al alone. At 4°C the Aβ 
self-aggregated into short irregular protofibrils, but the Aβ-Al complex was present as 
oligomers. Media was replaced every 2 days and the SH-SY5Y cells were incubated with 
0.5 μM Aß1–42 or Aß1–42 -Al complex for 24 h. Other cultures were incubated under 
identical conditions with 5 μM Al (10-fold higher than that used in the Aß1–42-Al complex) 
as Al(C3H5O3)3 alone. Culture with the Aß1–42 Al complex induced different gene 
expression patterns compared to the patterns induced after similar exposures to Aß or Al 
alone. Of a total of 28,676 transcripts, exposure to the Aß–Al complex promoted up-
regulation of 1535 genes and down-regulation of 1815 genes. A gene subset correlated with 
clinical AD was identified from 584 AD-related genes of which 29 were up-regulated and 23 
were down-regulated. Ingenuity pathway analyses revealed that these genes were involved in 
the modulation of Ca+2 homeostasis as well as regulation of glutamatergic transmission and 
synaptic plasticity. Microarrays of 35,129 genes were conducted to investigate changes 
induced via exposure to the Aß1–42–Al (Aß–Al) complex on the expression profile. Down-
regulated genes included those involved in cell–cell signaling, inflammation and free radical 
scavenging; up-regulated genes included those involved in amino acid and lipid metabolism 
and DNA replication. Based on these results, Gatta et al. (2011) concluded that the Aß–Al 
complex might be involved in regulation of neuronal as well as synaptic function/
dysfunction and that its presence might modulate AD-related pathways including 
glutamatergic transmission, Ca+2 homeostasis, oxidative stress, inflammation and neuronal 
apoptosis. Limitations identified for the Gatta et al. (2011) study include the fact that 
cultured transformed neuroblastoma cells have limited relevance to normal neurons (Lidsky 
2014). As with all of the in vitro assays (Table 3), Aremu et al. (2011), Castorina et al. 
(2010), Gatta et al. (2011), Nday et al. (2010), and Yang et al. (2011) provided no 
justification for the Al concentrations used in their assays. None of the authors compared 
their Al concentrations examined in vitro (Table 3) to the Al concentrations measured in 
human brain or other tissues (e.g., Akatsu et al. 2011, House et al. 2012, Rusina et al. 2011).
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There is evidence to show that the tangles found in AD patients are associated with elevated 
brain Al (reviewed in Exley and House 2011, Walton 2010), but there is no consistency in 
the results of historical (Kasa et al. 1965) or recent studies of brain Al concentrations in 
patients with AD. Some studies involving bulk analyses of brain samples provide evidence 
of increased brain Al concentrations in AD patients compared to non-demented controls, 
while other studies do not. Similarly, there is no agreement between the results of different 
studies examining Al accumulation in senile plaques and neurofibrillary tangles. Different 
measurement techniques and their inherent limitations, variations in sampling strategies and 
sample handling and possible laboratory Al contamination may contribute the explanations 
for the conflicting data (reviewed in Krewski et al. 2007, Willhite et al. 2012). While Al can 
be present in senile plaques, this observation alone does not imply a direct role for Al in the 
pathogenesis of AD (Exley and House 2011, Walton et al. 2010). Wu et al. (2012a) 
summarized the current state of the science as follows:
“The controversy whether Al has a direct link to common human 
neurodegenerative diseases, such as AD, has been debated for decades. Conflicting 
data exist in the literature (Mizoroki et al. 2007, Savory and Ghribi 2007, Savory et 
al. 2006). Although it is relatively certain that Al displays multifaceted and 
complicated neurotoxicity at low dosages, some of which appears relevant to AD 
disease, there is still no evidence to link Al as a high risk factor for AD as 
happening in the general population.”
The data published to date do not support identification of Al accumulation in brain as the 
etiologic basis of AD (summarized in Wu et al. 2012a, Lidsky 2014). With respect to the Al 
hypothesis for AD (Graves et al. 1990, Kawahara and Kato-Negishi 2011, Krewski et al. 
2007, Perl and Moalem 2006, Rusina et al. 2011, Tomljenovic 2011, Walton 2010, 2012a, 
2012b), it remains unclear why Al welders and other Al workers (Akila et al. 1999, 
Giorgianni et al. 2012, Graves et al. 1998, Gun et al. 1997, Hanninen et al. 1994, Rossbach 
et al. 2006, Salib and Hillier 1996, Santibáñez et al. 2007) or people who experience very 
high prolonged Al exposures via PN, renal dialysis, and/or Al phosphate binders (Jenkins et 
al. 1989, Klein et al. 1984, Ott et al. 1982, Pei et al. 1992, 1995, Salusky et al. 1984, 1990, 
1991, Smith et al. 1986) who accumulate substantial Al body burdens (serum Al 30–40 to ≥ 
100 μg/L) and who show clinical signs of Al intoxication do not experience elevated AD 
risk.
Since AD shows heritability of up to 79% and the apolipoprotein A (apoE e4) gene increases 
AD risk, contemporary AD research focuses on the different functional loci involved in lipid 
processing (apoE, ClU, and ABCA7), cell membrane integrity (PICALM, BIN1, CD33′, and 
CD2AP), and the immune system (CLU, CR1, ABCA7, CD33, and EPHA1) all of which play 
roles in Aβ clearance and confer increased AD susceptibility (Carrasquillo et al. 2011, 
Hollingworth et al. 2011). Other research that demonstrated “seeding” small soluble 
oligomers of human Aβ (complexed with other macromolecules) or aggregates of mutant 
P301S tau induced misfolding and filamentation of wild-type tau and AD pathology in naïve 
mice suggests infectious or prion-like actions in the pathogenesis of AD (reviewed in Guest 
et al. 2011).
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Respiratory
Kongerud and Søyseth (2014) summarized factors related to development of “potroom 
asthma” among Al smelter workers. Donoghue et al. (2010) studied occupational asthma 
among employees in Al pre-bake smelters. Regular medical surveillance, including 
respiratory questionnaires and spirometry, was conducted at all smelters with intervals from 
3 months to 2 years. No information was available on ages of the workers, gender or length 
of employment. Asthma cases were identified by surveillance and a few of the cases were 
diagnosed by family physicians. Pre-placement criteria and assessment of individual 
suitability for jobs with exposure to potroom dust, fumes, and gases were introduced before 
the study period; these criteria evolved over the course of the study and these criteria were 
not uniform at all smelters. Reported parameters included a history of asthma beyond 
childhood, reduced forced expiratory ratio and evidence of reversible airway obstruction. In 
some smelters, assessment of non-specific bronchial hyperresponsiveness using 
methacholine challenge was performed. Incidence rates for occupational asthma were 
calculated for each smelter and for all smelters combined and the data were presented for 
each year of the study. All cases of occupational asthma identified among smelter employees 
(regardless of job category) were divided by the total number of smelter employees 
(regardless of job category) and the incidence rates were expressed as the number of cases 
per 1,000 employees per year. Employees who worked “in close proximity to pot fume or 
bath material for several hours a week as part of their normal job” (e.g., potrooms, potroom 
services, rodding, potlining, cryolite recovery, scrubbing, and alumina) were defined as the 
highly “bath exposed” workers. Personal sampling of inhalable particulate, respirable 
particulate, particulate fluoride (F), gaseous hydrogen fluoride (HF), and total F were 
conducted for potroom employees. The study design was such that use of personal 
respiratory protection was not taken into account.
A total of 329 cases of occupational asthma were identified and the highest rate in 1992 
(9.46/1,000 per year) declined to 0.36/1,000 per year in 2006. Of the 329 cases, 180 (55%) 
occurred in potroom employees and 243 of those occurred among employees assigned to the 
“bath exposed” areas. A number of control measures were implemented and as a result, the 
concentrations of inhalable particulate, respirable particulate, particulate F, gaseous HF, and 
total F in the workers’ breathing zone declined over the study period. Significant 
correlations were observed between reductions in asthma and reductions in total respirable 
particulate, total F, particulate F, and gaseous HF.
In contrast, Martin and Larivière (2014) described a study of 5000 employees of Canadian 
Al smelters in which the incidence of post-hire asthma was no different between fume-
exposed workers and non-exposed workers. Another study that collated symptoms among 
490 male employees (36.75 ± 6.9 years) of three Al industries (mean duration 12.3 years) 
found that 77% complained of back, shoulder and other pain, but there was no indication of 
respiratory or any other health issues (Aghilinejad et al. 2012).
Mechanistic data
Aluminum added as AlCl3 at 1, 5, 10, 50, or 100 μM to cultured human transformed HaCat 
epidermal keratinocytes or primary human dermal fibroblasts for two or three days, 
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respectively, failed to induce significant proliferation. Based on these in vitro observations, 
Jenkins et al. (2011) suggested that the (conflicting) reports of pulmonary fibrosis in workers 
exposed to fine dusts of alumina, Al pyro powders or bauxite (reviewed in ATSDR 2008) 
were not due to Al-induced proliferation of fibroblasts.
Hematology and cardiovascular
Elevated Al reduces the erythrocyte lifespan and interferes with hemoglobin synthesis; these 
factors contribute to the microcytic hypochromic anemia that develops after prolonged Al 
exposure in patients with compromised kidney function (Lin et al. 1996, Rosenlof et al. 
1990, Touam et al. 1983). This Fe—resistant anemia is due to reduced erythrocyte 
membrane integrity, inhibition of δ-aminolevulinic dehydratase, reduced Fe uptake by 
Al•transferrin, down-regulation of transferrin receptor expression and impaired intracellular 
delivery of Fe from transferrin (McGregor et al. 1990, Niemoeller et al. 2006, Rosenlof et al. 
1990).
Elshamaa et al. (2010) compared serum Al in 43 children on chronic renal dialysis (where 
dialysate Al was less than 10 μg/L) to serum Al in 43 healthy children. The dialysis patients 
used Ca acetate or carbonate to control circulating phosphate, and none of these children 
received Al-containing phosphate binders. Serum Al was significantly higher (18.4 ± 4.3 
μg/L) in renal patients than in healthy referents (6.5 ± 1.6 μg/L). The source of the elevated 
serum Al in these cases appeared to be erythropoietin (EPO).
In a cross-sectional study of whole blood Al determined in men and women with a history of 
cardiovascular incidents or diabetes or who had taken diuretics, aspirin, antihyperlipidemics, 
or “any regular drug”, Lind et al. (2011) found a significant non-linear (inverted U-shape) 
relation between Al and the prevalence of ultrasound-confirmed atherosclerotic plaques in 
the carotid artery. This relation remained after adjusting for gender, waist circumference, 
body mass index, fasting blood glucose, systolic and diastolic blood pressure, HDL and LDL 
cholesterol, serum triglycerides, smoking, antihypertensives or statins, diabetes mellitus and 
coronary heart disease. Lind et al. (2011) offered the suggestion that development of carotid 
plaques might be associated with Al-catalyzed oxidation of low-density lipoproteins.
After male Wistar rats (200–230 g) were given repeated ip injections of AlCl3 at 15 mg/kg-
day for ten days, Cheng et al. (2012) found significant reductions in erythrocyte counts, 
hemoglobin concentrations, mean corpuscular volume, mean corpuscular hemoglobin and 
hematocrit. These animals also developed increased brain LPO and reduced GST and SOD; 
however, no mechanistic data were presented to explain the anemia. The Cheng et al. (2012) 
study is compromised by study of only one exposure level and failure to provide justification 
for the relatively high AlCl3 dose. Neither the pH of the test solution, mention of concurrent 
controls given equimolar injections of HCL, nor necropsy results of the peritoneal cavity 
were reported. Reductions in erythrocyte counts were also seen after rats consumed 430 
mg/L AlCl3 in their drinking water for 90–150 days (Zhang et al. 2011a). Prolonged 
exposure to this high concentration also reduced body weight gain and the limitations to the 
Zhang et al. (2011a) report are similar to those for Cheng et al. (2012).
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There are at least two recent publications concerning the influence of elevated Al on 
vascular cells. After 0.001–100 μg/ml Al2O3 (39.7 nm) particles were cultured with human 
cardiac microvascular endothelial cells for 24 h, there was no evidence for cytotoxicity, ROS 
generation, increased cell permeability or inflammatory markers (Sun et al. 2011b). 
Compared to the potent cytolethality of Cu, Mg, and Zn oxide nanoforms in vitro, Sun et al. 
(2011a) attributed the reduced toxicity of this nano Al oxide to its larger specific surface 
area. Mikkelsen et al. (2012) compared the toxicity of particulate platelet or 30–75 nm 
kaolinite (Al2SiO5) interior wall paint dust in cultured human umbilical vein endothelial 
cells to the toxicity of crystalline Al2O3 (20–40 to 1930 nm). Cytotoxicity was significant 
only after exposure to the highest concentration (100 μg/ml) of kaolinite. The Mikkelsen 
results confirm that toxicity depends on the particular Al physical and chemical form.
Of the recent mechanistic reports that by Vota et al. (2012) is one of the more informative. 
Since high Al concentrations interfere with heme synthesis and disrupt the EPO receptor 
(Vittori et al. 2005), fresh human erythrocytes were cultured in pH 7.3 medium at 4° C for 
21 days (during which time media was refreshed every two days) in the presence of 100 μM 
AlCl3 • 6H2O (equivalent to 11 μM Al or 298 μg Al/L). By way of comparison, plasma and 
serum Al concentrations in healthy humans range from less than 1.6 to 6 μg/L (median = 3.2 
μg/L or 0.12 μM) and very high Al concentrations (to 255 μg/L or 94 μM) occur in seriously 
ill renal patients (Krewski et al. 2007). These culture conditions increased the numbers of 
acanthocytes and stomatocytes, but failed to induce hemolysis. These conditions also 
increased the concentrations of O2 •− and OH• three-fold, increased intracellular Ca and 
reduced significantly the intracellular levels of GSH. These changes and the eryptosis were 
abolished in parallel assays that included 5 mM of the antioxidant thiol N-acetylcysteine. 
The Vota et al. (2012) results implicate the pro-oxidant properties of Al+3 in its adverse 
effects on erythrocytes.
Musculoskeletal
Humans—Gherardi and Authier (2012) presented evidence for Al oxyhydroxide 
[AlO(OH)]-induced MMF after its use as an adjuvant in French hepatitis and tetanus 
vaccines. The time that elapsed from vaccination until patient presentations ranged from 0.5 
to 84 months with most MMF diagnoses made long after the initial onset of symptoms. One 
remarkable feature was that although ultrastructual examination of muscle at the injection 
site confirmed macrophages with agglomerations of submicron/micron Al inclusions, almost 
never was muscle pain or tenderness associated with the injection site, but these symptoms 
occurred either in the legs or were non-specific and diffuse. Gherardi and Authier (2012) 
suggested that uptake by antigen-presenting cells of nano-size (~13 nm) AlO(OH) particles 
as submicron aggregates facilitated Al translocation to organs distant from the muscle via 
the lymphatics. However, the current literature search found no independent definitive 
characterization of the proposed MMF or ASIA (autoimmune syndrome induced by 
adjuvants) (Shoenfeld and Agmon-Levin 2011) condition.
Laboratory animals—del Pilar Martínez et al. (2011) compared Al(OH)3-induced 
reductions in bone strength in young Sprague-Dawley rats to that caused by reduced 
atmospheric pressure (hypobaric hypoxia). Two of four groups were given 20% glycerol as a 
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control and two groups were given three ip injections of 27 mg Al/kg as Al(OH)3 per week 
for three months. One Al-treated and one vehicle control group were maintained at sealevel 
barometric pressure; one Al-treated and one vehicle control group were exposed to 
simulated hypoxia (506 mbar equivalent to 5484 m altitude) 18 h/day for 30 days. Bone Al 
increased 14–15x among the Al(OH)3-treated groups compared to the vehicle controls. 
Repeated Al(OH)3 injections also reduced the mean hematocrit and increased the percent 
reticulocytes in both the ambient and hypobaric groups. Hypoxia increased erythropoiesis, 
hematocrit, and reticulocyte counts. Body weights and femur length and width were reduced 
with prolonged hypobaric exposures, and the reductions in bone strength (ultimate, elastic 
load, and elastic energy absorption) after hypoxia were more pronounced than after repeated 
Al injections. The effect of combined Al and simulated high altitude on bone was no greater 
than hypobaric conditions alone.
Li et al. (2010) studied Al ingestion in relation to Al levels in bone and cartilage in rats. 
Healthy rats were given drinking water (free access) containing 400 mg/L AlCl3 and control 
rats were given distilled water during 150 days. Ten rats from each group were sacrificed on 
Days 30, 60, 90, 120, and 150 at which times Al in serum, bone and cartilage was measured. 
The body weights of the treated rats were significantly less than the controls beginning at 
Day 60 and the serum, cartilage, and femur Al concentrations were significantly higher in 
the Al-treated rats. The Li et al. (2010) study examined the influence of Al on bone 
metabolism during the primary phases of skeletal growth, but failures to justify the single 
high AlCl3 concentration, report Al levels in the diet, report the pH of the drinking water, 
record drinking water consumption and the absence of precautions to avoid sample 
contamination by environmental Al detract from the study. The relatively high serum Al 
levels in the control group suggest that external Al contamination may have occurred or that 
background serum Al levels were elevated due to the diet or other factors.
Li et al. (2011a) examined the influence of drinking water (pH 5.6) containing 100 mg/L 
AlCl3•6H2O (99% purity) on bone Al, Ca, and P content during growth of young rats. A 
concurrent control group was given distilled drinking water (pH 7.0) for the same 150 days 
under the same conditions. All rats had free access to water and standard pellet diet (no 
details regarding the Al content of the diet or the control drinking water were reported). The 
body weights of the Al-treated rats were significantly lower than the controls from Day 60 
until Day 150. The serum pH of the Al-treated rats was reduced (p < 0.05) on Day 150. The 
mean Al content in femurs was significantly higher than the controls beginning at Day 30. 
Bone Ca and P concentrations were reduced significantly in the Al-treated group compared 
to the controls at Day 150. Li et al. (2011a) concluded that long-term ingestion of high Al 
concentrations in drinking water led to Al accumulation in bone, inhibition of bone 
formation, and bone loss in rats.
Li et al. (2011b) then conducted a follow-up investigation on the influence of 150-day 
consumption of 430 mg/L AlCl3 in drinking water on Ca, P, and Mg during rat bone 
formation. Ten rats from each group were killed every 30 days and the Al content in right 
femurs was measured. The body weights in the Al-treated group were significantly less than 
the controls from Day 60. The mean Al content in bone increased significantly compared to 
the control on Days 30–150 and the Ca, Mg, and P levels were significantly lower in the Al-
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treated group compared to the controls on Days 120–150. The results were similar to those 
reported by Li et al. (2011a) where a 100 mg/L AlCl3 concentration in drinking water was 
also associated with reduced bone Ca, Mg, and P. Li et al. (2011b) suggested that prolonged 
consumption of AlCl3 in drinking water increased Al levels in rat bone and inhibited bone 
mineralization through disruption of trace element metabolic pathways. The major 
limitations to the Li et al. (2011b) study are similar to those described for the Li et al. 
(2011a) study.
Hirayama et al. (2011) studied the influence of age on the endogenous or “background” 
concentrations of Al in rat femur. Groups of five female Wistar rats were reared from 4 
weeks to 113 weeks on a laboratory stock diet and tap water. Elemental Al concentrations in 
the stock diet and in tap water were 60 mg/kg and 0.038 mg/L, respectively. Five rats were 
sacrificed at 5, 9, 13, 17, 21, 25, 33, 42, 50, 59, 68, 77, 85, 95, 105, and 113 weeks of age (4 
rats at 113 weeks). The mean Al concentration in bone at 17 weeks was 0.31 μg/g and for all 
ages the mean was 0.53 μg/g. Uptake rates of Al into bone varied among individual rats and 
the values were broadly distributed.
Unlike healthy humans where bone Al increases with age (Hellstrom et al. 2005, Priest 
2004), accumulation of Al in rat bone is limited. The Hirayama et al. (2011) data are 
consistent with those of Slanina et al. (1984) who found little change in the Al content of 
adult rat bone even after daily oral dosing with 100 mg Al(OH)3 for nine weeks. Very young 
rats accumulate Al in bone, but older rats tend to accumulate Al in their kidneys (Greger and 
Radzanowski 1995). This response depends on exposure in that rats can accumulate 
sufficient Al in bone to elicit osteomalacia after repeated injections of very high Al doses 
(Goodman et al. 1984, Robertson et al. 1983).
In vitro—When transparent Al ceramic (Al23O27N5 and MgAl2O4) discs (99.7–99.8% 
pure) were incubated for five days with human fetal osteoblasts, cultures with MgAl2O4 
discs had higher mitotic rates than cells cultured on Al23O27N5 discs. Other than these 
differences in proliferation there was no evidence of cytotoxicity associated with these Al 
ceramics (Bodhak et al. 2011).
Digestive tract
Lindquist et al. (2011) compared the effects of reduced fat milk (pH 6.6), tap water (pH 7.0), 
carbonated mineral water (pH 7.0), gum Arabic and 1.1 g of a commercial Al(OH)3 gastric 
antacid tablet on neutralization of 10 ml of dilute HCl (pH 1 or 2) in the mouths of 11 
volunteers (33 ± 9.3 years). Volunteers used a series of two min oral rinses after each one 
min HCl rinse (to mimic the pH of acid reflux) and the acid: base balance in the mouth was 
followed for 30 min. There was no mention of irritation or other effects of any of the 
solutions, but overall the results with Al(OH)3 were consistent with those of Meurman et al. 
(1988) who found chewing an Al(OH)3 tablet was an effective means to combat dental 
softening and erosion due to chronic acid regurgitation.
Maghraoui and coworkers (2012) examined Al deposition in the gastric mucosa of rats. At 
two h after a single gastric intubation of Al(NO3)3 at 70 mg/kg, Al was retained in the 
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cytoplasm and lysosomes of the mucosal parietal cells similar to that seen in lysosomes of 
human gastric mucosal cells after ingestion of Al(OH)3 (Florent et al. 1991). There was no 
suggestion of histologic or ultrastructural damage to the liver or gastric mucosa after 
ingestion of either Al(NO3)3 or Al(OH)3.
Renal
Patients with compromised kidney function are at increased risk for systemic Al toxicity 
(Hou et al. 2010, Jenkins et al. 1989, Yokel 2012, 2013). Azik and associates (2011) 
compared circulating Al, P, Ca, and PTH concentrations in six girls and four boys diagnosed 
with urinary tract disease (reflux nephropathy, glomerulosclerosis, glomerulonephritis, and 
neurogenic bladder) to those parameters in 12 healthy girls and 8 boys. Of the 10 children 
who were in kidney disease stages 2–4, 3 were on peritoneal dialysis (mean = 44 months) 
and one was on HD (1 month). Mean circulating Al (27.2 μg/L) was significantly greater in 
those with renal disease than in the healthy referents (2.5 μg/L). Since PTH increases Al 
uptake by stimulating synthesis of 1, 25-DHC in the kidney, Azik et al. (2011) gave these 
children a four-week course of 1, 25-DHC at 15–45 ng/kg-day. Circulating Al declined 
promptly after dosing with 1, 25-DHC.
Mahieu et al. (2003) examined renal function in relation to histology and oxidative stress in 
rats given ip injections of Al lactate thrice/week at 5.7 mg/kg-day over 90 days. These 
injections failed to influence glomerular filtration or renal clearance. Repeated ip injections 
reduced GSH and GST and increased LPO in proximal tubule cells. These cells developed 
toxicity consistent with oxidative damage induced by Al+3 as seen in other studies (Bhaduria 
2012, Kaneko et al. 2004, Viezeliene et al. 2011, 2012).
Hepatic
Signs of systemic Al intoxication are manifest in skeletal and neurological damage and 
microcytic anemia, but there are few data to suggest liver disease (e.g., fatty degeneration, 
apoptosis, necrosis) in humans as a result of either acute or chronic high-dose Al exposure 
(ATSDR 2008, Krewski et al. 2007, Willhite et al. 2012). Nevertheless, studies of the liver in 
Al-treated animals and of hepatocytes in vitro have provided valuable insights into ROS and 
apoptosis (reviewed in Percy et al. 2011, Mailloux et al. 2011).
Humans
Gatti et al. (2011) measured Al concentrations in maternal blood and in fetal liver and 
kidney (characterized as micro- and nano-scale particles) in eight aborted fetuses (21–23 
weeks gestation) afflicted with spina bifida. Those concentrations were compared to Al from 
eight referent fetuses without defects of the neural tube. Aluminum concentrations in all 
maternal blood samples were less than the analytical limit of detection (data not shown). 
Aluminum concentrations were elevated significantly in the malformed fetuses. Routine 
pathology found no anomalies in the liver or kidney of any of the abortuses.
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Laboratory animals
Alemmari et al. (2011) studied intravenous AlCl3 at 1.5 mg/kg-day in newborn piglets (1978 
± 257 g) as a model of neonatal human PN. The dose given to piglets was substantially 
greater than the mean Al (15.2 ± 8.0 μg/kg-day) received by 10 human neonates from PN 
solutions (Bohrer et al. 2010, Poole et al. 2008). This 1.5 mg/kg-day dose was 750x the 
maximum Al recommended for adults (2 mg/kg-day) by the ASCN/ASPEN (1991) and it 
was up to 300x higher than the 4–5 μg Al/kg-day dose recognized by US FDA (2013) above 
which Al accumulates and produces systemic toxicity (Fewtrell et al. 2009, Smith et al. 
2007). Groups of four piglets each received AlCl3 for one, two, three or four days or an 
equivalent volume of saline via an indwelling venous catheter. Although Alemmari et al. 
(2011) acknowledged the magnitude of their Al exposure compared to humans, the authors 
based their study design on Klein et al. (1987) who found elevated serum bile acids and 
increased hepatic lysosomes in piglets subjected to identical doses. Serial timed sacrifice 
was made and blood, urine, bile, and liver samples were collected in Al-free containers. 
Serum, urinary, and hepatic Al concentrations increased as duration of exposure increased. 
There was a direct correlation between total bile acids and urinary Al levels with hepatic Al 
concentrations. Transmission electron microscopy confirmed dilated bile caniculi, 
inflammatory infiltrate and increased numbers of Al-containing hepatic lysosomes.
In discussing these data Alemmari et al. (2012) stated that small-volume parenterals are the 
main Al source providing typical infant doses of 10–60 μg Al/kg-day. The authors noted that 
more than 80% of the Al in infant PN comes from Ca gluconate and that if an Al-free Ca 
gluconate was to be used daily infant Al exposures could be reduced 85%. Those estimates 
were confirmed in Yucatan miniature piglets given an Al-free 98% pure Ca gluconate PN 
solution that delivered 6 μg Al/kg-day compared to a standard PN that delivered 38 μg 
Al/kg-day (Alemmari et al. 2012). Neonatal injury induced by Al in PN solutions is a 
multifaceted medical issue (Wier and Kuhn 2012) involving Al-contaminated nutrients 
(soluble vitamins, lipid emulsions, trace elements, and amino acids) (Popinska et al. 2010), 
bags, burettes and syringes (de Oliveira et al. 2010), prematurity, duration of exposure, lack 
of enteral feeding and the need to sterilize PN solutions.
Other reports of Al-associated hepatotoxicity in animals are confounded by selection of the 
particular Al salt, route of administration and magnitude of the dose. After a single ip 
injection of 32.5 mg/kg Al(NO3)3, increased serum AlT and AST, reduced hepatic GSH and 
catalase activities and increased LPO were evident in the liver, kidneys, and brains of adult 
rats (Bhaduria 2012). In another example, gross necropsy of male gerbils after five day per 
week ip injections of 10.4 μmol/kg (1.33 g/kg-day) of AlCl3 found accumulations of “white 
deposits” on the surface of the liver, kidneys, mesentery and throughout the peritoneum 
(Garrosa et al. 2011). These accumulations were accompanied by peritoneal irritation, 
diffuse granulomas, focal hepatocellular degeneration, and periportal inflammation. Garrosa 
et al. (2011) compared their results to those of Fiejka et al. (1996) who found no signs of 
peritonitis after repeated 233–265 mg/kg-day ip injections of Al(OH)3 in Pzh:SFIS strain 
mice. Aluminum chloride is a potent irritant (Krewski et al. 2007) and the development of 
chronic peritonitis after repeated injections of neat AlCl3 can be attributed to its hydrolysis 
product HCl (ATSDR 2008). Garrosa et al. (2011) qualified their experiment in that “the 
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particular properties of AlCl3 solution, such as its lower pH, might account for the 
appearance of peritonitis, adherences and portal inflammation, rather than the intrinsic toxic 
effect of Al”.
Zhu et al. (2013) gave AlCl3 in drinking water to rats at concentrations sufficient to deliver 
0, 64.18, 128.36, or 256.72 mg/kg-day for 120 days. These exposures resulted in a dose-
dependent increase in liver Al, reduced body weights, reduced liver: body weight ratios, 
decreased hepatic microsomal protein and reduced hepatic cytochrome P450 enzymes. As 
neither drinking water nor food consumption were measured and given that no concurrent 
controls given equimolar doses of HCl were included, it is difficult to determine whether the 
changes were due to the actions of ingested Al or were consequences of chronic 
dehydration/inanition associated with avoidance of acidic drinking water.
A number of laboratories identified Al-induced oxidative stress as a major or contributing 
factor to damage in the liver and other organs (reviewed in Krewski et al. 2007). In a series 
of studies by Viezeliene et al. (2011, 2012) concerning potential amelioration of Al—
induced liver damage by selenite, BALB/C mice were given ip injections of 25 mg/kg AlCl3 
and 1.25 mg/kg Na2SeO3; selenite injection was made 20 min prior to administration of 
AlCl3. At 16-h post-injection there was an increase in hepatic protein synthesis and serum 
ALT, but Na2SeO3 injection alone had no influence on ALT. When Na2SeO3 was given prior 
to AlCl3 serum ALT was no different from that after AlCl3 alone. Hepatic GSH was reduced 
significantly after AlCl3, but when selenite was given prior to AlCl3 the levels of oxidized 
glutathione (GSSG) and GSH in the liver were no different from the controls. Thus, 
parenteral Al reduced both hepatic GSH and the GSH/GSSG ratio. The authors interpreted 
these changes as indicative of Al-induced oxidative stress in mouse hepatocytes secondary to 
Al disruption of hepatocyte membranes and/or interference with PO4 and ATP generation. 
Limitations to the Viezeliene et al. (2011, 2012) reports include the absence of dose-
response descriptions and measures of Al and Se in blood or liver.
These observations of Al-induced oxidative stress were consistent with those made in liver 
(El-Demerdash 2004, González et al. 2007, Yousef 2004), testes (Guo et al. 2009), kidney 
(Kaneko et al. 2004), and brain (Chakrabarty et al. 2012, Gómez et al. 2005, Kaiser et al. 
2005, Kumar et al. 2009a, 2009b, Savory et al. 1999). Mechanistic studies with ip AlCl3 
have also been conducted in adult male CF-1 mice by El-Sayed et al. (2011) and in BALB/c 
and C57BL/6 mice by Shati et al. (2011). Among mice given a single 25 mg/kg injection, 
there was a significant increase in serum ALT and TNF-α at 24 h; hepatic MDA and reduced 
catalase, GST, GPx and NADPH-quinone oxidoreductase were increased compared to saline 
controls. However, there was no change in overall hepatic glutathione levels. Pretreatment of 
identical mice with taurine at 100 mg/kg-day for five days abolished the reductions in 
hepatic catalase, GST and GPx and the authors speculated taurine acted by scavenging free 
radicals to prevent lipid peroxidation. The observations by Shati et al. (2010) are consistent 
with El-Sayed et al. (2011) in that repeated ip injection of AlCl3 in saline (pH 6.8) at 40 
mg/kg-day for 45 days increased serum ALT, AST, and bilirubin in both mouse strains. The 
liver damage was consistent with increased hepatic LPO and increased circulating 
triglycerides and total cholesterol.
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In keeping with the Al metabolic disruptions articulated by Mailloux et al. (2011), Bhasin et 
al. (2012) examined the influence of supplemental Zn (given as ZnSO4) on AlCl3—induced 
hepatotoxicity in rats. Controls were given tap water ad libitum for 2 months; a second 
group was given AlCl3 by oral gavage at 100 mg/kg-day; a third group was given drinking 
water sufficient to provide 1–2 mg Zn/kg-day and a fourth group was given Zn along with 
AlCl3. Histologic study of the AlCl3—treated rats found increased vacuolization of 
hepatocytes. Gavage with AlCl3 increased cytosolic ALT and AST and reduced hepatic 
catalase and GST. Supplemental Zn restored catalase and GST activity to control levels. 
Catalase contains four porphyrin heme (Fe+3) groups and Bhasin et al. (2012) suggested 
(consistent with Mailloux et al. 2011) that the reduced catalase may be due to Al substitution 
for Fe or that Zn induction of metallothionine acted as a free radical scavenger. However, no 
kinetic or other mechanistic studies on Al inhibition of catalase or GST were included, and 
no data on hepatic Al or Zn concentrations were provided.
Development and reproduction
Humans—The hazards associated with excessive Al in neonates and young children are 
well known (Bozynski et al. 1989, Chedid et al. 1991, Crisponi et al. 2011, Freundlich et al. 
1985, 1986, 1990, IPCS 1997, Klein 1995, Klein et al. 1982, Klein and Coburn 1994). 
Historical Al concentrations in commercial PN solutions ranged from less than 50 to as high 
as 300 μg/L, but those levels declined over time (Arnold et al. 2003) primarily as a result of 
substitution of crystalline amino acids for casein hydrolysate. Calcium gluconate continues 
to be a source of Al contamination in PN solutions (Koo et al. 1986, Hernández-Sández et 
al. 2013), but elevated Al is also due to contamined inorganic PO4 and cysteine HCl 
(Hernández-Sández et al. 2013) and it leaches from glass containers during storage and 
autoclaving (Poole et al. 2011). Beaney and Smeaton (2010) reported 4925–6160 μg Al/L in 
commercial 10% Ca gluconate packaged in glass ampules for compounding PN injections 
compared to 30–33 μg Al/L when packaged in plastic.
Patients who receive repeated intravenous doses sufficient to supply higher than 4–5 μg 
Al/kg-day can accumulate sufficient body Al burdens so as to elicit encephalopathy, 
impaired neurologic development, and osteomalacia (Bates et al. 1985, Bishop et al. 1997, 
Klein 1995, Klein et al. 1991). Popinska et al. (2010) examined 24 patients on chronic PN 
(2–14.7 years) and found their Al intake was 5.8–29.6 μg/kg-day. United States regulations 
[21 CFR 201.323] intended to control Al concentrations in large volume parenterals (25 
μg/L) were issued years ago (US FDA 1998, 2003), but there is currently no limit on the Al 
content of pharmacy bulk packages or small volume parenterals (US FDA 2013). Excessive 
iatrogenic Al exposure among neonates continues (Bishop et al. 1997, Bohrer et al. 2010, 
Fewtrell et al. 2009, 2011, Poole et al. 2008, 2011). Poole and associates (2008) examined 
records for 13,384 in-patient days for premature neonates, children with reduced renal 
function and children on prolonged PN. Using the Al content printed on the manufacturer’s 
labels for PN constituents, Poole et al. (2008) calculated daily exposures for those with body 
weights less than 3 kg (who represented nearly 50% of all patients) at 30–60 μg Al/kg-day 
or 6–12x the recommended maximum 5 μg Al/kg-day. Compliance with the recommended 
maximum Al dose using standard PN solutions could be realized only in older children with 
body weights more than 50 kg. Poole et al. (2010) then compared empirical Al 
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concentrations in 40 different PN solutions and 16 different components used to formulate 
those products to the US FDA 25 μg/L limit on Al for large-volume parenterals. Using 
patient body weights to calculate daily Al exposure, the highest dose (23 μg Al/kg-day) was 
received by the smallest infants (≤ 1 kg). After comparing the Al content in PN solutions, 
the daily Al dose was 3–5x the US FDA (2013) maximum. Investigation of constituents used 
to formulate the PN solution found that Ca gluconate and the K and Na phosphates 
accounted for the majority of the Al present in hospital pharmacy-formulated PN solutions.
In a similar effort, Bohrer et al. (2010) studied 10 preterm hospitalized infants who received 
total PN over 5–10 days. The mean total Al dose given by infusion was 186 ± 106 μg (15 ± 8 
μg/kg-day; range: 5–27 μg/kg-day). Only two of ten patients received Al at less than 5 
μg/kg-day. Although the study was restricted to a small number of premature babies (32–36 
weeks gestation), the daily Al exposure was such that a majority received thrice the 
maximum tolerable dose.
Fewtrell et al. (2009) followed the long-term consequences of Al exposure on bone in young 
people. Among 59 adolescents, 26 had received neonatal PN that provided 45 μg Al/kg-day 
and 33 were given 4.0–4.5 μg Al/kg-day. The origin of the elevated Al in these solutions was 
traced to Al leachate from glass bottles used to store Ca gluconate. Children afflicted with 
neurologic conditions or who had a prior Bailey score less than 85 were excluded from the 
study. Participants were matched for birth weights, gestation, and duration of intravenous 
nutrition. Dual-energy radiograph absorptiometry was used to measure bone mineral content 
(BMC), bone area (BA), and bone mineral density at the lumbar spine (LS), hips, and WB. 
Total neonatal Al exposure, as a continuous and categorical variable (< 55 μg/kg vs. > 55 μg/
kg), was examined in relation with adolescent bone mass after adjusting for potential 
confounders including duration of PN and severity of neonatal illness.
Mean Al intake was significantly higher for those given the standard PN solution as 
compared with those given PN with low Al. The bone density measurements tended to be 
higher in the low Al group, but significant differences were observed only for BMC and BA 
at the LS (44.9 vs. 39.8 g and 40.5 vs. 37.8 cm2, respectively). The increase in LS BMC may 
be attributable to increased bone size in the low Al group, as no difference between the 
groups in LS BMC was seen after adjusting for height, weight, and LS BA.
After adjusting for relevant neonatal variables in a nonrandomized analysis, total Al 
exposure as a continuous variable was not a significant predictor of adjusted BMC at any 
site. When Al exposure was categorized using the median (55 μg/kg) as a cut-off, children 
with high exposure had significantly lower (7.6%) hip BMC. Children who experienced 
higher Al exposure as neonates had significantly reduced lower hip BMC than children 
whose neonatal Al exposures were some ten-fold lower.
Fewtrell et al. (2011) expanded the presentation and explained the results from Bishop et al. 
(1997) wherein 227 premature (gestational age < 34 weeks) infants who received either 
standard PN (25 μg Al/dl) or reduced Al (2.2 μg/dl) PN (equivalent to daily Al of 19 ± 8 or 3 
± 1 μg/kg-day) beginning at postnatal day 2 or 3 that continued for a median 10 days. There 
were marked individual variations in the daily Al dose. For 157 of these infants (with no 
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signs of neuromotor delay at 18 months), their Al doses were associated with a one point per 
day decline on the Bayley Mental Development Index. Those declines were considered 
materially significant and children exposed to elevated Al in PN solutions were at increased 
risk for cognitive problems and educational difficulties. Of the 59 adolescents followed at 15 
years of age, no consistent differences in academic achievement, memory, intelligence and 
ability to solve complex problems (e.g., planning and organizational behavior) could be 
detected. Fewtrell et al. (2011) noted the main limitation to their conclusion was the small 
number of children available for assessment.
Zeager and associates (2012) surveyed 23 clinical laboratories in the United States that 
measure Al in serum and urine and found these facilities use different criteria. The reference 
(“background”) concentrations used to compare different patients depended on whether the 
laboratory used atomic absorption or ICP-MS. When Zeager et al. (2012) attempted to align 
biological monitoring data with Al-induced pathology, they concluded “there is currently a 
lack of data to support a correlation between Al exposure doses, Al levels measured in 
biological samples and adverse clinical outcomes”. Krewski et al. (2007) described time 
lines for Al measures in plasma, serum and urine from non-exposed healthy individuals and 
in people who consume Al antacids, in people given PN and in occupational cohorts. Plasma 
collected from volunteers with no known Al exposure generally contains ≤ 2.7 μg/L (with an 
upper normal limit of ~6 μg/L), serum generally contains up to approximately 3 μg/L and 
urine generally contains approximately 1–9 μg/L. The Zeager et al. (2012) conclusion is not 
consistent with others who have used blood and urinary Al to monitor HD patients (Pei et al. 
1992, 1995), Al welders and other industrial workers (DFG 2007, Riihimaki et al. 2008, 
Riihimaki and Aitio 2012).
Two studies (Yu and Zhang 2011, Huang et al. 2011) were identified that examined 
associations between environmental Al exposures and the risk of neural tube defects 
(NTDs). Yu and Zhang (2011) collected samples of soil, water, and food from an area with 
elevated congenital defects (study area) and from an area with lower rates. Regression 
analyses revealed a significant correlation between lower Al levels in surface and 
groundwater and elevated rates of certain birth defects. Huang et al. (2011) examined 
associations between Al in soil and NTD risk in an area that had the highest prevalence of 
NTDs in China. Aluminum concentrations were measured in soil from 112 villages and 
those values were matched with village records of birth defects. The association between 
NTDs and soil Al levels was evaluated using the maximum likelihood method. Huang et al. 
(2011) concluded that higher Al concentrations in soil were associated with increased NTD 
risk. However, no actual Al exposure data were presented and no efforts were made to 
quantify maternal folate status (Bower et al. 1993, Czeizel and Dudas 1992) or related 
genetic factors (e.g., defects in the gene for 5, 10-methylenetetrahydrofolate reductase, folate 
receptor-α) (Finnell et al. 1998, Ou et al. 1996, van der Put et al. 1995, Whitehead et al. 
1995). Nevertheless, based on the results of controlled intervention studies (Czeizel and 
Dudas 1992, Wald 1993), Oakley (1993, 2002) concluded that up to 60% of all NTDs in 
China could be reduced with supplemental dietary folate. Given these deficiencies, the 
results of the Huang et al. (2011) study are not considered reliable.
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Bell et al. (2010) conducted a county-wide ecological study wherein ambient air particulate 
matter (PM2.5) exposures were calculated for mothers of 76,788 Connecticut and 
Massachusetts infants on a per week basis. The weekly exposures were extrapolated to total 
particulate exposure by trimester. The mothers were primarily Caucasian, married and had a 
mean age of 29.3 years; tobacco was used by not more than 13% and ethanol was used by 
not more than 1.8% of the mothers. Relative PM2.5 as Al was associated primarily with 
roadway dust, but the dust also contained Si, Ca, Fe, Mn, and Ti whereas regional ambient 
air PM2.5 also contained Na, S, V, Ni and chloride (due apparently to road salt). Linear 
regression was used to relate birth weight to PM2.5 total mass, sources and constituents and 
the results were presented as change in birth weight (grams) and increased risk of small-at-
term birth per quartile range (IQR) by source, PM 2.5 and constituent. The mean ambient air 
Al concentration (0.042 ± 0.02 μg/m3) corresponded to an IQR of 0.03 (μg/m3) and this was 
associated with an 11% increased risk (3–20%; 95% CI) for low birth weight. Strengths of 
the Bell et al. (2010) study stem from the large numbers of births and adjusting for 
gestational length, infant gender, prenatal care, maternal age, ethnicity, education, and 
tobacco and ethanol consumption during pregnancy. However, the protocol did not account 
for other constituents in ambient air (e.g., CO, NO, NO2, NOx, elemental carbon, and PM2.5 
from motor vehicle exhaust) or for maternal conditions (e.g., low pre-pregnancy weight, 
anemia, antibiotics, cardiovascular disease, multiple offspring, and low socioeconomic 
status) that are associated with low birth weight (Wilhelm et al. 2012, Yu et al. 2013). 
Moreover, the chemical form of Al in the airborne dust was not identified and no personal 
sampling was conducted. Given the mixed exposures it is not possible to conclude that one 
or another individual constituent in roadway dust was responsible for the results.
Giaccio et al. (2011) measured semen volume, pH, sperm concentrations, sperm motility, 
total sperm counts, and sperm Al for 600 infertile men. No mention was made concerning 
tobacco and ethanol use among the subjects. There was no correlation between soil Al and 
reduced fertility among these men.
Laboratory animals—The reproductive and developmental toxicity of Al was examined 
by Hirata-Koizumi et al. (2011a) in a two-generation study with Al2(SO4)3 (98.5%) 
administered to Crl:CD(SD) rats. A preliminary range-finding study was conducted with 
drinking water containing 0, 1000, 3000, 10,000, and 30,000 mg Al2(SO4)3/L. Males were 
dosed for 7 weeks, beginning 14 days before mating, and females were dosed for 6–8 weeks 
beginning 14 days before mating and until PND 4. Administration of Al2(SO4)3 reduced 
water consumption, reduced body weight gain and reduced food consumption at 
concentrations 3000 mg/L or higher. Among litters from dams given 10,000 mg/L Al2(SO4)3 
or higher there was a significant reduction in pup body weights on PND 4. The rats given 
30,000 mg/L were euthanized within 2 weeks of initial exposure due to dehydration and 
marked reductions in body weight. Macroscopic examination found thickening of the 
limiting ridge in the stomach and atrophy of the thymus and spleen in rats given 10,000 
mg/L. The relative liver, thymus, and spleen weights were reduced in females given 3000 or 
10,000 mg/L.
Based on the preliminary results, the concentrations of Al2(SO4)3 selected for the main 
study were 0, 120, 600, and 3000 mg/L (equivalent to total Al daily doses from food and 
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water of 1.62–2.35, 2.96–4.72, 8.06–14.0 and 31.2–55.6 mg Al/kg-day). The pH of the 
drinking water was 3.57–4.20. Twenty-four animals per sex and group (F0 generation) were 
given Al2(SO4)3 in deionized drinking water beginning at 5 weeks of age for 10 weeks until 
mating, during mating, throughout gestation and lactation. The control animals received only 
deionized water under the same conditions. Drinking water provided to the F1 offspring 
contained the identical Al2(SO4)3 concentrations as those of their parents. Endpoints 
included clinical signs, drinking water and food consumption, and body weights. Parameters 
recorded at parturition included the number of live and dead offspring, sex ratio and the 
numbers and types of gross malformations. The F1 and F2 pups were observed daily for 
clinical signs of toxicity, and the body weights of live pups were recorded. Developmental 
parameters included sex ratios, neonatal body weights, pinna unfolding, anogenital distance 
(AGD), incisor eruption, eye opening, surface righting reflex, negative geotaxis and mid-air 
righting reflex. In the F1 pups selected as parents, the males were observed for timing of 
preputial separation and the females were observed for timing of vaginal opening. 
Spontaneous locomotor activity was assessed at four weeks of age and at six weeks of age a 
water-filled multiple T-maze test was administered.
Reproductive success was evaluated based on copulation index (%), percentage of motile 
and progressively motile sperm, sperm swimming speed and pattern, sperm counts per gram 
epididymal tissue, the percentage of morphologically abnormal sperm, precoital interval, 
fertility index, gestation index, gestation length, delivery index, estrous cycle numbers of 
litters and numbers of pups. There were no clinical signs, but drinking water consumption 
was reduced significantly in all treated groups. Body weights and food consumption of the 
F0 males and females given 3000 mg/L were reduced significantly during the first few 
weeks of the study. No treatment-related changes were observed in the numbers of litters, 
numbers of pups delivered, sex ratios or viability on PND 0, 4, and 21. Gross examination 
found no differences in the incidence of malformations in either the F1 or F2 generations.
There were no significant treatment-related effects on age at completion of pinna unfolding, 
age at incisor eruption, eye opening, or AGD in the F1 and F2 male pups and in the F1 
female pups. In the female F2 pups, the completion time of pinna unfolding on PND 2 was 
delayed in those given 600 mg/L. There were no treatment-related differences in the time to 
F1 preputial separation and there were no significant differences in righting reflex (PND 5), 
negative geotaxis reflex (PND 8), or mid-air righting reflex (PND 18). In the F1 females 
vaginal opening was delayed in those given 3000 mg/L (31.4 ± 1.7 days vs. 29.5 ± 2.1 days 
in the concurrent controls). At the time of vaginal opening, the body weight “was slightly 
heavier than the control” (119.0 ± 13.3 g vs. 109.6 ± 11.6 g) in the 3000 mg/L group. No 
significant differences were observed in male and female F1 rats regarding spontaneous 
locomotor activity or in their performance on the water-filled T-maze test.
Ingestion of Al2(SO4)3 failed to influence the oestrus cycle in either the F0 or F1 generation. 
Following the F0/F1 or F1/F2 matings there were no significant differences in copulation, 
fertility index, gestation index, precoital interval, gestation length, numbers of implantations, 
pups delivered or delivery index (i.e., number of pups/number of implantations). There were 
no significant differences regarding sperm parameters with the exception of a reduction in 
the absolute number of sperm in the F0 males given 3000 mg/L, but this change was not 
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significant when expressed as per gram of tissue. Necropsy of the F0 and F1 parents found 
no treatment-related lesions or alterations in the reproductive organs. The results provide no 
evidence for adverse effects of daily Al2(SO4)3 ingestion on ovarian or testicular function in 
Crl:CD(SD) rats.
Despite the lower relative liver and spleen weights in the F1 males, examination of the F1 
and F2 weanlings showed no treatment-related histopathology in the liver or spleen. The 
primary changes observed in rats consuming 3000 mg/L Al2(SO4)3 were the reductions in 
pup body weight on PND21 (F1 males and females and F2 females) and a slight delay in 
vaginal opening (F1 females). However, interpretation of developmental landmarks is 
difficult due to treatment-related reductions in drinking water and food consumption. Hirata-
Koizumi et al. (2011a) found it was not possible to separate the effects of the reduced 
drinking water consumption and dehydration from the possible influence of Al on offspring 
body weight. Hirata-Koizumi et al. (2011a) assigned a conservative LOAEL for parental 
systemic toxicity and reproductive/developmental toxicity of 3000 mg/L (31.2 mg Al/kg 
bw/day or 188 mg Al2(SO4)3/kg bw/day) and identified a NOAEL of 600 mg/L (8.06 mg 
Al/kg bw/day or 41.0 mg Al2(SO4)3/kg bw/day. Grip strength was not measured, precluding 
comparisons with previous studies that found significant alterations in forelimb and 
hindlimb grip strength in rodents born to Al-treated dams (reviewed in ATSDR 2008).
The reproductive and developmental toxicity of ingested Al was also examined by Hirata-
Koizumi et al. (2011b) in a two-generation reproductive toxicity study of Al ammonium 
sulfate [NH4Al(SO4)2, 99.5%] administered to Crl:CD(SD) rats in drinking water. The study 
design complied with OECD TG 416. A preliminary range finding study was conducted 
with deionized drinking water containing NH4Al(SO4)2 (AAS) at 0, 300, 1000, 3000, or 
10,000 mg/L. Administration of AAS reduced water consumption in all groups and at 
concentrations 3000 mg/L or higher water avoidance was associated with reduced body 
weights. Gross necropsy found thickening of the gastric limiting ridge at 10,000 mg/L, but 
there were no changes in any reproductive or developmental parameter. Based on the results 
of the preliminary study, the AAS concentrations for the definitive study were 0, 50, 500, 
and 5000 mg/L (equivalent to total Al daily doses from food and water of 1.56–2.39, 1.98–
3.10, 5.35–9.36, and 36.3–61.1 mg Al/kg-day). The pH of the drinking water was not 
specified. The study design and parameters measured were the same as those described for 
Hirata-Koizumi et al. (2011a).
No treatment-related deaths or clinical signs of toxicity were observed. Water consumption 
among treated rats was reduced in males and females of both generations in a concentration-
dependent manner. In the F1 males and females given 5000 mg/L, body weights were 
reduced during the first 1–2 weeks of treatment. Food consumption was reduced among the 
F0 females of the 500 and 5000 mg/L groups during the first week of treatment and during 
the second and third weeks of lactation in both F0 and F1 dams given 5000 mg/L.
There were no treatment-related differences in the numbers of implantations, delivery index, 
incidence of malformations, sex ratio, or viability index. No gross abnormalities were found 
and there were no differences in birth weights. Reduced body weights were noted among the 
F1 offspring at 5000 mg/L, but no such change was seen at the lower concentrations. There 
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were no treatment-related effects on pinna unfolding, incisor eruption, eye opening, or AGD. 
There were no differences in age at preputial separation, but a significant delay in vaginal 
opening was evident in the F1 females given 5000 mg/L (32.3 ± 1.8 days vs. 30.2 ± 2.1 days 
in controls). There were no changes in estrous cyclicity or weight or histology of the 
weanling and adult reproductive organs among rats given 5000 mg/L. There were no 
significant differences in surface righting response times or negative geotaxis reflex. There 
were no consistent differences in behavioral parameters by gender, generation, or dose. No 
treatment-related changes were detected on the water-filled T-maze or in spontaneous 
locomotor activity.
No treatment-related gross lesions were found. Changes in body weights and in absolute 
and/or relative seminal vesicle, epididymis, testis, ovary, uterus, kidney, adrenal, liver, 
thymus, brain and pituitary weights were observed at 500 and 5000 mg/L, but there were no 
dose-response relations. Hirata-Koizumi et al. (2011b) considered these findings secondary 
to the reduced body weights and attributed the reductions in growth and development of the 
offspring to “the astringent taste of AAS which would decrease the palatability of drinking 
water in the AAS-treated groups”. There were no treatment-related histologic changes in the 
male or female reproductive organs.
Hirata-Koizumi et al. (2011b) identified a LOAEL of 5000 mg/L for AAS-induced parental 
toxicity and developmental toxicity based on the reduced body weight gains and delayed 
sexual development in the F1 females. The LOAEL corresponds to 305 mg 
NH4Al(SO4)2/kg-day or 36.3 mg Al/kg-day. The NOAEL corresponds to 33.5 mg 
NH4Al(SO4)2/kg-day or 5.35 mg Al/kg bw per day. However, due to the clear treatment-
related reductions in drinking water consumption taken together with the decreased food 
consumption by the F0 and F1 dams during the later stages of lactation, it is difficult to 
determine whether reduced growth was a direct effect of Al or whether reduced growth was 
due to dehydration, inanition, and/or decreased nursing by dehydrated dams. The strengths 
and limitations of the Hirata-Koizumi et al. (2011b) study are similar to those noted for 
Hirata-Koizumi et al. (2011a). Grip strength was not measured in this study, which limits 
comparison of the results with other studies that reported changes in neuromuscular 
parameters (ATSDR 2008).
Poirier et al. (2011) conducted a combined developmental toxicity/chronic toxicity study 
with Al citrate in deionized drinking water (pH 6–7) administered to Sprague-Dawley rats 
using a design based on OECD TG 426. Doses were selected based on the results of a 90-
day pilot drinking water study and the highest concentration was based on the maximum 
solubility of Al citrate in water. The study design included groups given deionized water, Na 
citrate in deionized water or Al citrate (equivalent to 30, 100, or 300 mg Al/kg-day). Fresh 
solutions were prepared each week and the Al concentrations in water were verified by 
independent ICP-MS. The study covered continuous exposure from 6 days post-conception 
until one year after birth. Behavioral endpoints (motor activity, T-maze, auditory startle, a 
FOB targeting autonomic, and sensimotor function and physical activity, neuromuscular and 
physiological function and cognition as measured on the Morris swim maze), brain weights, 
clinical chemistry, hematology, neuropathology, and Al concentrations in blood, liver, femur, 
brain cortex, cerebellum, brainstem, and cervical and thoracic spinal cord were measured.
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Whole blood Al concentrations in the water controls, the Na citrate controls and the low-
dose Al citrate males and females were similar. By Day 23 of Al citrate exposure the highest 
Al concentration was present in whole blood (800 μg/ml) and Al concentrations declined as 
blood > brainstem > femur ~ thoracic and cervical spinal cord > cerebellum > liver > 
cerebral cortex. The high-dose Al citrate rats developed a low-grade microcytic anemia 
(reduced hematocrit, mean cell hemoglobin, and mean cell volume) and elevated serum 
alkaline phosphatase. The most notable observation was hydronephrosis. Several animals 
developed distended abdomens, only to become hypothermic and die (due to apparent 
hyperkalemia). Morbidity was elevated among the high-dose Al citrate males and the 
survivors were euthanized on study day 98.
Body weights of Na citrate-treated male and female offspring were depressed compared to 
the low- and mid-dose Al citrate groups; pup development (measured as time to vaginal 
opening and preputial separation) was delayed in the Na citrate-treated group compared to 
those given deionized drinking water, but the developmental delay was longer in those given 
the highest Al citrate concentration. Treatment of identical rats with Na citrate alone reduced 
pre-weaning body weights in both sexes and there were consistent reductions in post-
weaning body weights among the female pups. Poirier et al. (2011) considered the delayed 
sexual development treatment-related, but whether the effect was secondary to growth 
retardation as evidenced by reduced body weight is not clear. Drinking water consumption 
was greater among those given Na citrate alone, but this could be due to the elevated Na 
content of the drinking water as contrast to the citrate concentration since circulating Na was 
elevated.
The highest dose (300 mg/kg-day) exceeded the maximum tolerated dose in that at PND 84 
pup mean body weights were 30% less than control. At 100 mg/kg-day, Poirier et al. (2011) 
found no adverse effects of ingested Al citrate on memory or learning, but stated that 
neuromuscular functions (hind limb grip strength and foot splay) were impaired in the mid- 
and high-dose Al citrate groups. There was no significant difference in any FOB parameter 
for neonatal males or females. Poririer et al. (2011) assigned a LOAEL of 100 mg Al/kg-day 
and a NOAEL of 30 mg Al/kg-day based on deficits in grip strength and foot splay in the 
mid-dose group. Poirier et al. (2011) qualified their conclusion in that “the high dose of Al 
citrate is therefore considered to have had an adverse effect on body weights of male pups” 
and that “Al may affect neuromuscular performance in a dose-dependent manner, either 
primarily or secondarily to its effects on body weight in the mid- to high-dose groups.” 
While the authors considered delayed development related to ingested Al, this delay also 
occurred in the reference citrate group without Al exposure and this speaks to a relation 
between high citrate consumption and delayed development. Aluminum concentrations 
among the high-dose rats were increased in the cerebral cortex, cerebellum, brainstem, and 
thoracic spinal cord, but whether the changes in hind limb grip strength and foot splay were 
the result of Al accumulation in those tissues or were secondary to reductions in body 
weight is not clear. The high citrate concentration in the Al-treated groups and the similar 
delays in sexual maturity in the Na citrate-treated rats “due to alterations in water and/or 
food consumption” cloud the contribution of Al to the changes reported.
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Prenatal and perinatal toxicity studies—Erazi et al. (2011) evaluated the effects of 
AlCl3 administration in drinking water at 0 or 0.3% (3000 mg/L) among four groups of five 
male and female Wistar rats in two separate protocols. In the first study, rats were given 
AlCl3 beginning at 3 months of age and this continued for 4 months. In the second study, 
maternal rats were given AlCl3 from mating through gestation, parturition and lactation. 
Newborns were not treated directly. After weaning the offspring were given AlCl3 in their 
drinking water until 3 months of age. The authors measured tyrosine hydroxylase (TH) 
immunoreactive neurons using a TH-specific antibody at four months of age. Prenatal, 
lactational, and perinatal exposure of rats to AlCl3 reduced the numbers of TH reactive 
neurons within the substantia nigra, reduced immunostaining in the substantia nigra and 
reduced locomotor activity in the offspring. Erazi et al. (2011) suggested that Al-associated 
changes in neurologic parameters were more pronounced in rats exposed to AlCl3 from 
conception to maturity compared to rats given AlCl3 as adults.
The Erazi et al. (2011) report cannot be relied upon due to limitations in experimental design 
and conduct: the authors failed to account for the physical condition of their rats as neither 
body weights nor food or drinking water consumption were recorded and there were no 
measures of the pH of the AlCl3 solution. High AlCl3 concentrations result in acidic 
drinking water of low palatability, leading to dehydration, inanition, reduced body weight 
gain, and poor nursing. Since only a single concentration was examined it is not possible to 
determine dose-response. The study design included neither pair-fed controls given 
equivalent volumes of drinking water nor controls given equimolar HCl in their drinking 
water. The very small numbers of rats per group (20 litters/dose group are normally 
required) compromise the study. No effort was made to quantify either circulating or tissue 
Al. Failure to document maternal and offspring body weights and to measure drinking water 
and food consumption leaves open the possibility that changes in TH immunoreactive 
neurons were due to impaired health of these animals as contrast to an Al-specific effect. 
The reported reduced spontaneous locomotor activity among rats given AlCl3 in their 
drinking water is not consistent with Hirata-Koizumi et al. (2011a) who found no such 
changes in male and female Crl:CD(SD) rats given drinking water with 3000 mg/L 
Al2(SO4)3 (up to 338 mg/kg-day) from conception until four weeks of age.
Abu-Taweel et al. (2011a) investigated neurobehavioral changes after AlCl3 was given in 
drinking water to pregnant Swiss-Webster mice. Mated females were provided tap water or 
300 or 600 mg/L AlCl3 in tap water ad libitum from gestation day 1 through PND 15. 
Significant concentration-dependent reductions in postnatal body weight gain, locomotor 
activity, learning ability, and cognitive performance were reported. Delays in eye opening, 
hair growth and sensory motor reflex were also reported. Significant concentration-related 
reductions in dopamine and serotonin were observed in homogenized forebrain (including 
hippocampus and cerebral cortex) from PND 7 until PND 36. The authors suggested that 
prenatal and lactational exposure to high Al levels can cause developmental toxicity in mice 
The pH of the AlCl3-treated drinking water was not specified and drinking water 
consumption was not measured; the authors acknowledged: “It is likely that the present high 
concentrations of Al used in the drinking water might have affected total fluid intake due to 
its astringent properties, but no efforts were made to assess any such differences in total fluid 
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intake specifically.” Abu-Taweel et al. (2011a) assumed based on rat (Yumoto et al. 2001, 
2003) and rabbit (Yokel and McNamara 1985) data that Al administered to the mother was 
passed to the pups via milk, but there were no significant changes in the reflexes of Al-
treated pups compared to the controls at the end of lactation. The authors suggested body 
weight, learning and memory declined in the post-weaning period, but given the astringent 
properties of high-concentration AlCl3 in drinking water it is possible avoidance of the water 
and dehydration may have contributed to the reported changes.
Moselhy et al. (2011) investigated changes in rat testes after 34 mg/kg AlCl3 was given 
(apparently by daily gavage) to 45 sexually mature Wistar rats for 60 days. Five rats from 
each group were sacrificed on Days 30, 45, and 60 of treatment. No significant changes were 
observed in testis, epididymis, prostate gland, and seminal vesicle weights compared with 
the controls. Significant reductions in serum testosterone were seen in the treated rats at 30, 
45, and 60 days of exposure. Testicular MDA levels were increased 163% after 60 days and 
sperm motility was reduced significantly at 30, 45, and 60 days. The percentages of live 
spermatozoa were reduced and the numbers of total sperm abnormalities increased 304, 211, 
and 283% compared to the controls at 30, 45, and 60 days.
Histological examination of the AlCl3-treated rats revealed degeneration of spermatogenic 
cells with exfoliation into the lumen “arrows” at 30 days. At 45 days those changes 
progressed to thinning and disorganization of the seminiferous germinal epithelium. By 60 
days degeneration and necrosis of spermatogenic cells were abundant. No differences were 
seen in the epididymis between the treated and control groups at 30 days post-exposure, but 
Moselhy et al. (2011) noted desquamation and vacuolation of some epithelial cells along 
with diminished amounts of intraluminal sperm at 45 days. By 60 days the damage 
progressed to the point of complete lack or only very few sperm in the epididymal lumen. 
No significant histological changes were seen in the prostate at 30 days post-exposure, but 
by 45 days the size of the prostatic acini without intra-luminal secretions was reduced. By 
60 days the epithelium became thin with multiple calcified intraluminal deposits. 
Limitations of the Moselhy et al. (2011) study include failure to justify the dose, study of 
only a single dose level and absence of information on clinical signs, body weights or food 
and drinking water consumption. There was no mention of the pH of the AlCl3 solution. 
Thirunavukkarasu et al. (2010) described damage in the seminiferous tubules and vascular 
degeneration in the spermatogenic epithelium and Sertoli cells of rats given AlCl3 at 100 mg 
AlCl3/kg-day by gavage for 90 days. The strain, age, and numbers of rats were not provided. 
The strength of the study rests with the subchronic duration of exposure, but there was no 
effort made to study the reproductive performance of these rats and the single dose level 
precludes dose-response. Limited details on body weight and food and water consumption as 
indicative of general health of these rats limit interpretation of the Thirunavukkarasu et al. 
(2010) report. Given the absence of testicular toxicity seen in the guideline-compliant 
Hirata-Koizumi et al. (2011a, 2011b) repeated oral (2–8x higher Al) dose studies with 
Al2(SO4)3 and AAS in rats, confidence in the Moselhy et al. (2011) and Thirunavukkarasu 
et al. (2010) conclusions is reduced.
Wang et al. (2012a) gave 40 female Wistar (5 weeks old) rats free access to drinking water 
with AlCl3 to provide 0, 64.18, 128.36, or 256.72 mg AlCl3/kg-day for 120 days. These 
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doses were extrapolated based on generic mean water consumption for a 100 g rat whereas 
rats that survived to 120 days weighed 250–300g. Serum and ovarian Al concentrations, 
estrogen (E2), progesterone (P), testosterone (T), follicle-stimulating hormone (FSH), and 
luteinizing hormone (LH) were measured at termination. There were significant 
concentration-related reductions in body weight among the treated groups beginning on Day 
30 and these decrements became more pronounced by Day 120. The authors reported E(2), 
P, FSH, and LH were reduced, that serum and ovarian Al concentrations were increased in 
all Al-treated groups and that ovarian Al concentrations were greater than those in serum. 
Testosterone concentrations were significantly higher in the low- and medium-dose groups, 
but not in the high-dose group compared with controls. Wang et al. (2012a) gave no 
information on pH of the AlCl3 drinking water and food and water consumption was not 
measured. No studies of fertility or reproductive performance of the AlCl3-treated rats were 
included. Wang et al. (2012a) also reported changes in reproductive hormones of AlCl3-
treated female rats, but those conclusions failed to account for avoidance of acidic drinking 
water leading to possible dehydration and inanition as contributors to the reductions in body 
weight gain and hormonal disruptions.
This same laboratory gave 40 young male Wistar rats AlCl3 at 0, 64, 128, or 257 mg/kg-day 
in drinking water ad libitum for 120 days. Circulating levels of T and LH in the mid- and 
high-dose groups were significantly lower than in controls, but no significant changes in 
FSH were detected. Androgen receptor (AR) protein expression and the levels of AR mRNA 
expression in mid- and high-dose groups were reduced. A positive dose–response relation 
was evident between AlCl3 exposure and AR protein expression. Sun et al. (2011b) 
considered their serum T results consistent with those of Reza and Palan (2006) and Guo et 
al. (2001, 2005) who treated male rats and male mice, respectively, with daily ip AlCl3 
injections at up to 175 mg/kg-day for 20 or 12–16 days. Sun et al. (2011b) gave no measures 
of drinking water consumption so it is difficult to determine how the Al doses were 
determined. No pair-fed controls, concurrent control HCl group, drinking water pH or body 
weight data were included. Sun et al. (2011b) did not evaluate reproductive performance or 
success of AlCl3-treated rats. The limitations to the Sun et al. (2011b) report are similar to 
those in the Wang et al. (2012a) report. In the absence of Al blood and tissue data, it is 
difficult to relate results with repeated high-dose AlCl3 injections in rodents compared to the 
far lower environmental Al exposures experienced by humans.
Overall, the non-guideline studies provide limited details on test material, study design, and 
exposure conditions (e.g., the actual doses cannot be established). Common features include 
failure to account for or control the astringent properties of the acidic Al salts in relation to 
drinking water consumption and failure to account for dehydration and reduced body 
weights in relation to the parameters examined. Other than the iatrogenic skeletal toxicity 
induced by excessive Al in neonates (Bohrer et al. 2010) and impaired neurological 
development in premature infants given standard PN solutions with elevated Al (Bishop et 
al. 1997), a direct causative role of Al in production of adverse effects on reproduction and 
development has not been demonstrated. It is noteworthy the (variable) reductions in grip 
strength seen in offspring of Al maltolate-treated mice (Golub et al. 2000) were consistent 
with the reductions in grip strength seen in the offspring of Al citrate-treated rats (Poirier et 
al. 2011).
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Endocrine
Following up on a 1989 report concerning 21 Al workers with reduced circulating 
thyrotropin (TSH) and prolactin at 12–18 months after initial employment (that subsequently 
resolved; Alessio et al. 1989), Orihuela (2011) gave 7 mg Al/kg-day as Al lactate in saline 
by ip injection to adult male Wistar rats for 6 weeks. Serum concentrations of TSH, 
triiodothyronine (T3), thyroxine (T4), and Al were measured along with thyroid Al and 125I 
uptake. Among the Al-injected rats mean serum Al increased 4500x compared to the saline-
injected controls and there was a significant increase in mean thyroid Al and thyroid gland 
lPO. There was no influence of repeated daily Al lactate injections on circulating TSH or 
T4. Thyroid 125I uptake was diminished in treated rats at 25 h after Al injection compared to 
that in controls, but by 50–100 h 125I uptake was no different between the two groups. No 
justification of dose, route or duration of exposure was offered and only a single dose level 
was examined, precluding dose-response or identification of a NOAEL. Regardless, the 
authors stated: “We can conclude that in adult rats the Al would not act as a thyroid 
disruptor.”
Contini et al. (2011) compared the effects of repeated (3/week for 12 weeks) ip doses of Al 
lactate (5.75 mg Al/kg at each injection) in 8-week-old intact and ovariectomized Wistar 
rats. There were no differences in food or drinking water consumption, serum E2 or estrous 
cycles for the intact rats and none of the animals showed clinical signs of Al intoxication 
(other than body weight reductions in ovariectomized rats who remained in permanent 
diestrus). Among the Al-injected rats, serum, renal, and hepatic Al increased 150-, 19- and 
30-fold, respectively. There was no influence of repeated Al injections on serum Na or K 
concentrations despite the fact that both intact and ovariectomized Al-treated rats had 
significantly higher serum aldosterone levels than rats that remained untreated. There were 
no differences in serum osmolality, urinary K excretion, or glomerular filtration rates 
between the groups. Consistent with reports by Bhadauria (2012), El-Demerdash (2004), 
González et al. (2007), Kaneko et al. (2004), Mahieu et al. (2003), Prabhakar et al. (2011) 
and Yousef (2004), Contini et al. (2011) found that hepatic LPO increased and catalase 
activity declined in the livers and kidneys of Al-injected rats compared to the untreated 
controls.
Citing the report by Alessio et al. (1989) and describing reductions in prolactin after high Al 
exposures in lambs, rats and mice, Calejo et al. (2010) cultured AlCl3 at 300 nM—3 mM 
with primary lactrophic cells isolated from the anterior pituitary of male Wistar rats for 1–4 
days. The highest concentration tested represented the limit of AlCl3 solubility in culture 
media. After incubation with up to 3 μM AlCl3, there was no influence on cell viability. 
Identical culture with 300 μM or 3 mM caused cell death within 30 min. Calejo et al. (2010) 
noted their data were consistent with the apoptotic cell death in cultured human lymphocytes 
treated with 25 mg/L AlCl3 (Banasik et al. 2005) and deformation of human erythrocytes 
treated with 10–100 μM AlCl3 (Niemoeller et al. 2006), but none of these studies accounted 
for the influence of elevated HCl on cultured cells.
Calejo et al. (2011) followed up their earlier work by observing 14–46% reductions in 
prolactin secreted from cultured Wistar rat pituitary lactotroph cells exposed for 24 h to a 
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sub-lethal 30 μM AlCl3 concentration. This reduction was associated with reduced 
exocytosis as a result of reduced membrane capacitance, perhaps related to reductions in the 
diameter of the fusion pore size. Calejo et al. (2011) suggested the spectrum of clinical signs 
seen in chronic Al intoxication include prolactin depletion, but other than the one report of a 
transient change in prolactin among Al workers (Alessio et al. 1989), no confirmation of that 
possible connection could be located. As with their previous study, Calejo et al. (2011) 
failed to report media pH or include concurrent HCl controls.
Skin
Controversy continues over whether Al in cosmetics and personal care products presents 
health risks (AFSSAPS 2011). While case reports cannot be utilized to assess quantitative 
health risk, those observations when aggregated can provide insights for more formal 
investigation. No guideline-compliant studies in animals were located that reported dermal 
reactions after acute or short-term repeated topical exposure to Al compounds. Clinical 
trials, recent case reports and in vitro assays support Al dermal irritation after application of 
Al-containing deodorants. This local irritation is usually mild, sensitization is rare and only a 
small fraction of the Al applied to intact healthy skin is available for uptake.
Swaile et al. (2012) described use of a 6.5% AlCl3 solution in anhydrous ethanol to treat 
profuse underarm perspiration. This solution acts by diffusion into the eccrine sweat gland 
where reactions with OH−, lactic acid, and protein generate Al(OH)3 that blocks sweat 
movement to the skin surface. At the same time, HCl liberated from AlCl3 can cause local 
irritation, pain, and erythema. When 35 healthy males were treated with AlCl3 or a 
commercial underarm deodorant with Al zirconium trichlorohydrate glycine using a 
randomized block (paired comparison) design, about 10% developed irritation by Day 7 and 
Day 10, 20% had objective skin irritation.
Consistent with observations that Al+3 binds structurally diverse anions, including histidine 
and hydroxyl-containing amino acids (Rezabal et al. 2007), polypeptides (Hollender et al. 
2006, Zuo et al. 2005) and protein (Bhasin et al. 2012, Tomljenovic 2011), Swaile et al. 
(2012) noted that men with unshaven axillae experienced less local irritation than those with 
shaved skin because Al+3 bound to underarm hair. Streker et al. (2010) found that among 20 
patients (26.9 ± 4.3 years) with excessive idiopathic axillary hyperhidrosis who used a 
commercial under-arm deodorant each day for 42 days, six experienced local skin irritation. 
Based on the incidence and nature of the response, the authors concluded that daily 
application of an AlCl3 antiperspirant was “an effective, safe and inexpensive treatment” for 
idiopathic hyperhidrosis.
Garg et al. (2010) described the case of a 28-year-old woman who presented at the hospital 
with eczema in both axillae. The patient complained that her condition occurred after the use 
of deodorants that contained ACH. Patch testing was performed to the British Contact 
Dermatitis Society baseline series, in addition to a fragrance series and AlCl3. The results 
were scored according to International Contact Dermatitis Research Group criteria. This 
patient responded with a 3 + reaction to 2% AlCl3 (in petrolatum), but there was no skin 
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reaction after contact with an 8-mm Aluminum Finn Chamber®. After she avoided all Al-
containing deodorants, her eczema cleared completely.
Watson et al. (2012) evaluated whether the use of Al-based antiperspirants while receiving 
external beam radiotherapy for Stage 0, I, or II breast cancer could exacerbate local irritation 
to damaged axilla skin. A total 198 participants were randomized to either the antiperspirant 
or a standard care-wash only control group. The skin reactions in both groups were 
measured weekly and at two weeks after cessation of treatment using the National Cancer 
Institute Common Toxicity Criteria Adverse Events (version 3) criteria. No significant 
differences were observed between the antiperspirant group and the control group.
Wooley-Lloyd and Valins (2009) (as described in Yanagishita et al. 2011) investigated 
topical exposure to Al chloride hexahydrate in a salicylic acid gel for treatment of 
hyperhidrosis. Local irritation with transient itching was evident after repeated gel 
application, but it should be noted that topical antiperspirants contain not only Al salts, but 
other active non-ionic and ionic agents (Quatrale 1985). As such, the Yanagishita et al. 
(2012) observations did not quantify the irritant potential of Al constituents present in 
commercial underarm deodorants.
Immunology and vaccine adjuvants
Aluminum adjuvants (often the oxyhydroxide and/or phosphate) are included in vaccines to 
enhance and extend the immune response (Exley et al. 2010, Kool et al. 2011). After Al 
adjuvant injection, Al-containing particles are taken up via phagocytosis by an antigen-
presenting cell. These actions increase the immune response by delivery of antigen to T-cells 
in the lymph nodes (Rimaniol et al. 2004, Sokolovska et al. 2007). Immunopotentiation was 
originally attributed to the formation of a depot of antigen at the inoculation site (Glenny et 
al. 1926) suggesting it provided prolonged exposure of the antigen to the immune system 
resulting in higher antibody titers than antigen alone; adsorption of the antigen with the Al 
adjuvant has been regarded as essential to this mechanism (Gupta 1998). However, a direct 
correlation between the persistence of antigen at the inoculation site and the resulting 
antibody response has never been demonstrated (Hutchison et al. 2012).
Noe et al. (2010) studied the relation between depot formation and immunopotentiation by 
comparing the retention of antigen at the inoculation site with antibody production in rats. A 
labeled alpha casein (IDCAS) antigen was adsorbed onto either Al(OH)3 or AlPO4 adjuvant, 
or onto a non-adsorbed IDCAS with phosphate-treated AlPO4 (PTAP). The response after 
inoculation of those preparations was compared with that after injection of an adjuvant-free 
IDCAS solution. The final Al concentration in all of these formulations was 1.7 mg/ml. 
When incubated with human plasma in vitro, approximately 90% of the IDCAS eluted from 
AlPO4 within 24 h while only 25% of the IDCAS eluted from Al(OH)3 at 72 h. Those 
results suggested that antigen adsorption was higher with Al(OH)3 than with AlPO4. 
Antigen retention at the inoculation site was Al(OH)3 > AlPO4 > non-adsorbed with PTAP. 
Adsorption with PTAP was equivalent to that seen with the adjuvant-free IDCAS solution. 
However, the AlPO4-adsorbed IDCAS produced a significantly higher antibody titer in rats 
than did the Al(OH)3-adsorbed IDCAS. Antibody titers declined as: non-adsorbed PTAP = 
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AlPO4 adsorbed > Al(OH)3 adsorbed solution. These data were consistent with Hansen et al. 
(2007, 2009) and Egan et al. (2009) who found that tight antigen binding to an Al-adjuvant 
inhibited antibody production by interfering with antigen processing in dendritic cells 
(DCs), resulting in reduced T-cell activation. Tight antigen binding may also reduce B-cell 
activation by reducing the amount of antigen available for B-cell recognition in the draining 
lymph node (Hansen et al. 2007). Noe et al. (2010) confirmed the concept that Al adjuvants 
are necessary for immunopotentiation, but that a “depot mechanism” was not supported by 
their results.
Following a similar line of inquiry De Veer et al. (2010) measured uptake of particulate 
antigen from an intradermal injection in sheep by lymphocytes in the presence or absence of 
50 mg Al adjuvant (Rehydragel). De Veer et al. (2010) concluded that the Al adjuvanticity 
failed to correlate with slow antigen release, but that it correlated with retention of antigen at 
the injection site and Al increased uptake of particulate antigen by mature migratory DCs. 
Wagner et al. (2012) compared the immunogenicity of anthrax vaccine in CD-1 mice 
immunized once by ip injection of fresh Al hydrogel formulations to the same formulations 
stored at 25° or 37° C for 3 weeks. Mice immunized with freshly prepared Al formulations 
developed significantly higher antibody titers compared to mice immunized with stored 
formulations. This difference might reflect the relative stability of Al adsorption over time or 
the influence of storage conditions on the vaccine itself.
Mechanisms of Al adjuvant actions—Although Al compounds have been used as 
human vaccine adjuvants for many decades, their mechanism of action is not completely 
understood. The influence of physico-chemical parameters on both the antigens and Al 
adjuvants and the associated immune response have only recently been investigated (Clapp 
et al. 2011). Early studies by Goto et al. (1997) and Naim et al. (1997) concluded that 
adjuvanticity of Al correlated with inflammation produced at the inoculation site. These 
inflammation-related pathways include: recruitment of phagocytic cells (including DCs) to 
the inoculation site (Guyton and Hall 2000), increased antigen uptake by DCs (Morefield et 
al. 2005), activation and maturation of DCs and macrophages (Kool et al. 2008a, Sokolovska 
et al. 2007), and release of DC cytokines (Kool et al. 2008a). Recent in vitro studies 
demonstrated direct activation by Al of the NlRP3 (also known as Nalp3 or cryopyrin) 
inflammasome complex leading to the processing of several pro-inflammatory cytokines 
including IL-1ß (Eisenbarth et al. 2008, Li et al. 2008). Some authors have pointed to 
indirect inflammasome activation via Al-induced release of uric acid crystals (Kool et al. 
2008b, Lambrecht et al. 2009, Marrack et al. 2009) and their role in activation of DCs and 
macrophages (Eisenbarth et al. 2008). At the same time, others found no involvement of the 
NlRP3 pathway in macrophage (Kuroda et al. 2011), DC or lymphocyte activation by Al 
salts or adjuvants (Franchi and Núñez 2008, Li et al. 2008, McKee et al. 2009). These 
differences could be related to different Al adjuvants, test systems or the different conditions 
and protocols used in these studies.
Adverse outcomes with Al adjuvants—Recent randomised controlled trials, semi-
randomised controlled clinical trials, and comparative cohort studies that investigated the 
safety and immunogenicity of Al-containing vaccines are summarized in Table 4. Most of 
Willhite et al. Page 61
Crit Rev Toxicol. Author manuscript; available in PMC 2016 August 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the recent studies did not include groups given only the Al adjuvant, but where concurrent 
Al referent groups were included those studies are described below.
Descamps et al. (2009) studied the safety of the human papilloma virus (HPV)-16/18 AS04-
adjuvanted cervical cancer vaccine (Cervarix™) in a cohort of almost 30,000 girls and 
women aged 10–14, 15–25 and above 25 years who received the same three-dose regimen at 
0, 1, and 6 months. The AS04 adjuvant is comprised of Al(OH)3 (500 μg per dose) and 3-O-
desacyl-4′-monophosphoryl lipid A (MPl) (50 μg per dose). Reference groups were given 
equivalent injections of Al(OH)3 alone. Compliance was 93.4% for the HPV-16/18 group 
and 96.4% for the Al(OH)3 group. No immediate hypersensitivity reactions occurred and 
injection site pain (consistent with results from Chotpitayasunondh et al. (2008); Ehrlich et 
al. (2008); Romanowski et al. (2011) and Zhu et al. (2009) with other vaccines) was the 
most common acute complaint. Erythema and swelling at the injection site developed in 
those aged 15–25 and above 25 years during the 7 days after each vaccination and these 
were 2.4–3.2 times, respectively, higher in the groups given the HPV-16/18 vaccine 
compared to those given Al(OH)3 alone. Complaints of fatigue, headache, and myalgia were 
common among those given the vaccine. There were no differences between the HPV-16/18 
vaccine group and the Al(OH)3 group with regard to fatigue, fever, gastrointestinal distress, 
headache, rash, arthralgia, myalgia, and urticaria. The overall rate of serious adverse effects 
(SAEs) after injection of Al(OH)3 was almost 10 times higher in women 15–25 years of age 
than among those above 25 years (8.4% compared with 0.9%, respectively). A higher 
percentage of SAEs—including spontaneous abortion—was observed among the 15- to 25-
year olds in the Al(OH)3 group compared to HPV-16/18 vaccine group. Descamps et al. 
(2009) observed that the spontaneous abortion rate for these women was within the range 
reported for the United States and explained that the increase could be due to differences in 
the longer follow-up for those in given Al(OH)3 (5.5 years) compared to 1.5 years for those 
given the HPV-16/18 vaccine. A higher percentage of new cases of chronic asthma, urticaria 
and hypersensitivity among the 15- to 25-year olds in those given only Al(OH)3 was 
recorded compared to those given the HPV-16/18 vaccine (1.1% compared with 0.3%, 
respectively). There were no differences in the frequency of new cases of autoimmune 
disease at any age. The Descamps et al. (2009) analysis examined large sample sizes (29,953 
subjects, 45,988 vaccine doses), gave separate presentations of outcomes for the vaccine and 
Al(OH)3 groups by age and it included follow-up observations at 0–7 months, 7–12 months 
and more than 12 months.
Netterlid et al. (2013) conducted a randomized, controlled, single-blind study of Al contact 
allergy. This was a multicentre evaluation of children and adults that involved patch-testing 
with allergen extracts containing Al(OH)3 and AlCl3•6H2O in white petrolatum at 2.0, 10.0, 
and 20.0% w/w. Seventy-eight children and 127 adults completed the study and positive 
results were found in eight (5/78 children and 3/127 adults). There were no positive 
reactions to the empty Finn Chamber, but seven tested positive to 10% AlCl3•6H2O and five 
tested positive to 2% AlCl3•6H2O. Four members of the control group also tested positive to 
Al. Six of eight participants with contact allergy to Al reported previous atopic dermatitis 
and four of those six were in the exposed group. In sum, the Netterlid et al. (2013) study 
demonstrated a 3.9% proportion of Al contact allergy in atopic individuals with allergic 
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disease. Among those who developed Al-induced allergic reactions, children and adults with 
atopic dermatitis were more highly represented.
A syndrome known as MMF has been associated with prolonged Al retention (e.g., years) at 
the site of vaccinations that contained Al(OH)3 (Exley et al. 2009, Gherardi and Authier 
2012). Aluminum-containing macrophages gather in the myofascii at the injection site and 
these accumulations have been confirmed in deltoid muscle biopsy (Siegrist 2005). A small 
proportion of vaccinated people present with delayed onset diffuse myalgia, chronic fatigue, 
and cognitive dysfunction. None of the clinical manifestations commonly associated with 
MMF (fever, myalgias, arthralgia, asthenia, and muscle weakness) are specific (Israeli et al. 
2011, Gherardi and Authier 2012). A number of attempts have been made to link local 
vaccine reactions to those complaints; however, no firm etiological association with 
vaccination has been established (Lindblad 2004, Batista-Duharte et al. 2011) and these 
conditions as related to Al adjuvants remain uncertain (Shoenfeld and Agmon-Levin 2011).
A number of studies examined the potential of Al adjuvant-containing vaccines to elicit 
inflammation, attention deficit hyperactivity disorders, delays in speech or language 
development (Tomljenovic and Shaw 2011a, 2011b, 2012), neurodevelopmental delay 
(Dorea 2011, 2012a, 2012b) and impaired cognition (Couette et al. 2009). These concerns 
were highlighted by Dorea and Marques (2010) who reported that infants receiving 
immunizations were given 225–1750 μg Al per injection. On the other hand, Nøkleby (2007) 
and Mitkus et al. (2011) concluded that the risk of adverse effects including neurotoxicity 
posed by Al adjuvants received during childhood vaccinations was “low” and Ehrlich et al. 
(2008) observed only increased complaints of headache. In their study of 9600 people 
enrolled in 13 clinical trials of vaccines against influenze H5N1 virus, Manzoli et al. (2009) 
found no serious adverse events associated with Al adjuvants. Theeten et al. (2005) found 
that systemic adverse events were rare and a significant difference among Al study groups 
was found only for fatigue. The Global Advisory Committee on Vaccine Safety concluded 
there was no discernible relation between vaccinations and adverse outcomes (GACVS 
2012, Kelso et al. 2012). Limitations to the published results include “incorrect assumptions 
about known associations of Al with neurological disease, uncertainty of the accuracy of the 
autism spectrum disorder prevalence rates in different countries, and accuracy of vaccination 
schedules and resulting calculations of Al doses in different countries” (GACVS 2012).
Twenty recent clinical studies of different Al-containing vaccines were available for review. 
Some of these studies reported a diminished or limited immunogenic role for Al(OH)3 
adjuvant in certain vaccines (Brady et al. 2009, Keitel et al. 2009, Manzoli et al. 2011, Liang 
et al. 2010, Yin et al. 2011, Zhu et al. 2009). Depending on the vaccine and dose, Bresson et 
al. (2006) and Ehrlich et al. (2008) found that influenza vaccines with alum adjuvant were 
no more effective toward inducing an immune response than influenza vaccines without 
adjuvant. Zhu et al. (2009) found that influenza H1N1 vaccine without Al adjuvant was 
associated with fewer local reactions and greater immune response than vaccine with 
adjuvant. Theeten et al. (2005) suggested limited or possible stimulatory roles for Al(OH)3 
in adsorbed DTaP vaccines, but there was no clear or consistent relation between 
immunogenicity and the Al quantity in the vaccine or total Al dose. The contributions of Al 
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adjuvants to immune response after vaccination appear to vary with antigen as well as with 
patient age (Zhu et al. 2009).
Contact reactions (delayed-type hypersensitivity with painful erythematous and pruritic 
eruptions, edema, and blistering) to Al at injection sites do occur (Table 5), but they are rare 
(Bergfors et al. 2005, Ehrlich et al. 2008, Leventhal et al. 2012, Zhu et al. 2009). These 
reactions can develop weeks, months, or even years after injection of an Al-containing 
vaccine (Leventhal et al. 2012). Histological examinations of biopsies from the injection 
sites revealed granulomatous and foreign body reactions (Garcia-Patos et al. 1995) and 
people with hypersensitivity to Al-containing vaccines generally demonstrate positive patch 
testing to Al (Bergfors and Trollfors 2012, Beveridge et al. 2011, Lehman et al. 2008, 
Netterlid et al. 2013).
There is little consistency among the 20 studies regarding their designs, event definitions, 
event types, and the age categories examined. The diversity of protocols, vaccines, methods, 
and data presentation in these publications makes it difficult to determine the relative safety 
of different Al adjuvants present in the different vaccines. Given the absence of standardized 
quantitative measures designed to calculate the therapeutic ratio, the comparative safety 
and/or efficacy of Al adjuvants in these vaccines, especially in children and pregnant women 
(Wijnans et al. 2011), remains unknown. Moreover, no formal effort was identified to 
establish causality between the systemic reactions following immunization with an Al 
adjuvant. A number of recent case reports describe delayed hypersensitivity after vaccination 
with Al adjuvants (Table 5) and while those results are suggestive, case reports cannot be 
considered definitive evidence for or the circumstances under which Al adjuvant injections 
may elicit undesirable effects in humans. In a 2012 study, Yokel found that of the Al present 
in pediatric vaccines (125–330 μg/dose) the amount absorbed each day from the depot was 
approximately 0.07 μg/kg (assuming 30 injections over the first 6 years of life and a mean 
body weight of 20 kg). The lack of suitable experimental models and standardized predictive 
methods, mixed exposures (Dorea 2010, 2012a, 2012b, Marques et al. 2010), issues in 
quantifying immunotoxicity and problems with detecting rare events make determination of 
causal relations between vaccines, their Al content and adverse outcomes difficult (Batista-
Duharte et al. 2011).
Laboratory animals—Recent reports on immune system parameters in rats exposed 
orally to Al are summarized in Table 6. Details of the multi-generation bioassays by Hirata-
Koizumi et al. (2011a, 2011b) with Al2(SO4)3 and NH4(Al(SO4)2 in rats are described at the 
preceding discussion of developmental toxicity. Findings there include reduced absolute and 
relative thymus and spleen weights after ingestion of 3000 ppm Al2(SO4)3 in drinking water, 
but necropsy found no dose-related histologic lesions in those organs. Interpretation of the 
reduced spleen and thymus weights is problematic due to the reductions in drinking water 
and food consumption. The Hirata-Koizumi et al. (2011b) study with NH4Al(SO4)2 also 
found reduced absolute and relative thymus and spleen weights. As these changes may be 
related to maternal dehydration and inanition the utility of these observations for health risk 
assessment is limited.
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There is some evidence that repeated exposure to high doses of different Al forms may 
stimulate (Lauricella et al. 2001, Yoshida et al. 1989) or suppress the immune response in 
rodents (Golub et al. 1993, Khalaf et al. 2008, Yoshida et al. 1989). Tsunoda and Sharma 
(1999) found no change in mRNA expression for cytokines TNF α, IL-1 β, and INFγ in 
peripheral cells of the immune system (TNF α and IL-1βin splenic macrophages and INFγ 
in splenic lymphocytes) of mice given Al2(SO4)3 in their drinking water at 0, 5, 25 or 125 
mg/L (equivalent to 0, 0.95, 4.3, and 21 mg Al/kg-day) for one month. An effect of Al on the 
rodent immune response appears to vary with age, dose, onset, and duration of exposure 
(Glynn et al. 1999, Becaria et al. 2006), study design and/or physiological state (Khalaf et al. 
2008, Yoshida et al. 1989). There is some evidence to suggest that changes in the immune 
system after high-dose Al exposure during development may be more pronounced in the 
offspring than in the dams (Khalaf et al. 2008). Zhu et al. (2012b) found decreased relative 
spleen weights in rats following ingestion of AlCl3 at up to 256 mg/kg-day during 120 days 
and suggested that Al immunotoxicity could be due to disruption of Fe, Cu, and Zn in the 
spleen and interference with cytokines that regulate immune activation and homeostasis. 
Golub et al. (1993) suggested that Al-induced immunosuppression might result from a 
specific extrinsic effect, from a specific intrinstic deficit or from nonspecific disruption of 
physiological, hormonal or metabolic processes. At the present time, the underlying 
mechanisms associated with an immunological role for Al in rodents cannot be defined.
Genotoxicity
Krewski et al. (2007) concluded that Al compounds produced mostly negative results in 
standard short-term prokaryotic and eukaryotic test systems. Some of the early studies with 
soluble Al conducted in mice and rats produced mixed results. Recent data point to cell 
culture conditions and administration of excessively high (near-lethal) doses that contribute 
to the mixed results seen in the earlier reports.
Laboratory animals—Turkez et al. (2010) studied the clastogenic activity of Al in 
hepatocytes of adult male Sprague–Dawley rats (8-weeks old, 5 animals per group) after 
gavage with 34 mg/kg bw AlCl3 along with 50 mg/kg bw propolis for 30 days. Turkez et al. 
(2010) found that repeated gavage with AlCl3 induced a significant increase in the numbers 
of micronucleated hepatocytes (MNHEPs). Simultaneous administration of propolis 
attenuated the increased numbers MNHEPs induced by oral AlCl3. Repeated high oral doses 
of AlCl3 also caused a significant increase in alkaline phosphatase, transaminases (AST and 
ALT) and LDH and induced histopathological changes in the liver. The authors suggested 
the observed clastogenicity after oral AlCl3 may have been mediated, at least in part, by free 
radicals (Abubakar et al. 2003). Similar MNHEP results were obtained after four repeated 
daily ip injections of 5 mg/kg of AlCl3 in rats (Turkez et al. 2013). There was no 
justification for the doses examined, there was no study of dose-response and the genetic 
damage occurred after exposures that induced cytotoxicity. As written, it is not possible to 
exclude the possibility that the genetic damage was associated with oxidative stress in the 
liver as contrast to direct actions of trivalent Al.
Geyikoĝlu et al. (2013) conducted a liver MN assay in adult male Sprague-Dawley rats 
given daily ip injections of AlCl3 at 5 mg/kg-day for 10 weeks. A control group of six rats 
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received daily ip injections of saline. The MN assay was performed in accord with methods 
described by Turkez et al. (2010). Daily injections of AlCl3 over 10 weeks resulted in a 4-
fold increase in the numbers of MNHEPs. Histopathology suggested that the clastogenicity 
might be a consequence of cytotoxicity. These findings mirrored those by Manna and Das 
(1972) who found increased CAs in mouse bone marrow following repeated ip injections of 
AlCl3. The Geyikoglu et al. (2013) report failed to identify the pH of the injected AlCl3 
solution, there were no concurrent controls given equimolar injections of HCl and there were 
no measures of circulating or tissue Al concentrations.
Cytotoxicity and genotoxicity in vitro—Table 3 summarizes recent observations on Al 
toxicity in cultured cells. Data considered more relevant to weight of evidence comparisons 
are described below.
Turkez and Geyikoĝlu (2011) conducted CA and SCE assays with Al2(SO4)3 in cultured 
human lymphocytes. Blood was collected from three healthy non-smoking donors with no 
history of exposure to genotoxic agents. The Al2(SO4)3 concentrations tested were 0, 10, 
and 20 μg/ml (equivalent as 0, 1.57 and 3.15 μg Al/ml). Addition of 10 μg/ml Al2(SO4)3 
failed to influence the frequency of SCEs or CAs; identical study with 20 μg/ml increased 
the frequency of SCEs per cell and CAs compared with controls, but the change was not 
biologically significant (< 2-fold change in SCEs/cell as shown in publication Figure 1). 
There was no effect of Al2(SO4)3 at 10 μg/ml on oxidative stress markers in erythrocytes, 
but treatment with 20 μg/ml reduced erythrocyte GSH and caused significant decrements in 
the activities of antioxidant enzymes (G-6-PDH, SOD and catalase). The authors suggested 
that the increased SCEs and CAs seen at 20 μg/ml were the result of reduced antioxidant 
enzyme activity. The Turkez and Geyikoglu (2011) protocol examined only one time point 
and no reference mutagen (positive control) was included. Only thirty well-spread 
metaphases were scored per sample for the CA assay whereas OECD Test Guideline #473 
requires at least 200 well-spread metaphases. The number of second cycle metaphases 
examined for SCEs was not reported. The highest Al concentration (3,157 μg/L) was ~300x 
the Al concentrations (1.9–10.3 μg/L) present in normal human plasma and serum (Krewski 
et al. 2007). No control cultures treated with equimolar concentrations of H2SO4 were 
included, there was no mention of media pH and there was no mention of light microscopic 
evaluations of these cells. Structural CAs can occur as a result of cytotoxicity (Galloway et 
al. 2000) and in the presence of > 50% cytotoxicity, CA increases are most all artifactual and 
can represent false positives (Battersby 2007, Kirkland et al. 2007, Galloway 2000). 
Cytotoxicity, solubility of the compound in the test system, changes in pH and changes in 
osmolality must always be considered in selection of the highest test substance concentration 
in these assays (OECD Test Guideline 473). Overall, the results of the Turkez and Geyikoglu 
(2011) study are equivocal.
Sappino et al. (2012) investigated 0, 10, 100 or 300 μM AlCl3 or ACH (purity ≥ 99%) in 
cultured MCF-10A cells and in cultured human primary mammary epithelial cells. Sappino 
et al. (2012) suggested that “at the expected pH of the cell culture medium (pH ~7.2), AlCl3 
and ACH yield the same dissociation product, aluminum hydroxide”. There were no visual 
precipitates in these cultures and addition of AlCl3 had a minor effect on pH. Incubation of 
MCF-10A cells with 100 μM AlCl3 for six weeks induced loss of contact inhibition and 
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increased anchorage-independent growth. Culture of MCF-10A cells with 100 or 300 μM 
AlCl3 reduced the numbers of cells, but there were no signs of apoptosis. Culture with 10, 
100 or 300 μM AlCl3 increased the percentage of senescence-associated ß-galactosidase-
positive cells in proliferating MCF-10A cells after 7 days. At the same time, exposure to 100 
or 300 μM AlCl3 increased the expression of p16/INK4a, a cyclin-dependent kinase 
inhibitor and tumour suppressor that enforces growth arrest (Baker et al. 2011). The addition 
of 10, 100 and 300 μM AlCl3 increased DNA DSBs in a dose- and time-dependent manner 
in proliferating MCF-10A cells, but it had little or no effect on proliferating HaCaT 
keratinocytes. There was no influence of AlCl3 on X-ray induced DSB repair in MCF-10A 
cells, but there was upregulation of the p53/p21 pathway. Companion studies found no 
effects of AlCl3 on anchorage-independent growth in HaCaT keratinocytes or C26Ci human 
colonic fibroblasts cultured for 17 weeks in the presence of 300 μM AlCl3. Based on their 
results with MCF-10A cells, Sappino et al. (2012) suggested that AlCl3 (at up to 300 μM or 
60 μM as Al) induced proliferation, increased DSBs and accelerated senescence. According 
to the authors, the results indicated that induction of DSBs by AlCl3 treatment occurred 
slowly, suggesting that this effect was indirect and possibly cell specific.
A number of observations can be made with regard to the Sappino et al. (2012) report. There 
was no justification offered for the Al concentrations examined and no empirical data were 
provided to support the suggested correlations between ACH and AlCl3 exposures. The Al 
concentrations examined by Sappino et al. (2012) were 800–4200x the median 0.07–0.38 
μM (< 10 μg/L) present in serum and plasma of healthy people (reviewed in Krewski et al. 
2007). No positive control group was included, no equimolar HCl controls were included 
and it was not clear if the expected pH (7.3) was measured in fresh or long-term culture 
media. Since cytotoxicity increases after in vitro exposure to HCl and other acids (Morita et 
al. 1992) and weakly acidic conditions (pH 6.6–6.8) are mutagenic and clastogenic for 
cultured cells, it is possible that the Sappino et al. (2012) findings (even at non-cytotoxic 
concentrations) reflect oxidative stress (e.g., increased free radicals and ROS associated with 
LPO) associated with HCl. While Sappino et al. (2012) pointed to positive results from other 
Al studies, exposure to acidic media in those older reports cannot be excluded (reviewed in 
Krewski et al. 2007). There is evidence to support the fact that acidic conditions in cultured 
human (Morita et al. 1992, Güngör et al. 2010) and rodent (Cifone et al. 1987, Morita et al. 
1989, 1992) cells can increase the numbers of CAs (e.g., chromatid breaks and gaps). At 
neutral pH AlCl3 transforms to Al trihydroxide and Al oxidehydroxide and these hydroxides 
precipitate (Mayeux et al. 2012). While Sappino et al. (2012) stated that they did not observe 
visually-evident precipitates (detection method not reported), microscopic Al precipitates 
may have existed in these cultures (particularly at the highest concentration). Therefore, in 
the absence of data on cytotoxicity, it is possible that these cells were exposed to HCl and 
Al(OH)3 particulate and that the findings are associated with acidic media and particulates 
as contrast to a direct genotoxic effect of Al+3.
Lima et al. (2011) summarized older reports on the genotoxic activity of Al-containing 
atmospheric dust, Al(NO)3, AlCl3 and irradiated Al ions. Other reports examined treatment 
of cells from Parkinson’s patients with 1 mM Al and study of waste materials from an Al 
products factory. These reports included results with cultured V79–4 Chinese hamster cells, 
cultured Balb c3T3 cells, Vicia faba and Allium cepa cells. The results with the waste 
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materials are confounded by a positive response in S. typhimurium tester strains associated 
with aromatic amine contaminants. Based on polyploidy and clastogenesis in cultured 
human lymphocytes with 5–25 μM AlCl3 (Lima et al. 2007), Lima et al. (2011) considered 
AlCl3 genotoxic. Lima et al. (2011) also noted cytotoxicity at those same concentrations and 
that gaps were included in the statistical comparisons of breaks and reduplications. 
Therefore, the Lima et al. (2007) conclusions regarding structural and numerical 
chromosome aberrations induced by AlCl3 may be called into question. Certainly all of the 
concentrations examined by Lima et al. (2007) are 42–360× higher than the mean or median 
Al concentrations in serum and plasma from healthy infants and adults (1.9–10.3 μg/L or 
0.07–0.38 μM) and in patients on PN (15.9 μg/L or 0.59 μM). The Al concentrations 
employed by Lima et al. (2007) are consistent with serum Al concentrations (to 808 μg/L or 
29.7 μM) in HD patients who died as a result of Al intoxication (reviewed in Krewski et al. 
2007). The conclusions reached by Lima et al. (2011) contrast with those drawn by others 
based on results of standard short-term in vivo and in vitro assays with water-soluble Al salts 
(IPCS 1997, Krewski et al. 2007, Willhite et al. 2012).
After correlating Al concentrations with reductions in % adenine + thymine interphase 
(quiescent) heterochromatin in relation to 50–500 nM Al2(SO4)3 inhibition of RNA 
polymerase II-mediated transcription in human neuronal glial cells, Lukiw (2010) 
formulated his ‘Al compaction’ hypothesis. This theory is based on Al+3 affinity for binding 
A-T nucleotides and suppression of regulatory promoter gene expression compared to Al+3 
affinity for G-C rich templates. This theory recalls Al binding to nucleotide phosphates 
previously held responsible for in vitro binding of Al(OH)2+ to DNA and that was thought to 
reduce unwinding at pH 6–7.5 and contribute to DNA crosslinking (Karlik et al. 1980). 
Lukiw (2010) presented neither in vivo nor other direct in vitro evidence to support the DNA 
binding theory in relation to Al-induced cytotoxic or genotoxic activity.
Carcinogenicity
It has been recognized for at least 30 years that exposures during Al production present an 
increased risk of lung and bladder cancer (IARC 1987). This increased risk has been 
attributed to the presence of known carcinogens including polynuclear aromatic 
hydrocarbons in those operations (ATSDR 2008). Gibbs and Labrèche (2014) confirmed 
those observations and noted that the airborne concentrations of benzo[a]pyrene are used as 
an index of exposure to carcinogenic (benzene-soluble) coal tar pitch volatiles. Krewski et 
al. (2007) concluded that experimental studies in animals failed to demonstrate 
carcinogenicity attributed solely to Al exposure. No reports of recent carcinogenicity 
bioassays or initiation/promotion protocols with any Al form were located in the open 
literature. Recent epidemiologic data and case reports are compared below with those 
summarized by Krewski et al. (2007).
Friesen et al. (2009) investigated associations between alumina and bauxite dust exposures 
with circulatory and respiratory disease mortality and cancer in employees of four bauxite 
mines and three alumina refineries. These individuals were employed on or after January 1, 
1983. For people employed prior to the initial 1995–1996 survey, work history and smoking 
status were obtained from company records. Outcomes were determined by linkage with the 
Willhite et al. Page 68
Crit Rev Toxicol. Author manuscript; available in PMC 2016 August 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
national mortality database and the national and state cancer incidence registries. 
Cumulative exposure to inhalable bauxite and alumina were estimated using a task-exposure 
matrix for those employed during 1995/1996. A less detailed job-exposure matrix was 
required for subjects who left employment before 1996. Before 1998, total dust was 
measured using a NIOSH cassette that was subsequently found to underestimate the 
inhalable fraction. Measurements taken after 1998 used an Institute of Medicine 
recommended device to quantify inhalable dust. The study cohort had a mean age of 32 
± 10.5 years at entry, a mean duration of 14.1 years and a mean person-year (PY) 
contribution of 16.2 ± 4.8 years (equal to 93,420 PYs of follow-up). A greater percentage of 
the bauxite-exposed workers were either current (29% vs 24%) or former (29% vs 25%) 
smokers compared to the unexposed referent group. The alumina-exposed workers and the 
unexposed workers did not differ with respect to smoking. The median, mean and maximum 
cumulative measures of bauxite dust among the bauxite-exposed workers were 5.7, 13.4, and 
187 mg/m3-yr, respectively. The median, mean and maximum cumulative measures of 
alumina dust among the alumina-exposed workers were 2.8, 14.5, and 210 mg/m3-yr, 
respectively. Exposure categories were defined based on the tertiles in the few cases. The 
relative risk of death from non-malignant respiratory disease showed a significant trend (7 
deaths; p < 0.01) with cumulative bauxite exposure after adjustments for age, calendar year 
and smoking. These deaths were due to chronic obstructive pulmonary disease, asbestosis, 
unspecified bronchopneumonia and interstitial pulmonary fibrosis. Cumulative alumina 
exposures showed a marginally significant trend with increased mortality from 
cerebrovascular disease (10 deaths; p = 0.04). No notable associations or trends were 
observed for cancer. These analyses were based on only a few cases that accrued during the 
relatively short follow-up and adjustment for smoking was done using only a crude 
categorical variable. The absence of significant associations between occupational Al 
exposures and cancer risk by Friesen et al. (2009) are consistent with the conclusions 
reached by Fritschi et al. (2008), IARC (1987) and ATSDR (2008).
Pan et al. (2011) investigated residential proximity to Canadian Al smelters and risk of 
female breast cancer in a population-based case-control study using data collected by the 
National Enhanced Cancer Surveillance System. This study was based on individual data 
collected from 21,020 Canadians diagnosed with one of 19 types of cancers and it included 
5039 population controls (aged 20–76 years). The study examined 2343 incident cases of 
breast cancer (863 premenopausal and 1480 postmenopausal) compared to 2467 controls. 
Breast cancer cases were identified by the population-based provincial cancer registries and 
all cases were verified by pathology reports. Breast cancer was defined as C50 according to 
the International Classification of Diseases for Oncology and questionnaires were sent to 
3013 cases and 2982 cases were contacted. Completed questionnaires were received from 
2362 cases, representing 78.4% of cases. Questionnaires were also mailed to 3847 women 
without diagnosis of cancer and these women were selected as potential controls using a 
random sample stratified by age group. In total, 2492 women without diagnosis of cancer 
completed and returned the questionnaire (representing 64.8% of the ascertained controls). 
These self-administered questionnaires collected information on education, average family 
income over the last five years, marital status, ethnic group, height, weight, physical activity, 
alcohol consumption, diet and vitamin and mineral supplements for the past 20 years. These 
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questionnaires also gathered smoking history, menstrual and reproductive history (including 
menopausal status), a lifetime residential and employment history, the distance between a 
residence and an industrial source and the number of years of proximity. Assessments also 
included dietary frequency, patterns and portion sizes for each of 69 foods consumed during 
the two years before interview. Distance to an industrial source was estimated using the 
locations and years of production for Al smelters and nine other major industries: copper 
smelters and refineries, lead smelters, nickel smelters and refineries, zinc smelters and 
refineries, petroleum refineries, paper mills, pulp mills, steel mills, and thermal power 
plants. Distance was categorized as less than 0.8 km (0.5 mile), 0.8–3.2 km (0.5–2 miles), 
and more than 3.2 km (> 2 miles). The change-in-point estimate approach was used to assess 
potential confounding factors: age, educational level, family income, alcohol consumption, 
smoking, body mass index, total calorie intake, recreational physical activity level, 
menopausal status, and number of live births. The final multivariate models were adjusted 
for age (years, continuous), province of residence, education (years, continuous), number of 
live births (none, 1, 2, 3, and ≥ 4), age at menarche (years, continuous), alcohol consumption 
(servings per week, continuous), pack-years of smoking (continuous), total caloric intake 
(kilocalories per week, continuous), and employment in the specific industry under 
consideration (yes or no). For postmenopausal women, the models were also adjusted for 
body mass index and recreational physical activity. In order to evaluate the trends for all 
models of categorized data, the different categories were treated as a single ordinal variable. 
The risk of breast cancer associated with residential proximity to Al industrial facilities was 
estimated based on odds ratios and corresponding 95% confidence intervals using 
unconditional logistic regression.
Data from 2343 breast cancer cases (863 premenopausal cases and 1480 postmenopausal 
cases) and 2467 controls (835 premenopausal controls, 1604 postmenopausal controls, and 
the menopausal status unknown for 28 controls) were used. The premenopausal cancer 
patients were older, had slightly higher family income, started menstruation at an earlier age 
and had longer menstruation compared with their controls. The postmenopausal women 
were slightly younger, had higher education, consumed more alcohol and tobacco, had 
higher body mass index, started menstruation at an earlier age and had fewer live births and 
more years of menstruation compared with their controls. The results indicated no increased 
risk of breast cancer among premenopausal or postmenopausal women living within 0.8–3.2 
km of an Al smelter. After adjustment for age, province of residence, education, smoking 
pack-years, alcohol consumption, number of live births, age at menarche, total energy 
intake, and employment in the industry under consideration, the odds ratios were not 
statistically significant for premenopausal breast cancer among women living 0.8–3.2 km 
from Al smelters compared to the controls (8 breast cancer patients and 13 controls; OR = 
0.52 [0.21–1.31]) or for those living less than 0.8 km from smelters (two breast cancer 
patients and one control; OR = 2.08 [0.18–23.72]). After adjustment for age, province of 
residence, education, smoking pack years, alcohol consumption, numbers of live births, age 
at menarche, total energy intake and employment in the industry under consideration, the 
odds ratios for postmenopausal breast cancer patients were not statistically significant for 
women living 0.8–3.2 km from Al smelters compared to the controls (19 breast cancer 
patients and 14 control; OR = 1.06 [0.50–2.23]) or for those living less than 0.8 km from 
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smelters (six breast cancer patients and six controls; OR = 0.97 [0.27–3.41]). For both pre- 
and postmenopausal breast cancer patients, the odds ratios for those living greater than 3.2 
km from an Al smelter were all unity.
Among the strengths of the Pan et al. (2011) population-based study are the relatively large 
sample sizes and the length of time that participants had lived near Al smelters. A number of 
potential confounders were controlled, including employment in the specific industry under 
consideration. The Pan et al. (2011) inquiry has a number of limitations including no 
information on the ages of the women when they resided near a plant; information was not 
available for all patients on family history of breast cancer, benign breast disease, BRCA1/2 
status or use of oral contraceptives or estrogen replacements. No exposure measures for Al 
or any other airborne material were provided.
Donoghue and Coffey (2014) described community health risk assessments for five 
Australian Al smelters with NO2, SO2, PM10, arsenic, and cadmium emissions that found 
arsenic accounted for 75% of the total incremental cancer risk (1.2 × 10−6) 3 km downwind 
of these facilities. The 0.3–1.1 acute hazard index for those residents was due to airborne 
PM10, formaldehyde, NO2, SO2, CO, and mercury, but the elevated risk was not related to 
Al.
Darbre (2001, 2006) declared that Al underarm antiperspirants and cosmetics cause human 
breast cancer, a conclusion based in part on a data from a Comet assay with cultured canine 
cells (Yiu 2004). However, Yiu (2004) evaluated complex mixtures (e.g., Secret Platinum® 
for women, Old Spice® for men and Crystal Natural®) and the Darbre conclusion (2001 
(2006) ignored the absence of AlCl3 and Al2(SO4)3 mutagenic activity in standard assays 
(reviewed in IPCS 1997, Krewski et al. 2007, Willhite et al. 2012). Notable among the oft-
cited reports concerning Al – induced clastogenesis are those by Banasik et al. (2005) and 
Lima et al. (2007) who cultured human peripheral lymphocytes for 72 h with AlCl3. The 
Lankoff et al. (2006) study with cultured human lymphocytes examined AlCl3 • 6H2O at 
4.15–103.75 μM (equivalent to 0.8–21 μM Al+3) where the higher concentrations induced 
apoptotic death. The DNA damage occurred after exposure to 40 μM AlCl3 (equivalent as 8 
μM Al+3), a concentration that was at least 67x normal median human blood Al 
concentrations (3.2 μg/L or 0.12 μM) (Krewski et al. 2007). These in vitro results are 
difficult to interpret due to the high AlCl3 concentrations and whether the apoptosis and 
increased MN at cytotoxic concentrations were due to Al+3 or to HCl. Nevertheless, 
reversible Al(OH)2+ binding with DNA bases can occur in vitro, and Al-DNA binding can 
be attenuated by chelators; these changes are related to Al+3 binding with nucleotide 
phosphates and these reactions can precipitate DNA crosslinks in vitro (reviewed in Willhite 
et al. 2012).
Exley et al. (2007b) measured Al in mastectomy tissues from 17 patients treated for breast 
cancer. Defatted dry weight Al concentrations were between 4–437 nmol/g. Exley et al. 
(2007b) suggested ‘within-individual trends’ were seen for Al in mammary adipose tissue, 
but neither those distributions nor the total Al concentration in mammary fat were 
significant. No comparisons were made between the Al concentrations in these patients and 
Al concentrations in mammary adipose tissue from healthy matched donors. Exley et al. 
Willhite et al. Page 71
Crit Rev Toxicol. Author manuscript; available in PMC 2016 August 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(2007a) concluded: “we have no direct evidence that the aluminum measured in these breast 
biopsies originated from antiperspirant”.
Mannello et al. (2011) compared Al concentrations in nipple aspirate from 16 healthy 
women (131 ± 9.6 μg/L) to those in 19 women diagnosed with breast cancer (268 ± 28.1 
μg/L). Based on the highly significant (p < 0.0001) difference, Mannello et al. (2011) 
suggested that either human breast tissue accumulates Al or that the elevated Al 
concentrations were related to use of Al-containing underarm antiperspirants. Following up 
on that suggestion, Darbre et al. (2011) cultured human mammary adenocarcinoma MCF-7 
cells with 0 or 0.0001 M (100 μM) ACH (equivalent to 31 μM Al) for 21 weeks. There was 
no influence of ACH on cell proliferation, but 50 genes (including mRNAs for five Ca-
binding proteins) were up-regulated and 57 were down-regulated. No protein synthesis data 
were included, no effort was made to establish concentration-response relationships and the 
single concentration examined was > 250x the median Al (0.12 μM) present in plasma from 
healthy humans (reviewed in Krewski et al. 2007).
There are at least two large epidemiology studies that examined antiperspirant/deodorant use 
and risk of female breast cancer, one of which was a population-based case-control study 
that found no relation whatsoever (Mirick et al. 2002). The second suggested an earlier age 
for diagnosis of the disease with increasing antiperspirant use (McGrath 2003). McGrath 
(2009) suggested a novel, indirect potential [but not empirically-verified] observation 
between topical Al-containing antiperspirant use and human breast and prostate cancer and 
put forward the idea that Al(OH)3 obstruction of sweat glands in an as-yet unidentified 
manner increased systemic uptake of “sex hormones and phermones (androgens) from 
apocrine sweat glands”.
Fakri et al. (2006) compared antiperspirant use by 54 women who presented with breast 
cancer to that of 50 healthy women of similar age; 82% of the healthy women reported 
antiperspirant use compared to 51.8% of those with the disease. Fakri et al. (2006) 
concluded that underarm antiperspirant use had no association with risk of female breast 
cancer, but that family history and oral contraceptive use were related to excess risk. 
However, neither Fakri et al. (2006), Darbre (2001, 2006, 2011) nor McGrath (2003, 2009) 
accounted for BRCA1/2 mutations, the dose and duration of oral contraceptives or addressed 
other well-known risk factors for human breast cancer (Lee et al. 2008).
Namer et al. (2008) identified 59 studies published to 2007 in an effort to determine a) 
whether existing biological data support an association between the use of underarm 
deodorants/antiperspirants and female breast cancer, b) whether use of those products 
increased breast cancer risk and c) whether data exist to support a causal relation between 
use of underarm deodorants/antiperspirants and increased risk for breast cancer. Of the 59 
candidate studies, 19 were judged appropriate to evaluate the hypothesis. Namer et al. 
(2008) concluded that there was “no scientific evidence to support the hypothesis” that use 
of Al-containing antiperspirants increased the incidence of human mammary upper outer 
quadrant gland cancer.
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Alumina-on-alumina total hip arthroplasty has been popular for at least three decades 
(Hannouche et al. 2011) during which time at least three case reports of soft tissue sarcoma 
have appeared (Ingram 1988). Yoon et al. (2011) described the case of an 80-year-old 
woman who received a titanium hip prosthesis with an alumina-on-alumina bearing. At five 
years after surgery, she developed a palpable cystic mass around her greater trochanter. 
Upon resection the mass was identified as a malignant fibrous histiocytoma and metastatic 
nodules were present in her lungs and axillary lymph nodes; her death was attributed to 
multiple lung metastases. Yoon et al. (2011) noted the similarities in their case to that 
detailed by Ryu et al. (1987) who noted the contribution of wear debris to sarcomatous 
degeneration.
Nanomaterials
Synthetic alumina, mixed Al silicate (SiO2/Al2O3) and Al oxide nano materials have a host 
of industrial (Kaste and Rice 2004, Najafpour et al. 2012, Patra et al. 2012, Yu et al. 2011), 
agricultural (Costa et al. 2011, Stadler et al. 2010), consumer product (Maquire-Boyle et al. 
2012, Sadiq et al. 2009) and medical (Monteiro-Riviere et al. 2010, Li et al. 2011c, Zhao and 
Castranova 2011) applications. Aluminum-reinforced carbon nanotubes and composites with 
Al oxide coatings are increasingly common (Gupta et al. 2011, Keshri et al. 2010, Seo et al. 
2012).
Nanosized Al oxide particles are also generated during Al welding and corundum grinding 
(Curwin and Bertke 2011, Dasch and D’Arcy 2008, Gomes et al. 2012a, 2012b, Pfefferkorn 
et al. 2010). The Al nanoparticles generated during Al fettling, cutting and molding are 
comprised of metallic Al and Al oxides and as are those those generated during Al thermal 
spray (Bémer et al. 2010). The primary Al nanoparticles present in Al welding fume (10–75 
nm) agglomerate in air by adhesion into larger particles and the primary Al nanoparticles in 
corundum (crystalline Al2O3) dust (10–35 nm) also aggregate (Schneider et al. 2013).
Controversy exists over the (potential) toxicity of engineered nanotubes, nanocapsules, 
nanospheres, nano quantum dots and nanoshells (Card et al. 2011, Nel et al. 2006, 
Oberdörster et al. 2005, Powers et al. 2013, Yokel and MacPhail 2011). Some (Chen et al. 
2008, Oesterling et al. 2008, Zhang et al. 2011b) have suggested nanoscale alumina is a 
more potent pro-oxidant than bulk or common micron-sized Al oxides whereas others 
(Radzium et al. 2011, Sun et al. 2011b) concluded that Al2O3 nanomaterials pose little 
hazard. Oesterling et al. (2008) observed that primary nano alumina agglomerated at 
physiological pH in serum-containing culture media giving rise to particles ranging from 
nano to micron size. The primary particles agglomerate in culture media due to hydrophobic 
and Van der Waals forces and binding with protein and polysaccharides (Powers et al. 2006).
Data that might be taken to support the view that Al nanoparticles may be of greater concern 
than similar micron-sized particles include those from Lordan et al. (2011) who cultured 
human HepG2 cells with different montmorillonite particles (one tactoid at 30–100 μm and 
one agglomerated at 3–35 μm). After 24 h in culture these Al particles clumped into larger 
bundles to the point that the cultures were obscured and the cells could not be seen under a 
light microscope. At these concentrations there was an increase in intracellular reactive 
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oxygen and viability was reduced 23–27%, but there was no increase in caspase-3/7 activity. 
These particles were relatively non-toxic in that at 500–1000 μg/ml there was no or only a 
slight elevation in LDH release. Lordan et al. (2011) considered that the death of these cells 
was not due to apoptosis; death was attributed to necrosis, but no histologic or other data 
were presented to support that conclusion. Long-term dietary studies with refined 
montmorillonite and related Al silicate particles in humans (Afriyie-Gyawu et al. 2008) and 
rodents (Afriyie-Gyawu et al. 2005, Phillips 1999, Phillips et al. 2008, Wiles et al. 2004) 
found no evidence for particle accumulation or toxicity, but fatty hepatic degeneration 
occurred in mice after chronic feeding as a result of particle binding with choline in the 
intestine (Wilson 1953, 1954).
Prabhakar et al. (2011) compared the acute oral toxicity of bulk Al2O3 (99%) with that of 30 
nm or 40 nm Al2O3 in rats given 0, 500, 1000 or 2000 mg/kg. No adverse signs were evident 
and food consumption and organ weights were no different from those of the controls. 
Among rats given 30 or 40 nm Al2O3 there was a significant increase in hepatic lPO; 
catalase activity increased, reduced GSH declined and SOD activity decreased. These 
changes resolved by day 14 save in those given the highest dose. Intubation of 30 or 40 nm 
Al2O3 caused greater GSH reductions than did an equivalent dose of bulk Al2O3. Dilated 
central veins and distended portal tracts developed in rats given 2000 mg/kg of the nano 
Al2O3 whereas rats given an identical dose of bulk Al2O3 showed no anomalies. The extent 
of LPO was greater in rats given nano Al than in those given bulk Al, but there was no 
significant difference in hepatic LPO between rats given the 30 or 40 nm Al2O3. Prabhakar 
et al. (2011) attributed the higher oxidant response in the liver after nano Al compared to 
bulk Al to a higher delivered dose but no empirical data were presented to support that 
conclusion.
Substantial differences exist regarding Al nanoparticle cytotoxicity in vitro. Many of these 
differences likely relate to the physical form(s) of these materials in culture media (Powers 
et al. 2006). There is no question that sufficiently high (μM-mM) concentrations of synthetic 
Al nanoparticles can kill cultured fibroblast, keratinocyte, melanoma, and mammary 
carcinoma cells (Maduray et al. 2012, Rocha et al. 2012). Rocha et al. (2012) attributed Al 
nanoparticle-induced cytotoxicity to generation of O2 • −, OH• and related free radicals. 
After cultured rat alveolar macrophages were exposed to nanoscale metallic Al at 100–250 
μg/ml for 24 h significant reductions in viability were observed. When macrophages were 
treated with Al2O3 nanoparticles under the same conditions, phagocytosis was impaired but 
only ‘marginal’ reductions in viability were seen (Wagner et al. 2007). In contrast, there was 
no evidence of cytotoxicity after 24 h culture of human epidermal keratinocytes with 50–80 
nm Al nanoparticles at 0.0004–4.0 mg/L (Monteiro-Riviere et al. 2010) and there was no 
significant toxicity in human lung fibroblasts (Zhang et al. 2011c), human lung epithelial 
l929 and A549 carcinoma cells (Kim et al. 2010), human foreskin BJ and mouse fibroblasts 
(Radziun et al. 2011) or primary human brain microvascular endothelial (hCMEC/D3) cells 
(Chen et al. 2008). Extraordinarily high concentrations in vitro (≥ 100 μg/ml) can reduce 
viability, increase cell shrinkage and promote apoptosis, but whether those changes are 
specific to Al+3 released from the particles or whether these represent non-specific 
particulate damage is not clear. Differences in nano Al cytotoxicity in vitro depend on 
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particle behavior just as was the case in vivo after inhalation of 10 or 40 nm γ-AlOOH 
(Pauluhn 2009a).
Neutral Al nanoparticles can bind purines and pyrimidines in vitro (Jin et al. 2012). High 
concentrations (5–10 mg/L) of Al2O3 nanoparticles increase ROS, increase TNF-α, increase 
IL-6 and induce cyclooxygenase-2 in cultured murine macrophages (Nishanth et al. 2011). 
Aluminum nanoparticles increased micronuclei in cultured Chinese hamster ovary cells, but 
failed to increase the frequency of SCEs (Di Virgilio et al. 2010). These particles (20–30 
nm) were neither clastogenic for cultured human fibroblasts (Tsaousi et al. 2010) nor 
mutagenic in S. typhimurium strains TA 100, TA 1535, TA 98, TA97a or TA 102 either in 
the presence or absence of fortified rat liver S9 (Balasubramanyam et al. 2010, Pan et al. 
2010).
Dong et al. (2011) compared the toxicity of four nano γ-aluminas to that of Al2O3 powder 
in cultured C17.2 neural stem cells (NSC). The study included cell morphology, viability, 
membrane integrity, necrosis, apoptosis and particle uptake. All of these primary nano γ-
alumina particles were crystals; sample numbers 1, 2 and 4 were rods and sample 3 particles 
were of irregular shapes. The chemical purity was 99.9% and the mean primary particle size 
was 6.3–18.9 nm. The agglomerated particle sizes in the media varied from 420–650 nm. 
Particle solubility in the media ranged from less than the limit of detection for sample 
number 1 to 180 ng Al/ml for sample number 2. Irregular micron size crystalline Al2O3 
particulates (402 nm) were used as a reference and these had the highest solubility (920 ng 
Al/ml) of all of the forms.
Dong et al. (2011) cultured the NSC in 10% fetal bovine serum and 5% horse serum under 
humidified 5% CO2 and 95% air at 37°C for 24 h with 0 or 10–500 μg/ml test material. All 
of the nano Al particles aggregated to the point that they had similar sizes in the media 
(450–650 nm). Concentration-dependent toxicity was observed after treatment with nano 
sample 4 at 72 h. The duration of exposure (up to three days) failed to influence cell viability 
and there were no adverse effects of media pre-treated with alumina (to evaluate the 
influence of nutrient depletion) on viability. A concentration-related release of LDH was 
observed in all Al nano-treated cultures, but the differences between the four types of Al 
nano-forms were small. After 24 h many particles accumulated in the NSC cytoplasm, but 
there were no particles in the nucleus. There were no ultrastructural anomalies at 24 or 72 h 
culture with any of the Al nanoforms. A concentration-dependent increase in ROS was seen 
at 24 h following treatment with 100 μg/ml N1–N4 and the increased ROS was consistent 
with concentration-dependent reductions in viability. There was no evidence of apoptosis 
following exposure to nanoAl (N1–N4) or Al2O3 at 24 h. Dong et al. (2011) concluded that 
alumina particles were readily internalized by cultured cells but that the cytotoxicity of nano 
γ-alumina in cultured NSC cells was low. The Dong et al. (2011) study is important because 
it compared the toxicity of various agglomerated Al nanoparticles to that of conventional 
Al2O3 and found that none of the Al nanoforms were significantly more toxic than the bulk 
Al2O3. However, the brief durations of exposure and the in vitro nature of the study make 
extrapolations to in situ conditions tenuous.
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Definitive studies on the pulmonary toxicity of Al oxide nanoparticles are those by Pauluhn 
(2009a, 2009b, 2009c, 2011) and Adamcakova-Dodd et al. (2012). These studies point to 
general principles of the behavior of inhaled ultrafine Al particles. One goal of the Pauluhn 
(2009a) investigation was to “test whether the pulmonary effects (toxicity and fate) 
following exposure to aluminum oxyhydroxides of differing primary and agglomerated 
particle size are more dependent on the primary than agglomerated particle size”. Pauluhn 
(2009b, 2009c) then followed the initial observations with more detailed analyses of 
cumulative lung particle burden in relation to inhaled concentrations, particle volume, 
macrophage activity and pulmonary inflammation. The Pauluhn (2009a, 2009b, 2009c, 
2011) series explains Al nanoparticle characteristics [primary particle size, chemical 
composition, shape, diameter and surface properties (e.g., smooth, thin) that determine 
relative flexibility/rigidity] in relation to agglomeration, deposition and retention in the 
respiratory tract. Among the generalizations that come from this and related work on the 
inhalation toxicology of poorly soluble ultrafine particulates include the observation that 
acute pulmonary inflammation after high dose exposure appears more closely related to 
particle surface area and reactivity, but the sustained inflammation seen after prolonged 
pulmonary retention depends more on particle volume than on particle surface area.
Pauluhn (2009a) exposed groups of 54 adult male Wistar Bor:WISW (SPF-Cpb) rats by 
nose-only inhalation 6 h/day, 5 days/week for 4 weeks to 0, 0.4, 3 and 28 mg/m3 of 10 or 40 
nm calcined Al oxyhydroxide (γ-AlO(OH) or boehmite) crystals. The particle mass median 
aerodynamic diameter (MMAD) of one boehmite was 1.7 μm (10 nm Dispersal® of 39.4% 
Al) and that of the other was 0.6 μm (40 nm Pural® of 43.9% Al). Despite the differences in 
primary particle size, the geometric diameters of the agglomerated particles in the inspired 
air were identical (2.7 and 2.6 μm, respectively). The post-exposure observation period was 
three months. An interim sacrifice was made on day 10 during exposure and post-exposure 
sacrifices were carried out one day after the end of exposure then at 12 days, 33 days and 91 
days after termination of exposure. Twelve animals were exposed per concentration and 
time-point; six were subjected to bronchoalveolar lavage and histopathology and six were 
used in determination of Al tissue concentrations. Pulmonary inflammation was assessed by 
measuring total protein and total cell counts, numbers of neutrophilic granulocytes (PMNs) 
and LDH, γ-glutamyltransferase (γ-GT) and β-N-acetylglucosaminidase (β-NAG) activities 
in bronchoalveolar lavage fluid (BALF) and histopathological examination included all five 
lung lobes, bronchi, lung-associated lymph nodes, olfactory bulb, ethmoid turbinates and the 
olfactory nerve. Aluminum concentrations were measured in urine, brain, the right lung 
lobe, BAL cells, hilar lymph nodes, kidney and liver.
There were no deaths, clinical signs or treatment-related changes in body weight. As the 
concentration and duration of exposure increased, Al concentrations in the lung increased. 
The increase in lung Al was greater in rats that inhaled the 40 nm particulate than in rats that 
inhaled the 10 nm particulate. Rats that inhaled the 40 nm particulate consistently received 
higher daily Al doses (1.85, 15.7 and 130 μg/day) than rats that inhaled identical 
concentrations of the 10 nm particulate (1.06, 8.7 and 77.2 μg/day). Pulmonary Al 
elimination t½ values were similar for both particulates at the lower concentrations, but 
pulmonary elimination by rats inhaling 28 mg/m3 found the smaller 10 nm particulate had 
an Al elimination half-time that was more than twice that of the larger 40 nm particulate. 
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There was no measurable increase in Al in lung-associated lymph nodes after rats inhaled 
0.4 or 3 mg/m3 of either preparation and there were no time or concentration-dependent 
increases in brain, liver or kidney Al. There were no changes in urinary Al associated with 
either duration or magnitude of exposure.
There were no significant differences in BALF cytology or biochemical parameters at 0.4 or 
3 mg/m3 of either preparation, but after rats inhaled 28 mg/m3 was there an inflammatory 
response in the lung. Histology after four weeks of exposure to the highest concentration 
found particles within the alveoli and particle accumulation in enlarged, foamy alveolar 
macrophages. Slight to minimal focal septal thickening, increased numbers of epithelial cells 
and increased inflammatory infiltrate were evident. Increased LDH activity followed a 
similar profile for both the 10 and 40 nm boehmites and increased levels of β–NAG, total 
protein and γ-GT followed increased total cell and PMN counts. Focal septal collagen 
increased only after rats inhaled 28 mg/m3 of either preparation. Even though measurable Al 
was present in lungs from rats inhaling 0.4 or 3 mg/m3, there were no adverse effects in the 
lung despite the sensitive endpoints employed to evaluate toxicity. Histopathological study 
of the bulbus olfactorius and ethmoid nasal passages found neither signs of local tissue 
alterations nor evidence for γ-AlO(OH) particle translocation. The results demonstrated that 
the size of the agglomerated γ-AlO(OH) particles was more closely related to total lung 
particle burden than was the size of the primary particle.
Lung Al concentrations increased after male C57Bl/6 mice inhaled (WB exposure) 3.3 
mg/m3 of a dry aerosol of 2–4×2800 nm Al2O3 nanowhiskers, 4 h/day, 5 days/week for two 
or four weeks (Adamcakova-Dodd et al. 2012). Measures of particle size distribution found 
the primary particles formed 150 nm agglomerations with protruding nanowhiskers. 
Although pulmonary macrophage increased with duration of exposure, there were no signs 
of pulmonary damage or inflammation (based on LDH, IL-6, IFN-γ, MIP-1α, TNF-α and 
MIP-2 in BAlF) among treated mice compared to their controls. Methacholine challenge 
found no evidence for airway hyperreactivity and histology found no sign of airway 
remodeling, inflammation, lymphoid aggregates or fibrosis. The results from Adamcakova-
Dodd et al. (2012) are consistent with the results from Pauluhn (2009a), but the former is 
limited by examination of only a single concentration.
Pauluhn (2009b) extended his work to quantify exposure using the kinetics of inhaled 10 and 
40 nm γ-AlO(OH) particulates. The pulmonary elimination t½ values for γ-AlO(OH) 
increased as the particle concentrations in the inspired air increased. The t½ was longer for 
the 10 nm (177 days) than for the 40 nm (94 days) particles and the elimination rates 
correlated with lung burden. The cumulative lung particle burden was proportional to the 
PM concentrations in the inspired air; rats that inhaled the highest γ-AlO(OH) PM 
concentrations accumulated the highest particle concentrations in their lungs. Rats that 
inhaled the 40 nm PM had higher pulmonary loads than those that inhaled an identical 
concentration of the 10 nm particles. Pulmonary inflammation (measured as relative PMN 
counts) was most closely correlated (r = 0.93–0.97) with mass-based measures of dose than 
with particle surface area. Pulmonary inflammation was not evident when lung particle loads 
did not impede normal macrophage clearance. These data point to the conclusion that the 
toxicity of γ-AlO(OH) in rat lung was not due to leaching or dissolution of Al+3 from these 
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non-redox active agglomerates, but it was reflected in the capacity of pulmonary 
macrophages to clear these poorly-soluble particles.
The work by Pauluhn (2009c) builds on concepts of pulmonary particle overload and 
toxicity in the lung (Oberdörster 1995, Oberdörster et al. 2005). Pulmonary overload has 
been defined as a two- to four-fold reduction in alveolar clearance beginning when 
pulmonary macrophages accumulate a particle mass ≥ 60 μm3 and become immobilized. 
This value is equivalent to a lung particle burden of ~ 1 mg/g (ILSI 2000). In the case of 10 
and 40 nm γ-AlO(OH) particles, the size of their closely-packed, poorly soluble 
agglomerates leads to high composite volumes of phagocytized particles. A smaller total 
nanoparticle mass than that seen with larger microsized particles can exceed the volumetric 
overload limits of pulmonary macrophages. It is only after sufficient agglomerates are 
retained in immobilized macrophages that pulmonary inflammation was evident in rats that 
inhaled 10 or 40 nm γ-AlO(OH). The work by Pauluhn (2009a, 2009b, 2009c) supports the 
concept that prolonged pulmonary retention and sustained inflammation depend upon 
particle volume as contrast to particle surface area.
Pauluhn (2011) extrapolated the γ-AlO(OH) data together with the results of other studies 
on ultrafine PM to calculate a generic OEL based on volume-based mass concentrations. 
This OEL (0.54 μl PMresp/m3) is designed to preclude lung particle overload and prevent 
intraluminal pulmonary inflammation after exposure to poorly soluble nano- to submicron-
size PM. Assumptions implicit to those calculations were that the inhaled Al PM presents no 
risk for neoplastic lung disease and that systemic uptake of the Al PM is insignificant. In the 
case of inhaled γ-AlO(OH) there was no evidence for extra pulmonary translocation 
(Pauluhn 2009a). Pauluhn (2011) advanced the concept of non-reactive lung particle 
overload as the determining factor in health risks posed by airborne Al nanoparticles. The 
potential for pulmonary inflammation and damage associated with exposure to airborne 
nanoscale aluminas is related primarily to the size and composite volume of the 
agglomerated material as contrast to the size of the primary crystals.
Standards and guidelines
Current standards and guidelines include German and United States regulations on Al in 
foods, the EFSA Tolerable Weekly Intake (TWI), the Minimal Risk level (ATSDR 2008), the 
WHO drinking water limit, the French deliberations on Al in cosmetics (AFSSAPS 2011) 
and Occupational Exposure limits (OELs) (Table 7). At the present time, there is no 
European Union OEL for metallic Al or its compounds (Health Council of the Netherlands 
2010).
Food standards
The US FDA considers common Al compounds used as multiple purpose, sequestrant, 
anticaking, leavening and emulsifying agents in foods ‘generally recognized as safe’ 
(GRAS) (Yokel 2012). Stahl et al. (2011) summarized German regulations on the maximum 
permissible levels of Al in food. Australia and New Zealand (FSANZ 2011) as well as 
Brazil (Aparecida 2009) have adopted standards for the maximum Al content in foods.
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The United States has been content to require warning labels on PN materials that contain > 
25 μg Al/L (US FDA 1998, 2003). The United Kingdoma Medicines and Healthcare 
Regulatory Agency (2010a, 2010b) issued contraindications for Ca gluconate packaged in 
small-volume glass containers (10 ml) used to compound PN solutions. The intent of the UK 
action is to reduce the adverse effects of parenteral Al on bone mineralization and 
neurological development in premature infants.
TWI
The European Commission has been considering directives to ensure that the EFSA 
recommended TWI (equivalent to 280 μg/kg-day) (Benford et al. 2012) for dietary Al is not 
exceeded (EFSA 2011). In contrast to the EFSA (2011, 2013) assumption that 
gastrointestinal uptake of all ingested Al materials is equivalent to that measured for Al 
citrate, Berthon (2002) compared the different dietary constituents that either promote (e.g., 
ascorbate, citrate, glutamate, malate, oxalate, tartrate) or retard (e.g., phosphate, soluble 
silicates) Al uptake. Under current EFSA (2011, 2013) and Benford et al. (2012) guidance, 
Al exposures associated with consumption of trace levels of bentonite/montmorillonite 
([Na,Ca)0.33(Al, Mg)2 (Si4O10) (OH)2 • nH2O]) in wine that are not systemically available 
(Wiles et al. 2004) are cumulative with total Al exposures from more water-soluble and 
bioavailable forms like Al2(SO4)3 (van der Voet and de Wolff 1986–87).
MRL
ATSDR (2008) calculated an intermediate (15–364 day) minimal risk level (MRL) for 
ingested Al of 1.0 mg/kg-day. The ATSDR (2008) identified a NOAEL of 26 mg/kg-day and 
applied a total uncertainty factor of 100 and used a modifying factor of 0.3 (to account for 
differences in gastrointestinal uptake of Al lactate compared to the Al forms in drinking 
water and food) to calculate the intermediate MRL. The ATSDR (2008) also calculated a 
chronic (≥ 365 day) MRL for ingested Al of 1.0 mg/kg-day.
Drinking water
In 1984 the WHO recommended a maximum drinking water concentration of 0.2 mg Al/L to 
control discoloration. This recommendation was based on consumer complaints of ‘foul’ or 
discolored water at Al concentrations > 0.1 mg/L (WHO 2004, 2010).
Cosmetics
The US FDA limits the concentrations of Al in cosmetics as the polymerized 
Aly(OH)3y-2Cl2 • H2O to ≤ 25% w/v and Al2Cl7H7O7Zr2 to ≤ 20% w/v (US DHHS 1982, 
2003). The US FDA commented that underarm deodorants with higher Al concentrations 
(e.g., up to 35%) can be skin irritants; increasing the concentrations of Al antiperspirant 
ingredients in these products “increases the acidity of the material and irritation of the skin”. 
The final decision included epidemiologic data from Graves et al. (1990) and concluded: 
“The agency does not find the current evidence sufficient to conclude that aluminum from 
antiperspirant use results in Alzheimer’s disease.”
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On January 4, 2013 the European Commission limited the concentration of AlxZr(OH)yCl2 
and AlZrClOH glycine complexes in cosmetics to not more than 20% and prohibited their 
use in aerosol spray dispensers (EC 2013).
Vaccines
Of the vaccines currently registered in the United States (Leventhal et al. 2012), 12 contain 
Al(OH)3 and 23 contain other Al compounds (Kelso et al. 2012). Standard adjuvants in 
diphtheria, tetanus, and pertussis (DTP) and other vaccines include alum (AlK(SO4)2, 
Al2(SO4)3, Adju-Phos (Al(PO4)3) Imject Alum (Al(OH)3 + MgOH) and alhydrogel 
(Al(OH)3) (Kelso et al. 2012, Marrack et al. 2009). The United States FDA limits the 
elemental Al content of a single vaccine injection to 0.85 mg (Eickhoff and Mayers 2002), a 
value equivalent to 2.45 mg Al(OH)3 per dose.
OELs
Different OELs for Al have been adopted in different countries (ILO 2011, IFA 2011a, 
2011b); some countries rely on OELs developed in the United States whereas others rely on 
those adopted by the Deutsche Forschungsgemeinshaft (DFG), Safe Work Australia, the 
United Kingdom Health & Safety Executive, the Health Council of the Netherlands or by the 
Nordic Expert Group (Arbete Och Hälsa) (Table 7). Some OEls are legally enforceable 
limits (e.g., OSHA Permissible Exposure Limits (PELs), 1993, Institut für Arbietsschutz der 
Deutschen Gesetzlichen Unfallversicherung (IFA), 2011b). The enforceable limits may be 
identical to or may be substantially different from non-binding ‘guidance’ values for the 
same material (Deveau et al. 2014).
Riihimäki and Aitio (2012) reviewed occupational exposure to Al welding fume in relation 
to Al concentrations in urine and blood and concluded that urinary Al was a more sensitive 
indicator of Al uptake and body burden than serum Al. Yokel (2012) calculated daily Al 
uptake from the lung after exposure to workplace air containing 25–2500 μg/m3 and found 
that pulmonary uptake (0.6–8 μg/kg-day) was substantially greater than that received after 
swallowing airborne Al particles (0.008–1.0 μg/kg-day). The Finnish Institute of 
Occupational Health adopted a limit of 6 μmol/L for Al in pre-shift urine after two days 
without Al welding. The current German Biological Workplace Chemical Tolerance Value 
(BAT) is 2.2 μmol Al/g creatinine (pre-or postshift) corresponding to the MAK maximum Al 
concentration in workplace air of 1.5 mg/m3 (respirable fraction). The Polish MAC for 
airborne Al2O3 dust (1.05 mg/m3) corresponds to 2.1 μmol Al/L urine. Riihimäki and Aitio 
(2012) proposed a urinary Al ‘action limit’ of 3 μmol/g (corrected to a relative urine density 
of 1.021 or 2.3 μmol Al/g creatinine) based on reports of impaired cognition in Al welders 
with many years of exposure to the fume. This proposed limit assumes workers do not 
consume Al-containing antacids or buffered aspirin and that diet and beverages do not 
contribute to elevated urinary Al.
The Health Council of the Netherlands (2010) considered the available data insufficient to 
derive health-based OELs for metallic Al or Al compounds other than ACH. The Health 
Council assigned an OEL to ACH of 0.05 mg/m3 based on the development of multifocal 
granulomatous pneumonia and microgranulomas in the peribronchial lymph nodes of rats 
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and guinea pigs inhaling ACH (Steinhagen et al. 1978). The Health Council of the 
Netherlands (2010) emphasized that except for ACH, existing data are not adequate to 
recommend OELs for bulk Al metal or other Al compounds. The Nordic Expert Group 
(2011) concurred with the Health Council of the Netherlands (2010) in that the repeat 
exposure ‘minimal’ inhalation LOAEL (0.061 mg Al/m3) was an appropriate point of 
departure for derivation of an OEL for ACH.
Synthesis and conclusions
The results of the present review demonstrate that health risks posed by exposure to 
inorganic Al depend on its physical and chemical forms and that the response varies with 
route of administration, magnitude, duration and frequency of exposure. These results 
support previous conclusions that there is little evidence that exposure to metallic Al, the Al 
oxides or its salts increases risk for AD, genetic damage or cancer (Krewski et al. 2007). The 
present review also found that the notion that Al dose can be accounted for, measured by, 
and the data interpreted as ‘total Al’ (e.g., Sorenson et al. 1974), as contrast to chemical-
specific analyses (BASF 2011, Rödelsperger et al. 1987), can lead to possibly inappropriate 
conclusions regarding Al health risks.
The present review found that the majority of the rodent studies (Tables 2 and 3) are of 
limited relevance for Al human health risk assessment. The designs of exploratory studies 
(e.g., Abdel-Aal et al. 2011a, 2011b, Abu-Taweel et al. 2011a, 2011b, Akiyama et al. 2012, 
Cheng et al. 2012, Cui et al. 2012, Elsaid et al. 2011, Garrosa et al. 2011, Kumar et al. 2011, 
Moselhy et al. 2011, Sun et al. 2011b, Thirunavukkarasu et al. 2010, 2011, 2012, Viezeliene 
et al. 2011, 2012, Wang et al. 2010a, Xiao et al. 2011) and of even those that meet current 
regulatory guidelines (e.g., Hirata-Koizumi et al. 2011a, 2011b) failed to include concurrent 
controls treated in an identical manner with equimolar doses of the hydrolysis products (e.g., 
HCl, H2SO4). It is clear these hydrolysis products confound the interpretation of in vivo 
(e.g., Hirata-Koizumi et al. 2011a) and in vitro (Castorina et al. 2010, Cifone et al. 1987, 
Güngör et al. 2010, Kamalov et al. 2011, Morita et al. 1989, 1992) data, particularly where 
media Al concentrations ≥ 10 μM are equivalent to lethal or near-lethal serum Al 
concentrations in humans (Krewski et al. 2007). Only a handful of the relatively large 
numbers of published studies were designed for regulatory purposes. While ip injections and 
gastric intubations represent convenient routes of administration in the laboratory, inhalation 
and dietary studies are more appropriate for assessing human health risk.
The current pathways, sources and magnitude of current human Al exposures are broadly 
consistent with those measured four decades ago (reviewed in Krewski et al. 2007). Dietary 
Al intake depends on the age of the individual, soil characteristics (including pH) and local 
dietary customs. These differences are reflected in Al doses that range from 1.61 μg/kg-
week for Russian infants to 8.47 mg/kg-week for Russian adults, values that were consistent 
with or higher than those for adolescent boys living in the Czech Republic (1.14 mg/kg-
week) or for those living in Washington, D.C., San Francisco and St. Louis (1.14–6.68 
mg/kg-week) (Sorenson et al. 1974). Other surveys found Al dietary exposure was no 
greater than the 2 mg/kg-week PTWI for those living in the United States, Western Europe 
and the Canary Islands (ATSDR 2008, EFSA 2008, González-Weller et al. 2010), but it was 
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above the PTWI for toddlers living in the United Kingdom (2.4 mg/kg-week) (Rose et al. 
2010), Japan (2.0–3.0 mg/kg-week) (Sato et al. 2014) and the EU (11.3–156 mg/kg-week) 
(EFSA 2013). The PTWI is based on studies with the highly bioavailable Al citrate (Benford 
et al. 2012, EFSA 2011); however, the oral bioavailability of the soluble and sparingly-
soluble Al forms varies at least 10-fold (EFSA 2011) and insoluble Al silicates present in 
foods and beverages demonstrate essentially no uptake (Willhite et al. 2012). The validity of 
the assumption that the gastrointestinal bioavailability of all forms of ingested Al is 
equivalent to that of Al citrate (EFSA 2013) warrants further consideration.
Aluminum contamination of PN solutions continues to be of concern (Bohrer et al. 2010, 
Fanni et al. 2014, Hernández-Sandez et al. 2013, Poole et al. 2008, 2010, 2011, Popinska et 
al. 2010, Wier and Kuhn 2012). Recent reports (Fewtrell et al. 2009, 2011) confirm previous 
observations that Al contamination in PN solutions presents serious health risks for infants 
and neonates (Bates et al. 1985, Bishop et al. 1997, Fanni et al. 2014, Klein 1995, Klein et 
al. 1991).
The results of the present review support previous conclusions that there were no clear 
associations between vaccinations using Al adjuvants and serious adverse events (GACVS 
2012, Kelso et al. 2012). Nevertheless, Al adjuvants increased injection site pain and 
tenderness (Table 4) and elicited sensitization to the metal (Table 5). The present review also 
identified controlled trials wherein vaccination without Al adjuvant provided equivalent 
response to vaccination with adjuvant and that vaccination with different Al forms produced 
a different response. Other recent studies found a limited immunogenic role for Al(OH)3 
adjuvant, or a diminished immune response to certain vaccines (Brady et al. 2009, Keitel et 
al. 2009, Manzoli et al. 2011, Liang et al. 2010, Yin et al. 2011, Zhu et al. 2009). Based on 
results with the relatively few published controlled trials with Al adjuvants it is not clear 
whether routine use of Al adjuvants represents best clinical practice. Where Al adjuvants 
provide demonstrable benefit, it is not clear which Al form(s) and dose(s) have the highest 
therapeutic ratio (Batista-Duharte et al. 2011).
Some (Byrne and Baugh 2008, Nel et al. 2006) have expressed concern that nanoparticles 
can be dangerous and that platelet and tubular Al nanoclays are cytotoxic (e.g., Lordan and 
Higginbotham 2012, Lordan et al. 2011, Verma et al. 2012, Wallace et al. 1985). However 
there is little correlation between Al nanoparticle toxicity in vitro and that observed in vivo, 
partly because the physical properties of the primary Al nanoparticles differ from the larger 
aggregates (Al nanoclusters) (Murdock et al. 2008) to which people are exposed. Acute oral 
(Prabhakar et al. 2011) and repeat exposure inhalation studies in rats (Pauluhn 2009a) and 
mice (Adamcakova-Dodd et al. 2012) with Al nanoparticles failed to identify adverse effects 
except at very high levels of exposure. Chronic occupational inhalation of nanoparticle-
containing bauxite and other non-reactive Al dusts (Altekruse et al. 1984, Beach et al. 2001, 
Donoghue et al. 2014, Edling 1961, Gibbs and Pooley 1994, Hale et al. 1956, Lynch and 
McIver 1954, Oldham 1983, Rawlings et al. 1983, Sakula 1961, Taiwo 2014, Waxweiler et 
al. 1988) was associated with pneumoconiosis in exposed workers. These conditions are 
related to excessive particle loading of lung macrophages and impaired pulmonary clearance 
(Oberdörster 1995). Given the results with controlled inhalation of γ-AlO(OH) in rats, it 
appears preliminary estimates of health risk based on aggregate Al nanoparticle pulmonary 
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overload (Pauluhn 2011) are appropriate. The data suggest that the pulmonary response to 
inhaled engineered Al oxide nanoparticles will be similar to that seen after naturally-
occurring bauxite nanoparticles are inhaled.
There is considerable variation in the OELs for metallic Al and the Al oxides under similar 
frequency and durations of exposure (Table 7). Both the Health Council of the Netherlands 
(2010) and the Nordic Expert Group (2011) concluded that existing data for metallic Al and 
its oxides are inadequate upon which to derive evidence-based OEL values. There remain 
concerns about reduced attention span, impaired cognition and deficits in fine motor skills 
among workers exposed to Al fume for many years (reviewed in Riihimäki and Aitio 2012). 
Nine studies (Akila et al. 1999, Bast-Petterson et al. 1994, 2000, Bowler et al. 2003, Flaten 
et al. 1996, Giorgianni et al. 2012, Hannien et al. 1994, Polizzi 2002, Riihimäki et al. 2000, 
Sjogren et al. 1990) identified adverse effects of Al fume on worker cognition, but four other 
studies Buchta et al. 2005, Kiesswetter et al. 2007, 2009, Meyer-Baron et al. 2007) found no 
such changes. The reasons for these differences are unclear.
Of the many health risk issues discussed in this review, several in particular warrant further 
attention. These include consideration of relative bioavailability of different Al species in 
deriving human exposure guidelines, Al contamination of PN solutions, justification of the 
use of Al as vaccine adjuvants and the basis for and derivation of OELs for Al compounds. 
Resolution of these issues will require additional investigation, and the application of 
appropriate risk assessment methodologies to arrive at evidence-based risk management 
decisions (Landry and Sibbald 2001, Guzelian et al. 2005).
Abbreviations
Aβ amyloid β peptide
ACH aluminum chlorhydrate Al2Cl(OH)5•2H2O
AChE acetylcholinesterase
AD Alzheimer’s disease
AE adverse events
AGD anogenital distance
Al aluminum
ALT alanine aminotransferase
APP β-amyloid precursor protein
apoE apolipoprotein E
AST aspartate aminotransferase
ATSDR Agency for Toxic Substances and Disease Registry
AUC area under concentration:time curve
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BAT Biologischer Arbeitsstoff-Toleranz-Wert
Bax proapoptotic Bcl-2 associated protein
Bcl2 anti-apoptotic B-cell lymphoma-2-protein
BMC bone mineral content
CA chromosomal aberration
CAA congophilic amyloid angiopathy
DBCP double-blind placebo-controlled
DC dendritic cells
DFO desferrioxamine
DLB dementia with Lewy bodies
DNEL derived no effect level
DPT diphtheria/pertussis/tetanus
DSB double strand breaks
DTaP diphtheria/tetanus acellular pertussis
EC European Commission
EFSA European Food Safety Authority
EPO erythropoietin
ERER erythrocyte rosette forming enhancing rate
ERIR erythrocyte rosette forming inhibitory rate
FAO/WHO Food and Agriculture Organization of the United Nations/World Health 
Organization
FDA Food and Drug Administration
FOB functional observational battery
FSH follicle stimulating hormone
GD gestational day
GFAAS graphite furnace atomic absorption spectrophotometry
GLP Good Laboratory Practice
GPx glutathione peroxidase
GSH reduced glutathione
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GST glutathione-S-transferase
HD hemodialysis
HFT hyperphosphorylated tau
ICP-AES inductively-coupled plasma atomic emission spectroscopy
ICP-MS inductively-coupled plasma mass spectrometry
IE immunogenicity endpoints
IL interleukin
im intramuscular
ip intraperitoneal
IPCS WHO International Programme on Chemical Safety
Ire1β serine/threonine-protein kinase/endoribonuclease 1
LDH lactate dehydrogenase
LPO lipid peroxidation
LTP long-term potentiation
MAK Maximale Arbeitsplatz-Konzentration
MDA malondialdehyde
MEDI maximum estimated daily intake
MN micronuclei
MMF macrophagic myofaciitis
MRL minimal risk level
MMSE Mini-Mental Status Examination
NSAID non-steroidal anti-inflammatory drug
N2a strain A mouse neuroblastoma
NDA new drug application
NFT neurofibrillary tangle
NFκB anti-apoptotic nuclear factor kappa light-chain-enhancer of activated B cells
NLRP3 nucleoside binding domain, leucine-rich-repeat-containing family, pyrin 
domain-containing 3 inflammasome complex
OECD Organisation for Economic Co-Operation and Development
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OEL Occupational Exposure Limit
OSHA Occupational Safety and Health Administration
PEL permissible exposure limit
PM particulate matter
PN parenteral nutrition
PND postnatal day
PS presenilin
RBC-C3bRRerythrocyte C3b receptor rate
RCT randomized control trial
PTWI provisional tolerable weekly intake
RBC-ICR erythrycyte C3B immune complex rosette rate
REL recommended exposure limit
RfD reference dose
ROS reactive oxygen species
SALP sodium aluminum phosphate
sc subcutaneous
SCE sister chromatid exchange
SEM scanning electron microscopy
SOD superoxide dismutase
T testosterone
TBARS thiobarbituric acid reactive substances
TEM transmission electron microscopy
THGA transversely heated graphic atomizer
TLV® threshold limit value
TWA time-weighted-average
TWI tolerable weekly intake
UCL upper confidence limit
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l d
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 p
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l m
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t c
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 d
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 d
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 c
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↓ c
yt
ot
ox
ic
ity
 a
nd
 a
m
yl
oi
d 
fib
ril
s
Ch
en
 e
t a
l. 
(20
10
a)
A
lC
l 3 
•
 6
H
2O
 (S
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at
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β o
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at
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 c
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 c
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 d
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rul
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ra
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at
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ra
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 p
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 m
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 c
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at
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at
io
n
↓ γ
-
B
ut
yr
ob
et
ai
ne
 a
ld
eh
yd
e 
de
hy
dr
og
en
as
e
↓ B
ut
yr
ob
et
ai
ne
 d
io
xy
ge
na
se
Le
m
ire
 e
t a
l. 
(20
11
)
K
[A
l (
C 7
H
11
O
6) 3
] (
Al
 
qu
in
at
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ra
t h
ip
po
ca
m
pa
l 
ce
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pr
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A
l +
3
A
l 2 
(S
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d 
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y
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nt
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fir
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2,
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v
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 d
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1
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ro
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t r
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v
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V
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ith
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m
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ig
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 c
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nt
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 μg
) w
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dju
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n
t, 
G
M
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-a
dju
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n
t f
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m
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at
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 an
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tiv
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w
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r 
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t f
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m
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at
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A
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lle
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ic
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io
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v
en
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r 
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en
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ge
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v
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o
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w
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t f
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m
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at
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ra
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v
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n
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 a
nt
ig
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 d
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v
er
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Th
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s m
en
tio
ne
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V
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ul
at
io
n 
w
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o
t g
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en
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 c
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n 
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ad
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ce
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se
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f c
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tio
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d
R
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A
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f d
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m
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ng
 e
t 
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0) 
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y
H
ea
lth
y 
vo
lu
nt
ee
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 (n
 
=
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52
0),
 st
rat
ifi
ed
 b
y 
ag
e 
(3–
7, 
8–
12
, 1
3–
18
, 
19
–4
0,
 4
1–
60
 an
d 
≥ 
61
 
ye
ar
s)
A
l (
OH
) 3 
in
 in
flu
en
za
 A
 (H
1N
1) 
sp
lit
-v
iri
on
 (S
V)
 va
cc
in
e 
fo
rm
ul
at
io
ns
; 2
 d
os
es
 (0
.5 
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 A
l/m
l 
pe
r d
os
e),
 21
 da
ys
 ap
art
Co
nt
ro
l g
ro
up
 re
ce
iv
ed
 st
er
ile
 w
at
er
 
o
r 
ph
os
ph
at
e 
bu
ffe
re
d 
sa
lin
e 
in
jec
tio
n
IE
s: 
In
cr
ea
se
 in
 G
M
T 
fro
m
 
da
y 
0 
(va
cc
in
at
io
n) 
to 
da
y 2
1, 
35
 an
d 
42
 co
m
pa
re
d 
to
 n
on
-
ad
juv
an
t v
ac
ci
ne
IE
s: 
R
ed
uc
ed
 im
m
un
e 
re
sp
on
se
 a
fte
r 
co
n
sid
er
in
g 
tim
e 
po
st-
va
cc
in
at
io
n,
 a
ge
 
an
d 
ge
nd
er
 w
as
 r
ep
or
te
d 
in
 A
l-a
dju
va
n
t-
co
n
ta
in
ed
 v
ac
ci
ne
 g
ro
up
. P
ea
k 
im
m
un
e 
re
sp
on
se
 (G
M
T)
 w
as
 o
bs
er
ve
d 
on
 d
ay
 3
5 
in
 n
on
-a
dju
va
n
t g
ro
up
. H
ig
he
st 
G
M
Ts
 
fo
r a
dju
va
n
t g
ro
up
 w
er
e 
ob
se
rv
ed
 o
n 
da
y 
41
Y
in
 e
t a
l. 
(20
11
)
D
B
PC
*
H
ea
lth
y 
ad
ul
ts 
(m
ale
s 
an
d 
fe
m
al
es
), 2
3–
42
 
ye
ar
s (
n
 
=
 5
–3
0/
ra
n
do
m
ly
 a
ss
ig
ne
d 
fo
r 
ea
ch
 g
ro
up
, s
tra
tif
ie
d 
by
 g
en
de
r w
ith
 a
 1
: 1
 
al
lo
ca
tio
n 
ra
tio
)
A
l (
OH
) 3 
in
 in
flu
en
za
 A
/H
1N
1 
m
o
n
o
v
al
en
t v
ac
ci
ne
; 2
 d
os
es
 (0
.25
 
m
g 
pe
r d
os
e),
 21
 da
ys
 ap
art
7.
5 
an
d 
3.
5 
μg
 (H
A)
 w
ith
 A
l (
OH
) 3 
(G
rou
p I
 an
d G
rou
p I
I, r
esp
ec
tiv
el
y
Co
nt
ro
l g
ro
up
 re
ce
iv
ed
 p
ho
sp
ha
te
 
bu
ffe
re
d 
sa
lin
e
IE
s3
: 
Pe
rc
en
ta
ge
 
se
ro
co
nv
er
sio
n4
 
at
 d
ay
 2
1 
(%
) a
fte
r f
irs
t a
nd
 se
co
nd
 
v
ac
ci
na
tio
n,
 th
e 
pr
op
or
tio
n 
of
 
se
ro
pr
ot
ec
te
d 
pa
rti
ci
pa
nt
s 
(w
ith
 po
st-
va
cc
in
at
io
n 
H
I 
an
tib
od
y 
tit
er
 ≥
 1
: 4
0) 
(%
), 
in
cr
ea
se
 in
 G
M
T 
m
ea
su
re
d 
be
fo
re
 a
nd
 2
1 
da
ys
 a
fte
r e
ac
h 
v
ac
ci
na
tio
n
A
Es
: 
Pa
rt
ic
ip
an
ts 
re
co
rd
ed
 
th
e 
oc
cu
rre
nc
e 
of
 u
ns
ol
ic
ite
d 
an
d 
so
lic
ite
d 
lo
ca
l (
pa
in,
 
br
ui
sin
g,
 re
dn
es
s, 
an
d 
sw
el
lin
g),
 an
d s
ys
tem
ic 
(fe
v
er
,
 
ch
ill
s, 
m
al
ai
se
, m
us
cl
e 
ac
he
s, 
ar
th
ra
lg
ia
, n
au
se
a,
 a
nd
 
he
ad
ac
he
) s
ym
pto
ms
 du
rin
g 
th
re
e 
da
ys
 a
fte
r e
ac
h 
v
ac
ci
na
tio
n
O
f 3
57
 su
bje
cts
 as
ses
sed
, 2
66
 un
de
rw
en
t 
ra
n
do
m
iz
at
io
n.
 T
he
 a
ge
 a
nd
 g
en
de
r 
di
str
ib
u
tio
ns
 w
er
e 
sim
ila
r a
m
on
g 
th
e 
gr
ou
ps
. 1
00
%
 (n
 
=
 2
66
) r
ec
eiv
ed
 th
e 
fir
st 
v
ac
ci
na
tio
n 
an
d 
94
.4
%
 (n
 
=
 2
51
) r
ec
eiv
ed
 
th
e 
se
co
nd
 v
ac
ci
na
tio
n.
 T
he
 a
ge
 a
nd
 
ge
nd
er
 d
ist
rib
u
tio
ns
 w
er
e 
sim
ila
r a
m
on
g 
gr
ou
ps
IE
s: 
Se
ro
co
nv
er
sio
n 
at
 d
ay
 2
1 
(af
ter
 fir
st/
se
co
n
d 
va
cc
in
at
io
n 
[m
ea
n (
95
% 
Co
nf
id
en
ce
 In
te
rv
al
 (C
I)]
:
G
ro
up
 I:
 4
7.
6(2
5.7
–7
0.2
)/6
0.0
(36
.1–
80
.9
)
G
ro
up
 II
: 2
6.
9(1
1.6
–4
7.8
)/4
8.0
(27
.8–
68
.7
)
Co
nt
ro
l g
ro
up
: 0
(0–
52
.2)
/0(
0–
52
.2)
Pr
op
or
tio
n 
of
 se
ro
pr
ot
ec
te
d 
pa
rti
ci
pa
nt
s 
(af
ter
 fir
st/
se
co
nd
 v
ac
ci
na
tio
n) 
[m
ea
n 
(95
% 
Co
nfi
de
nc
e 
In
te
rv
al
 (C
I)]
G
ro
up
 1
: 5
7.
1(3
4.0
–7
8.2
)/7
0.0
(45
.7–
88
.1
)
G
ro
up
 II
: 3
8.
5(2
0.2
–5
9.4
)/5
2.0
(31
.3–
72
.2
)
Co
nt
ro
l: 
0(0
–5
2.2
)/0
(0–
52
.2)
In
cr
ea
se
 in
 G
M
T 
(af
ter
 fir
st/
se
co
nd
 
v
ac
ci
na
tio
n[
me
an
 (9
5%
 C
on
fid
en
ce
 
In
te
rv
al
 (C
I)]
):
G
ro
up
 I:
 3
6.
2(2
2.6
–5
8.0
)/3
8.6
(27
.1–
55
.2
)
G
ro
up
 II
: 2
1.
7(1
5.2
–3
1.0
)/3
3.9
(23
.1–
49
.6
)
Co
nt
ro
l g
ro
up
: 1
0(5
.4–
18
.4)
/10
(5.
4–
18
.4
)
A
Es
: 
N
o 
de
at
hs
 o
r o
th
er
 S
A
Es
 w
er
e 
re
po
rte
d.
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o 
lo
ca
l a
dv
er
se
 e
v
en
ts
 w
er
e 
re
po
rte
d 
by
 G
ro
up
 II
 p
ar
tic
ip
an
ts 
an
d 
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54
%
 G
ro
up
 I 
pa
rti
ci
pa
nt
s. 
M
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 an
d 
m
o
de
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te
 p
ai
n 
(19
 an
d 2
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), m
od
era
te 
re
dn
es
s a
nd
 sw
el
lin
g 
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an
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re
sp
ec
tiv
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 m
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t f
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ue
nt 
lo
ca
l e
v
en
ts
 re
po
rte
d 
by
 p
ar
tic
ip
an
ts 
fro
m
 
G
ro
up
 I.
 O
nl
y 
m
ild
 p
ai
n 
at
 th
e 
in
jec
tio
n 
sit
e 
w
as
 r
ep
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te
d 
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 C
on
tro
l g
ro
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pa
rti
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s (
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ste
m
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re
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tio
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M
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se
a 
an
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he
ad
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he
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m
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te
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by
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 e
t a
l. 
(20
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)
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g c
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 o
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s o
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s o
r o
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A
l (
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) 3 
in
 in
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1N
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m
o
n
o
v
al
en
t, 
sp
lit
-v
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s v
ac
ci
ne
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s (
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ter
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lu
m
e 
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re
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rte
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2 m
g a
lum
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l o
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v
ac
ci
ne
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1 d
ay
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pa
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A
 w
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w
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A
l (
OH
) 3,
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μg
 o
f H
A
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(O
H)
3
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ro
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ro
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 re
ce
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ed
 p
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e
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or
tio
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bje
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se
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H
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r b
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 d
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 p
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m
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 re
ac
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tio
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 m
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t d
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e 
an
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r t
he
 se
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e
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bje
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cei
v
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 d
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 d
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o
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at
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-re
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at
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dju
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y. 
Th
e 
m
os
t c
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 p
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r d
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d H
AI
 as
say
s
A
Es
: 
N
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 d
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m
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o
ra
l t
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v
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in
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, r
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ne
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, a
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lin
g) 
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m
pt
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s (
fev
er
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ne
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, 
m
al
ai
se
, m
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s, 
he
ad
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he
, 
an
d 
na
us
ea
) d
uri
ng
 7 
da
ys
 
af
te
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ac
h 
im
m
un
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at
io
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n
u
rs
es
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te
rv
ie
w
ed
 p
at
ie
nt
s i
n 
th
e 
cl
in
ic
 o
n 
da
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 a
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te
r e
ac
h 
va
cc
in
at
io
n,
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w
 
u
p 
in
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at
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n 
w
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o
lle
ct
ed
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 d
ay
s a
fte
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h 
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cc
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n 
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m
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th
s a
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r t
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 se
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nd
 
v
ac
ci
na
tio
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 th
e 
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te
rim
 
m
ed
ic
al
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or
y 
w
as
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ev
ie
w
ed
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0 
su
bje
cts
 w
ere
 en
rol
led
 in
 th
e s
tud
y; 
59
9 
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ce
iv
ed
 th
e 
fir
st 
va
cc
in
at
io
n 
an
d 
54
5 
re
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iv
ed
 th
e 
se
co
nd
. N
o 
di
ffe
re
nc
es
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nd
er
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ic
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ra
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o
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e 
w
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. G
M
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N
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t b
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at
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o
n
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s
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se
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t 2
8 
da
ys
 a
fte
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n
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at
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 b
ot
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e 
ad
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s (
p 
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s 
o
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v
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l(O
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 d
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A
A
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rt
ic
ip
an
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w
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ce
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ac
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w
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l(O
H)
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ha
d 
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cr
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se
d 
in
jec
tio
n s
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te
nd
er
ne
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 w
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A
 d
os
es
 (e
x
ce
pt
 a
t 4
5 
μg
 H
A
) d
uri
ng
 7 
da
ys
 af
ter
 th
e f
irs
t a
nd
 
th
e 
se
co
nd
 v
ac
ci
na
tio
ns
 (p
 
≤ 
0.
01
) a
nd
 
pa
in
 a
fte
r t
he
 fi
rs
t v
ac
ci
na
tio
n 
on
ly
 
co
m
pa
re
d 
to
 v
ac
ci
ne
 w
ith
ou
t A
l(O
H)
3.
 
In
 
th
e 
45
 μ
g 
H
A
 d
os
e g
ro
up
, t
he
 fr
eq
ue
nc
ie
s 
o
f t
en
de
rn
es
s a
nd
 p
ai
n 
in
cr
ea
se
d 
af
te
r t
he
 
fir
st 
va
cc
in
at
io
n 
co
m
pa
re
d 
to
 th
e 
se
co
nd
 
v
ac
ci
na
tio
n.
 N
o 
ge
nd
er
-
re
la
te
d 
di
ffe
re
nc
es
 in
 in
jec
tio
n s
ite
 re
act
ion
s 
w
er
e 
n
o
te
d.
 T
he
re
 w
er
e 
no
 H
A
 d
os
e-
re
la
te
d 
in
cr
ea
se
s i
n 
sy
ste
m
ic
 re
ac
tio
ns
 in
 
B
ra
dy
 e
t a
l. 
(20
09
)
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St
ud
y 
de
sig
n
Po
pu
la
tio
n/
Sa
m
pl
e
Su
bs
ta
nc
es
O
ut
co
m
es
 st
ud
ie
d
R
es
ul
ts
R
ef
er
en
ce
s
ei
th
er
 A
l(O
H)
3 
ad
juv
an
t o
r n
on
-a
dju
va
n
t 
gr
ou
ps
R
CT
*
*
H
ea
lth
y 
ch
ild
re
n,
 
st
ra
tif
ie
d 
by
 a
ge
 (0
.5–
3 
ye
ar
s, 
3–
18
 y
ea
rs
, a
nd
 
9–
17
 y
ea
rs
 (n
 
=
 3
0 
pa
rti
ci
pa
nt
s p
er
 e
ac
h 
gr
ou
p)
A
l (
OH
) 3 
in
flu
en
za
 m
on
ov
al
en
t A
/
H
5N
1 
va
cc
in
e 
fo
rm
ul
at
io
ns
; 2
 d
os
es
 
(0.
25
–0
.5 
ml
 pe
r d
os
e w
ith
 1.
2 m
g 
A
l/m
l o
f v
ac
ci
ne
), 2
1 d
ay
s a
pa
rt
30
 a
nd
 1
5 
μg
 o
f H
A
 w
ith
 an
d 
w
ith
ou
t 
A
l a
dju
va
n
t, 
re
sp
ec
tiv
el
y,
 
an
d
7.
5 
an
d 
3.
5 
μg
 o
f H
A
 w
ith
ou
t A
l 
ad
juv
an
t
N
o 
co
nt
ro
l g
ro
up
IE
s: 
In
cr
ea
se
 in
 G
M
T 
fro
m
 
v
ac
ci
na
tio
n 
da
y 
0 
to
 d
ay
 2
1
A
Es
: 
Pa
re
n
ts
 re
co
rd
ed
 
ad
ve
rs
e 
ev
en
ts
 o
cc
ur
rin
g 
up
 
to
 d
ay
 2
1 
af
te
r v
ac
ci
na
tio
n.
 
Th
e 
da
ily
 o
cc
ur
re
nc
e 
of
 
so
lic
ite
d 
sy
ste
m
ic
 a
nd
 
in
jec
tio
n s
ite
 re
act
ion
s w
ere
 
re
co
rd
ed
 u
p 
to
 d
ay
 7
 
fo
llo
w
in
g 
va
cc
in
at
io
n.
 D
ur
in
g 
th
e 
fo
llo
w
in
g 
vi
sit
, 
in
v
es
tig
at
or
s 
co
lle
ct
ed
 
in
fo
rm
at
io
n 
fro
m
 th
e 
ch
ild
re
n 
an
d 
th
ei
r p
ar
en
ts 
an
d 
as
se
ss
ed
 
w
he
th
er
 th
ey
 w
er
e 
va
cc
in
e-
re
la
te
d
IE
s: 
Th
e 
fu
ll 
do
se
 (3
0 μ
g +
 A
l) 
fo
rm
ul
at
io
n 
w
as
 m
o
re
 im
m
un
og
en
ic
 th
an
 
th
e 
ha
lf 
do
se
 (7
.5 
μg
 − 
Al
) i
n a
ll a
ge
 
gr
ou
ps
. I
n 
th
e 
fu
ll 
do
se
 (3
0 μ
g +
 A
l) 
gr
ou
p,
 th
e 
pr
op
or
tio
n 
of
 su
bje
cts
 w
ith
 
G
M
Ts
 ≥
 3
2 
af
te
r t
he
 se
co
nd
 v
ac
ci
na
tio
n 
w
as
 6
0%
 (9
–1
7 y
ea
rs)
, 7
0%
 (3
–8
 ye
ars
) 
an
d 
50
%
 (0
.6–
3 y
ea
rs)
 an
d i
n t
he
 ha
lf-
do
se
 (1
5 μ
g +
 A
l) 
gro
up
 – 
30
% 
(0.
5–
3 
ye
ar
s).
 In
 th
e f
ull
 do
se 
(30
 μg
 + 
Al
) 
gr
ou
p,
 n
eu
tra
liz
in
g 
an
tib
od
y 
re
sp
on
se
 2
1 
da
ys
 a
fte
r t
w
o
 in
jec
tio
ns 
wa
s 
92
%
 (9
–1
7 
ye
ar
s),
 10
6%
 (3
–8
 ye
ars
) a
nd
 72
% 
(0.
5–
3 
ye
ar
s);
 in
 th
e h
alf
 do
se 
(15
 μg
 + 
Al
) 
gr
ou
p,
 re
sp
on
se
 w
as
 6
0.
2%
 (0
.5–
3 y
ea
rs)
A
Es
: 
In
 g
ro
up
 g
iv
en
 3
0 
μg
 +
 A
l(O
H)
3 
pa
in
 w
as
 r
ep
or
te
d 
in
 4
0%
 a
nd
 6
3%
 o
f 9
–
17
 a
nd
 3
–8
 y
ea
r o
ld
 p
ar
tic
ip
an
ts,
 
re
sp
ec
tiv
el
y.
 
Co
m
pl
ai
nt
s o
f t
en
de
rn
es
s a
t 
th
e 
in
jec
tio
n s
ite
 in
 44
% 
of 
0.5
–3
 ye
ars
 
o
ld
 p
ar
tic
ip
an
ts.
 P
ai
n 
w
as
 th
e 
m
os
t 
fre
qu
en
tly
 re
po
rte
d 
ev
en
t i
n 
ch
ild
re
n 
ag
ed
 0
.5
–3
 y
ea
rs
 w
ho
 re
ce
iv
ed
 h
al
f-d
os
e 
(15
 μg
 + 
Al
) f
orm
ula
tio
n. 
Sy
ste
mi
c 
re
ac
tio
ns
 w
er
e 
he
ad
ac
he
 1
0%
 (9
–1
7 
ye
ar
s),
 m
ya
lgi
a 4
0%
 (3
–8
 ye
ars
), 
v
o
m
iti
ng
 3
0%
, i
rri
ta
bi
lit
y 
30
%
, a
bn
or
m
al
 
cr
yi
ng
 5
0%
, a
no
re
x
ia
 3
6%
 (0
.5–
3 y
ea
rs)
. 
In
 th
e 
ha
lf 
do
se
 (1
5 μ
g +
 A
l) 
gro
up
, o
ne
 
ch
ild
 (2
 ye
ars
) h
ad
 m
us
cu
lo-
pa
pu
le 
ras
h 
fo
r 1
 d
ay
 a
nd
 a
no
th
er
 (2
 ye
ars
 ol
d) 
ha
d 
an
 in
jec
tio
n s
ite
 pa
pu
le 
an
d m
ild
 itc
hin
g 
th
at
 re
so
lv
ed
 a
fte
r 2
 d
ay
s
Ch
ot
pi
ta
ya
su
no
nd
h 
et
 a
l. 
(20
08
)
R
CT
*
*
H
ea
lth
y 
fe
m
al
es
 (n
 
=
 
96
0),
 st
rat
ifi
ed
 b
y 
ag
e:
 
9–
14
, 1
5–
19
, a
nd
 3
0–
25
 y
ea
rs
 (n
 
=
 2
40
–2
41
/
gr
ou
p)
A
l (
OH
) 3 
in
 th
e 
hu
m
an
 
pa
pi
llo
m
av
iru
s
(H
PV
) –
 16
/18
 A
SO
46
 
ad
juv
an
te
d 
v
ac
ci
ne
2 
do
se
s (
0.5
 m
l) 
of 
20
/20
 F7
 
at
 0
, 6
 
m
o
n
th
s, 
40
/4
0F
 a
t 0
, 6
 m
on
th
s, 
40
/4
0 
F8
 
at
 0
, 2
 m
on
th
s, 
or
 3
 d
os
es
 o
f 2
0/
20
 
F 
at
 0
, 1
 o
r 6
 m
on
th
s
Co
nt
ro
l d
os
e 
co
nt
ai
ne
d 
0.
5 
m
g 
A
l(O
H)
3.
IE
s: 
G
eo
m
et
ric
 m
ea
n 
an
tib
od
y 
tit
er
 (G
M
T)
 on
e 
m
o
n
th
 a
fte
r t
he
 la
st 
ac
tiv
e 
do
se
; a
nt
ib
od
y 
co
nc
en
tra
tio
ns
 
to
 H
PV
-
16
 an
d 
H
PV
-
18
 w
er
e 
m
ea
su
re
d 
by
 th
e 
en
zy
m
e-
lin
ke
d 
im
m
un
os
or
be
nt
 a
ss
ay
 
(E
lIS
A)
 an
d a
nti
bo
dy
 
co
n
ce
n
tr
at
io
ns
 g
re
at
er
 th
an
 o
r 
eq
ua
l t
o 
th
e 
lo
w
er
 li
m
it 
of
 
de
te
ct
io
n 
fo
r e
ac
h 
as
sa
y 
w
er
e 
pr
e-
sp
ec
ifi
ed
 to
 in
di
ca
te
 
se
ro
po
sit
iv
ity
9
A
Es
: P
ar
en
ts
 o
r p
ar
tic
ip
an
ts 
re
co
rd
ed
 so
lic
ite
d 
lo
ca
l 
sy
m
pt
om
s (
pa
in,
 re
dn
ess
 or
 
sw
el
lin
g 
at
 in
jec
tio
n s
ite
) a
nd
 
ge
ne
ra
l s
ym
pt
om
s (
fev
er
,
 
96
1 
gi
rls
 an
d 
yo
un
g 
w
o
m
en
 w
er
e 
en
ro
lle
d 
in
to
 st
ud
y. 
96
0 
re
ce
iv
ed
 a
t l
ea
st 
o
n
e 
v
ac
ci
ne
 in
jec
tio
n
IE
s: 
Th
e 
ki
ne
tic
s o
f a
nt
ib
od
ie
s a
ga
in
st 
bo
th
 H
PV
-
16
 an
d 
H
PV
-
18
 in
 th
e 
2-
do
se
 
v
ac
ci
ne
 g
ro
up
s f
or
 g
irl
s (
9–
14
 ye
ars
) 
w
er
e 
sim
ila
r t
o 
th
os
e 
ob
se
rv
ed
 in
 th
e 
lic
en
se
d 
3-
do
se
 v
ac
ci
ne
 g
ro
up
 fo
r y
ou
ng
 
w
o
m
en
 (1
5–
25
 ye
ars
)
A
Es
: 
N
o 
pa
rti
ci
pa
nt
s w
ith
dr
ew
 fr
om
 th
e 
st
ud
y 
du
e 
to
 a
n 
A
E 
or
 S
A
E.
 P
ai
n 
w
as
 th
e 
m
o
st
 fr
eq
ue
nt
ly
 re
po
rte
d 
lo
ca
l s
ym
pt
om
 
(81
 to
 86
% 
of 
all
 do
ses
 ac
ros
s g
rou
ps
). 
N
o 
ur
tic
ar
ia
 o
r r
as
h 
w
as
 o
bs
er
ve
d 
w
ith
in
 
30
 m
in
 a
fte
r a
ny
 v
ac
ci
ne
 d
os
e 
in
 a
ny
 
gr
ou
p.
 H
ea
da
ch
e,
 fa
tig
ue
 a
nd
 m
ya
lg
ia
 
w
er
e 
th
e 
m
os
t f
re
qu
en
tly
 re
po
rte
d 
sy
ste
m
ic
 c
om
pl
ai
nt
s. 
In
 to
ta
l c
oh
or
t (
n
 
=
 
R
om
an
ow
sk
i e
t a
l. 
(20
11
)
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St
ud
y 
de
sig
n
Po
pu
la
tio
n/
Sa
m
pl
e
Su
bs
ta
nc
es
O
ut
co
m
es
 st
ud
ie
d
R
es
ul
ts
R
ef
er
en
ce
s
he
ad
ac
he
, f
at
ig
ue
, 
ga
st
ro
in
te
sti
na
l s
ym
pt
om
s, 
ar
th
ra
lg
ia
, m
ya
lg
ia
, r
as
h 
or
 
u
rt
ic
ar
ia
) o
cc
urr
ing
 30
 m
in 
an
d 
7 
da
ys
 a
fte
r e
ac
h 
v
ac
ci
na
tio
n 
w
er
e 
re
co
rd
ed
 
u
sin
g 
a 
di
ar
y 
ca
rd
. S
A
Es
, 
o
th
er
 m
ed
ic
al
ly
 si
gn
ifi
ca
nt
 
co
n
di
tio
ns
 (i
.e.
, A
Es
 
pr
om
pt
in
g 
em
er
ge
nc
y 
ro
om
 
o
r 
ph
ys
ic
ia
n 
vi
sit
s t
ha
t w
er
e 
n
o
t r
el
at
ed
 to
 c
om
m
on
 
di
se
as
es
), n
ew
 o
n
se
t c
hr
on
ic
 
di
se
as
es
 in
cl
ud
in
g 
ne
w
 o
n
se
t 
au
to
im
m
un
e 
di
se
as
es
 a
nd
 
pr
eg
na
nc
ie
s o
cc
ur
rin
g 
th
ro
ug
h 
m
on
th
 2
4 
w
er
e 
do
cu
m
en
te
d.
 P
re
gn
an
ci
es
 
w
er
e 
fo
llo
w
ed
 u
nt
il 
de
liv
er
y.
 
N
ew
 o
n
se
t c
hr
on
ic
 d
ise
as
es
 
an
d 
ne
w
 o
n
se
t a
ut
oi
m
m
un
e 
di
se
as
es
 (p
ote
nti
al 
au
to
im
m
un
e 
ev
en
ts
, w
hi
ch
 
ex
cl
ud
ed
 a
lle
rg
y-
re
la
te
d 
ev
en
ts
 o
r i
so
la
te
d 
sig
ns
 a
nd
 
sy
m
pt
om
s) 
we
re 
ide
nti
fie
d 
by
 
co
m
pa
rin
g 
al
l r
ep
or
te
d 
A
Es
 
w
ith
 a
 p
re
-d
ef
in
ed
 li
st 
of
 
po
te
nt
ia
l c
hr
on
ic
 d
ise
as
es
 
de
riv
ed
 fr
om
 th
e 
M
ed
ic
al
 
D
ic
tio
na
ry
 fo
r R
eg
ul
at
or
y 
A
ct
iv
iti
es
72
1) 
thr
ou
gh
 m
on
th 
24
, n
o a
dv
er
se
 
ev
en
ts
 le
ad
in
g 
to
 p
re
m
at
ur
e 
di
sc
on
tin
ua
tio
n 
of
 v
ac
ci
ne
 w
er
e 
re
po
rte
d.
 
M
ed
ic
al
ly
-s
ig
ni
fic
an
t a
dv
er
se
 e
ffe
ct
s a
nd
 
n
ew
 o
n
se
t a
ut
oi
m
m
un
e 
di
se
as
es
 w
er
e 
re
po
rte
d 
at
 a
 si
m
ila
r f
re
qu
en
cy
 a
cr
os
s 
gr
ou
ps
R
CT
*
*
H
ea
lth
y 
ad
ol
es
ce
nt
s, 
10
–1
8 
ye
ar
s o
f a
ge
, 
ra
n
do
m
ly
 a
ss
ig
ne
d 
to
 
th
re
e 
gr
ou
ps
 st
ra
tif
ie
d 
by
 th
e 
re
ce
iv
ed
 d
os
e 
(n 
=
 2
09
–2
24
/g
ro
up
)
A
l (
OH
) 3 
in
 c
om
bi
ne
d 
di
ph
th
er
ia
-
te
ta
nu
s-
ac
el
lu
la
r p
er
tu
ss
is 
(dT
pa
) 
v
ac
ci
ne
; 1
 d
os
e 
(0.
5 m
l p
er 
do
se 
wi
th 
0.
13
3,
 0
.3
 o
r 0
.5
 m
g 
A
l p
er
 0
.5
 m
l 
do
se
 o
f v
ac
ci
ne
)
A
ll 
th
re
e 
va
cc
in
e 
fo
rm
ul
at
io
ns
 w
er
e 
di
ffe
re
nt
 o
nl
y 
in
 th
ei
r t
ot
al
 A
l c
on
te
nt
 
A
ll 
an
tig
en
s w
er
e 
fu
lly
 a
ds
or
be
d 
w
ith
 
A
l (
OH
) 3
Va
cc
in
e 
fo
rm
ul
at
io
ns
 w
er
e 
pr
es
er
va
tiv
e-
fre
e
N
o 
co
nt
ro
l g
ro
up
 w
as
 in
cl
ud
ed
IE
s1
0 :
 B
oo
st
er
 re
sp
on
se
 ra
te
 
to
 a
ll 
va
cc
in
e 
an
tig
en
s 
(di
ph
the
ria
 an
d t
eta
nu
s o
r 
pe
rtu
ss
is)
 an
d p
os
t-
v
ac
ci
na
tio
n 
in
cr
ea
se
 o
f 
ge
om
et
ric
 m
ea
n 
an
tib
od
y 
co
n
ce
n
tr
at
io
n 
(G
M
C)
 in
du
ce
d 
by
 e
ac
h 
of
 th
e 
fo
rm
ul
at
io
ns
 a
t 
1 
m
on
th
 a
fte
r b
oo
ste
r 
ad
m
in
ist
ra
tio
n
A
Es
: P
at
ie
nt
s s
el
f-m
on
ito
re
d 
ad
ve
rs
e 
ev
en
ts
 to
 re
co
rd
 lo
ca
l 
re
dn
es
s, 
sw
el
lin
g 
an
d 
pa
in
, 
sy
ste
m
at
ic
 sy
m
pt
om
s o
f 
fa
tig
ue
, f
ev
er
,
 
he
ad
ac
he
, 
m
al
ai
se
 a
nd
 v
o
m
iti
ng
 a
t t
he
 
da
y 
of
 v
ac
ci
na
tio
n 
an
d 
du
rin
g 
14
 d
ay
s a
fte
r v
ac
ci
na
tio
n;
 
fo
llo
w
-u
p 
in
fo
rm
at
io
n 
on
 
u
n
so
lic
ite
d 
sy
m
pt
om
s, 
SA
Es
 
w
er
e 
co
lle
ct
ed
 fr
om
 p
at
ie
nt
s 
64
7 
su
bje
cts
 w
ere
 va
cc
in
at
ed
. 2
14
 (3
3%
) 
re
ce
iv
ed
 th
e 
0.
13
3 
m
g 
A
l f
or
m
ul
at
io
n,
 
20
9 
(32
%)
 − 
0.3
 m
g A
l f
orm
ula
tio
n a
nd
 
22
4 
(35
%)
 − 
0.3
 m
g A
l f
orm
ula
tio
n. 
Al
l 
su
bje
cts
 w
ere
 in
clu
de
d i
n t
he
 sa
fet
y 
an
al
ys
is 
an
d 
63
1 
su
bje
cts
 – 
in 
im
m
un
og
en
ic
ity
 a
na
ly
sis
. T
he
 
de
m
og
ra
ph
ic
 p
ro
fil
es
 o
f t
he
 th
re
e 
gr
ou
ps
 
w
er
e 
co
m
pa
ra
bl
e.
 A
ll 
gr
ou
ps
 w
er
e 
sim
ila
r i
n 
th
ei
r p
re
-v
ac
ci
na
tio
n 
se
ro
lo
gi
ca
l s
ta
tu
s
IE
s: 
Th
e 
bo
os
te
r i
m
m
un
e 
re
sp
on
se
 to
 
di
ph
th
er
ia
 a
nd
 te
ta
nu
s w
as
 n
o
t 
sig
ni
fic
an
tly
 d
iff
er
en
t a
m
on
g 
di
ffe
re
nt
 
gr
ou
ps
. P
os
t-v
ac
ci
na
tio
n 
an
ti-
PT
 G
M
C 
w
as
 s
ig
ni
fic
an
tly
 h
ig
he
r i
n 
th
e 
0.
5 
m
g 
A
l 
gr
ou
p 
co
m
pa
re
d 
to
 b
ot
h 
gr
ou
ps
 w
ith
 
re
du
ce
d 
A
l c
on
te
nt
 (p
 
<
 0
.0
16
7).
 A
mo
ng
 
th
e 
th
re
e 
dT
pa
 fo
rm
ul
at
io
ns
, t
he
 0
.5
 an
d 
0.
3 
m
g 
A
l d
os
es
 p
ro
du
ce
d 
a 
PT
 re
sp
on
se
 
w
ith
in
 c
lin
ic
al
ly
 a
cc
ep
ta
bl
e 
lim
its
Th
ee
te
n 
et
 a
l. 
(20
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St
ud
y 
de
sig
n
Po
pu
la
tio
n/
Sa
m
pl
e
Su
bs
ta
nc
es
O
ut
co
m
es
 st
ud
ie
d
R
es
ul
ts
R
ef
er
en
ce
s
du
rin
g 
30
 p
os
t-v
ac
ci
na
tio
n 
da
ys
In
iti
al
 se
ro
lo
gi
ca
l s
ta
tu
s i
nf
lu
en
ce
d 
th
e 
im
m
un
e 
re
sp
on
se
 in
 a
ll 
gr
ou
ps
. A
m
on
g 
pa
rti
ci
pa
nt
s s
er
on
eg
at
iv
e 
pr
io
r t
o 
bo
os
te
r 
v
ac
ci
na
tio
n,
 p
os
t-v
ac
ci
na
tio
n 
G
M
T 
co
n
ce
n
tr
at
io
ns
 w
er
e 
re
du
ce
d 
an
d 
bo
os
te
r 
re
sp
on
se
 ra
te
s w
er
e 
in
cr
ea
se
d
A
Es
: 
N
o 
sig
ni
fic
an
t d
iff
er
en
ce
s a
m
on
g 
st
ud
y 
gr
ou
ps
 in
 lo
ca
l o
r s
ys
te
m
ic
 e
ffe
ct
s 
w
er
e 
o
bs
er
ve
d.
 T
he
 in
ci
de
nc
e 
of
 fe
v
er
,
 
he
ad
ac
he
, f
at
ig
ue
, a
nd
 g
as
tr
oi
nt
es
tin
al
 
di
str
es
s h
ad
 a
n 
on
se
t w
ith
in
 2
 d
ay
s o
f 
fo
llo
w
 u
p 
an
d 
w
er
e 
sim
ila
r b
et
w
ee
n 
gr
ou
ps
. 6
5%
 in
 ea
ch
 g
ro
up
 re
po
rte
d 
at
 
le
as
t o
ne
 sy
ste
m
ic
 sy
m
pt
om
. S
ys
te
m
ic
 
ev
en
ts
 te
nd
ed
 to
 in
cr
ea
se
 w
ith
 in
cr
ea
sin
g 
A
l d
os
e.
 S
ol
ic
ite
d 
ge
ne
ra
l s
ym
pt
om
s 
w
er
e 
ra
re
 b
u
t t
en
de
d 
to
 in
cr
ea
se
 w
ith
 
in
cr
ea
se
d 
A
l d
os
e.
 A
 si
gn
ifi
ca
nt
 
di
ffe
re
nc
e 
am
on
g 
stu
dy
 g
ro
up
s w
as
 
fo
un
d 
on
ly
 fo
r f
at
ig
ue
 (g
rad
e 3
) w
ith
 
o
n
se
t w
ith
in
 1
4 
da
ys
 p
os
t-v
ac
ci
na
tio
n 
(nu
mb
er/
pe
rce
nta
ge
 of
 su
bje
cts
/95
% 
CI
) 
[4
/1.
9 (
0.5
–4
.7)
, 9
/4.
3 (
2.0
–8
.0)
, a
nd
 
18
/8
.0
 (4
.8–
12
.4)
 fo
r 0
.13
3, 
0.3
 an
d 0
.5 
m
g 
A
l d
os
e 
gr
ou
ps
, r
es
pe
ct
iv
el
y]
.
Pr
os
pe
ct
iv
e 
o
bs
er
va
tio
na
l s
tu
dy
H
ea
lth
y 
ch
ild
re
n,
 6
–7
 
ye
ar
s o
ld
 (n
 
=
 2
43
)
A
l (
OH
) 3 
in
 te
ta
nu
s t
ox
oi
d,
 re
du
ce
d 
di
ph
th
er
ia
 to
xo
id
, a
nd
 a
ce
llu
la
r 
pe
rtu
ss
is 
(T
da
p) 
va
cc
in
es
; s
in
gl
e 
do
se
 
(0.
33
 m
g A
l (
OH
) 3/
do
se
). A
ll 
ch
ild
re
n 
re
ce
iv
ed
 g
ov
er
n
m
en
t-
pr
ov
id
ed
 d
ip
ht
he
ria
-p
er
tu
ss
is 
an
d 
te
ta
tu
s 
(D
Pw
T)
 va
cc
in
e 
fo
r t
he
 fi
rs
t 3
 
do
se
s
N
o 
co
nt
ro
l g
ro
up
 w
as
 in
cl
ud
ed
A
Es
: R
ed
ne
ss
, i
nd
ur
at
io
n,
 
te
nd
er
ne
ss
, i
tc
hi
ng
, f
ev
er
,
 
he
ad
ac
he
, v
o
m
iti
ng
 w
er
e 
re
co
rd
ed
 b
y 
th
e 
ph
ys
ic
ia
n 
at
 
1,
 2
, 4
, a
nd
 7
 d
ay
s p
os
t-
in
jec
tio
n. 
So
lic
ite
d a
dv
er
se
 
ev
en
ts
 in
cl
ud
ed
 in
jec
tio
n s
ite
 
re
dn
es
s, 
in
du
ra
tio
n,
 
te
nd
er
ne
ss
, i
tc
hi
ng
, f
ev
er
,
 
he
ad
ac
he
, a
nd
 g
as
tr
oi
nt
es
tin
al
 
sy
m
pt
om
s w
er
e 
re
co
rd
ed
 
ac
co
rd
in
g 
to
 th
e 
ch
ild
re
n’
s 
de
sc
rip
tio
n
A
 to
ta
l 2
63
 ch
ild
re
n 
w
er
e e
v
al
ua
te
d 
an
d 
24
3 
w
er
e 
en
ro
lle
d 
in
 th
e 
stu
dy
.
A
Es
: 
In
cr
ea
se
d 
lo
ca
l s
ki
n 
re
dn
es
s 4
7 
(19
%)
 ch
ild
ren
, in
du
rat
ion
 in
 57
 (2
3%
), 
te
nd
er
ne
ss
 in
 1
30
 (5
3%
), a
nd
 fe
v
er
 in
 1
2 
(5%
) c
hil
dre
n. 
Tw
en
ty
-o
ne
 (9
%)
 
pa
rti
ci
pa
nt
s r
ep
or
te
d 
itc
hi
ng
 a
ro
un
d 
th
e 
in
jec
tio
n s
ite
, w
ith
 or
 w
ith
ou
t lo
cal
 
re
dn
es
s a
nd
 in
du
ra
tio
n.
 R
ed
ne
ss
 a
nd
 
in
du
ra
tio
n 
re
so
lv
ed
 in
 7
 d
ay
s a
nd
 fe
v
er
 
re
so
lv
ed
 o
n 
da
y 
4.
 T
he
 a
dv
er
se
 e
v
en
ts
 
w
er
e 
n
o
t a
ss
oc
ia
te
d 
w
ith
 g
en
de
r o
r B
M
I 
ab
ov
e 
th
e 
m
ea
n
N
o 
se
iz
ur
es
, m
ajo
r n
eu
rol
og
ic 
rea
cti
on
s 
o
r 
o
th
er
 ra
re
 ev
en
ts
 w
er
e 
ob
se
rv
ed
; 
re
po
rte
d 
ad
ve
rs
e 
ev
en
ts
 a
fte
r T
da
p 
v
ac
ci
na
tio
n 
w
er
e 
m
ild
W
ei
 e
t a
l. 
(20
11
)
Pr
os
pe
ct
iv
e 
o
bs
er
va
tio
na
l s
tu
dy
H
ea
lth
y 
ad
ul
ts,
 h
ea
lth
 
ca
re
 w
o
rk
er
s,
 fr
om
 3
0 
to
 ≥
 5
0 
ye
ar
s (
n
 
=
 2
07
)
A
ll 
pa
rti
ci
pa
nt
s r
ec
ei
v
ed
 th
e 
te
ta
nu
s-
di
ph
th
er
ia
-a
ce
llu
la
r p
er
tu
ss
is 
(T
da
p) 
v
ac
ci
ne
 (n
o o
the
r d
eta
ils
 av
ai
la
bl
e)
Po
st-
va
cc
in
at
io
n 
A
E 
(up
 to
 5 
ye
ar
s a
fte
r l
as
t v
ac
ci
na
tio
n):
 
Lo
ca
l a
dv
er
se
 e
v
en
ts
 (p
ain
, 
re
dn
es
s, 
an
d 
sw
el
lin
g) 
an
d 
sy
ste
m
ic
 a
dv
er
se
 e
v
en
ts
 (e
.g.
, 
fe
v
er
,
 
he
ad
ac
he
, a
nd
 fa
tig
ue
), 
as
 w
el
l a
s e
nt
ire
 li
m
b 
sw
el
lin
g 
w
er
e 
re
co
rd
ed
. U
ns
ol
ic
ite
d 
ad
ve
rs
e 
ev
en
ts
 th
at
 o
cc
ur
re
d 
af
te
r T
da
p 
va
cc
in
at
io
n 
w
er
e 
al
so
 re
co
rd
ed
. S
pe
ci
fic
 
26
8 
el
ig
ib
le
 su
bje
cts
 w
ere
 id
en
tifi
ed
 a
nd
 
20
7 
w
er
e 
in
cl
ud
ed
 in
 th
e 
su
rv
ey
A
Es
: 
16
7 
pa
rti
ci
pa
nt
s (
81
%)
 re
po
rte
d a
t 
le
as
t 1
 a
dv
er
se
 e
v
en
t: 
0.
5%
 re
po
rte
d 
se
v
er
e 
fe
v
er
,
 
he
ad
ac
he
, a
nd
 fa
tig
ue
, 1
2 
(6%
) r
ep
ort
ed
 pa
in.
 Fe
ma
le 
ge
nd
er 
wa
s 
an
 in
de
pe
nd
en
t p
re
di
ct
or
 o
f l
oc
al
 a
dv
er
se
 
ev
en
ts
 (o
dd
s r
ati
o (
OR
), 3
.06
 [9
5%
 
co
n
fid
en
ce
 in
te
rv
al
, 1
.5
1–
6.
23
]).
 L
oc
al 
ad
ve
rs
e 
ev
en
ts
 w
er
e 
al
so
 m
or
e 
co
m
m
on
 
am
o
n
g 
th
os
e 
w
ho
 re
ce
iv
ed
 th
e 
Td
ap
 
v
ac
ci
ne
 le
ss
 th
an
 5
 y
ea
rs
 af
te
r r
ec
ei
pt
 o
f 
Sa
nd
or
a 
et
 a
l. 
(20
09
)
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St
ud
y 
de
sig
n
Po
pu
la
tio
n/
Sa
m
pl
e
Su
bs
ta
nc
es
O
ut
co
m
es
 st
ud
ie
d
R
es
ul
ts
R
ef
er
en
ce
s
se
v
er
ity
 c
at
eg
or
ie
s w
er
e 
no
t 
pr
ov
id
ed
 o
n 
th
e 
su
rv
ey
te
ta
nu
s-
di
ph
th
er
ia
 v
ac
ci
ne
. S
ys
te
m
ic
 
ad
ve
rs
e 
ev
en
ts
 w
er
e 
m
or
e 
co
m
m
on
 
am
o
n
g 
th
os
e 
< 
30
 y
ea
rs
 a
ge
 (O
R,
 4.
15
 
[9
5%
 co
nfi
de
nc
e 
in
te
rv
al
, 1
.9
4–
8.
86
]).
 
Li
m
ite
d 
de
ta
ils
 av
ai
la
bl
e 
re
ga
rd
in
g 
stu
dy
 
de
sig
n 
an
d 
ou
tc
om
es
M
et
a-
an
al
ys
is
12
,3
75
 ch
ild
re
n 
(up
 to
 
18
 m
on
th
s a
nd
 1
0–
16
 
ye
ar
s o
f a
ge
)
A
l (
OH
) 3 
ad
juv
an
t-
co
nt
ai
ni
ng
 
v
ac
ci
ne
s
Su
m
m
ar
y 
da
ta
 fr
om
 st
ud
ie
s 
o
n
 a
dv
er
se
 e
v
en
ts
 fo
llo
w
in
g 
ad
m
in
ist
ra
tio
n 
of
 A
l (
OH
) 3-
co
n
ta
in
in
g 
va
cc
in
es
A
Es
: 
Va
cc
in
es
 w
ith
 A
l (
OH
) 3 
in
cr
ea
se
d 
er
yt
he
m
a 
an
d 
in
du
ra
tio
n 
co
m
pa
re
d 
to
 
n
o
n
-a
dju
va
n
te
d 
va
cc
in
es
 (O
R)
 1.
87
 [9
5%
 
CI
 1
.5
7–
2.
24
]) 
an
d s
ign
ifi
ca
nt
ly
 fe
w
er
 
re
ac
tio
ns
 o
f a
ll 
ty
pe
s (
OR
 0.
21
 [9
5%
 C
I 
0.
15
–0
.2
8]
). F
req
ue
nc
ies
 of
 lo
ca
l 
re
ac
tio
ns
 o
f a
ll 
ty
pe
s, 
co
lla
ps
e 
or
 
co
nv
u
lsi
on
s, 
an
d 
pe
rs
ist
en
t c
ry
in
g 
or
 
sc
re
am
in
g 
di
d 
no
t d
iff
er
 b
et
w
ee
n 
th
e 
co
ho
rts
. T
he
re
 w
as
 n
o
 a
ss
o
ci
at
io
n 
be
tw
ee
n 
A
l a
dju
va
n
t-
co
nt
ai
ni
ng
 v
ac
ci
ne
s 
an
d 
on
se
t o
f l
oc
al
 in
du
ra
tio
n 
or
 sw
el
lin
g.
 
In
cr
ea
se
d 
lo
ca
l p
ai
n 
w
as
 r
ep
or
te
d 
up
 to
 
14
 d
ay
s (
OR
 2•
05
 [9
5%
 C
I 1
.25
–3
.38
])
Je
ffe
rs
on
 e
t a
l. 
(20
04
)
M
et
a-
an
al
ys
is
18
 ra
nd
om
iz
ed
 c
lin
ic
al
 
tr
ia
ls 
(n 
=
 1
8,
44
4)
A
l a
dju
va
n
t-
co
nt
ai
ni
ng
 v
ac
ci
ne
s
IE
s: 
Se
ro
co
nv
er
sio
n1
1  
an
d 
se
ro
re
sp
on
se
/
se
ro
pr
ot
ec
tio
n1
2
A
Es
: N
ur
se
s a
nd
/o
r 
pa
rti
ci
pa
nt
s r
ec
or
de
d 
fe
v
er
,
 
an
y 
sy
ste
m
ic
 re
ac
tio
n,
 
in
jec
tio
n- 
sit
e p
ain
 an
d a
ny
 
lo
ca
l r
ea
ct
io
n 
du
rin
g 
th
e 
fir
st 
7–
10
 d
ay
s a
fte
r v
ac
ci
na
tio
n.
 
Se
rio
us
 ev
en
ts
 (l
ife
-
th
re
at
en
in
g 
ev
en
ts
, o
r e
v
en
ts
 
re
su
lti
ng
 in
 p
er
sis
te
nt
 
di
sa
bi
lit
y, 
ho
sp
ita
liz
at
io
n 
or
 
de
at
h) 
we
re 
rec
ord
ed
 
se
pa
ra
te
ly
IE
s: 
Co
m
pa
rin
g 
A
l a
dju
va
n
te
d 
to
 A
l n
on
- 
ad
juv
an
te
d 
va
cc
in
es
 a
t e
qu
al
 d
os
e,
 A
l 
ad
juv
an
t v
ac
ci
ne
s w
er
e 
le
ss
 
im
m
un
og
en
ic
 th
an
 n
on
- a
dju
va
n
t 
fo
rm
ul
at
io
ns
 a
t a
ny
 a
ge
, e
sp
ec
ia
lly
 a
fte
r 
sin
gl
e 
do
se
 in
jec
tio
n
A
Es
: 
D
ire
ct
-c
om
pa
ris
on
 m
et
a-
an
al
ys
es
 
sh
ow
ed
 th
at
 A
l a
dju
va
n
te
d 
va
cc
in
es
 a
t 
th
e 
sa
m
e 
do
se
 c
om
pa
re
d 
to
 th
e 
no
n-
ad
juv
an
te
d 
va
cc
in
es
 si
gn
ifi
ca
nt
ly
 
in
cr
ea
se
d 
th
e 
ris
k 
of
 lo
ca
l r
ea
ct
io
ns
, 
sp
ec
ifi
ca
lly
 in
jec
tio
n s
ite
 pa
in.
 A
Es
 
de
fin
iti
on
 w
as
 n
o
t a
lw
ay
s f
ul
ly
 
st
an
da
rd
iz
ed
 a
nd
 si
m
ila
r a
cr
os
s t
ria
ls.
 
Po
te
nt
ia
l l
im
ita
tio
ns
 to
 th
e 
da
ta
ba
se
 
in
cl
ud
e 
so
m
e 
no
n-
ra
nd
om
iz
ed
 tr
ia
ls 
th
at
 
w
er
e 
u
se
d 
in
 th
e 
pr
op
or
tio
n 
m
et
a-
 
an
al
ys
es
M
an
zo
li 
et
 a
l. 
(20
11
)
In
te
gr
at
ed
 a
na
ly
sis
In
te
gr
at
ed
 a
na
ly
sis
 o
f 
da
ta
 c
on
tri
bu
te
d 
by
 >
 
68
,5
00
 p
ar
tic
ip
an
ts
H
PV
 A
l a
dju
va
n
t-
 c
on
ta
in
in
g 
v
ac
ci
ne
s
Im
m
un
og
en
ic
ity
 e
nd
po
in
ts 
an
d 
ad
ve
rs
e 
ev
en
ts
A
Es
: 
A
t m
ea
n 
fo
llo
w
-u
p 
to
 2
1.
4 
m
on
th
s 
th
e 
co
m
bi
ne
d 
H
PV
-
16
/1
8,
 H
SV
 an
d 
H
B
V
 v
ac
ci
ne
s a
nd
 th
e 
se
pa
ra
te
 
H
PV
-
16
/1
8 
va
cc
in
es
 fa
ile
d 
to
 sh
ow
 
in
cr
ea
se
d 
re
la
tiv
e 
ris
ks
 fo
r a
ut
oi
m
m
un
e 
di
so
rd
er
s i
n 
pa
rti
ci
pa
nt
s r
ec
ei
v
in
g 
v
ac
ci
ne
s c
on
ta
in
in
g 
A
l a
dju
va
n
ts
 
co
m
pa
re
d 
w
ith
 c
on
tro
ls 
(re
lat
ive
 r
isk
 o
f 
0.
98
 fo
r t
he
 H
PV
-
16
/1
8,
 H
SV
 an
d 
H
BV
 
an
al
ys
is 
an
d 
0.
92
 fo
r t
he
 H
PV
-
16
/1
8 
an
al
ys
is)
. N
o s
ign
ifi
ca
nt
 d
iff
er
en
ce
 in
 
n
eu
ro
in
fla
m
m
at
or
y 
di
so
rd
er
s (
rel
ati
v
e 
ris
k 
of
 1
.0
0 
fo
r t
he
 H
PV
-
16
/1
8,
 H
SV
 an
d 
H
B
V
 v
ac
ci
ne
 a
na
ly
sis
, a
nd
 0
.6
7 
fo
r t
he
 
H
PV
-
16
/1
8 
va
cc
in
e) 
we
re 
fou
nd
. 
Ve
rs
tr
ae
te
n 
et
 a
l. 
(20
08
)
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St
ud
y 
de
sig
n
Po
pu
la
tio
n/
Sa
m
pl
e
Su
bs
ta
nc
es
O
ut
co
m
es
 st
ud
ie
d
R
es
ul
ts
R
ef
er
en
ce
s
A
cc
or
di
ng
 to
 st
ud
y 
de
sig
n,
 b
ot
h 
pa
rti
ci
pa
nt
s w
ho
 re
ce
iv
ed
 A
l a
dju
va
n
t –
 
co
n
ta
in
in
g 
va
cc
in
es
 a
nd
 th
os
e 
th
at
 
re
ce
iv
ed
 A
l(O
H)
 al
on
e w
ere
 in
clu
de
d i
n 
th
e 
co
nt
ro
l g
ro
up
3
*
D
B
PC
 d
ou
bl
e-
bl
in
d,
 p
la
ce
bo
-c
on
tro
lle
d.
*
*
R
CT
 ra
nd
om
iz
ed
 c
on
tro
lle
d 
tri
al
.
1 A
 si
gn
ifi
ca
nt
 a
nt
ib
od
y 
(se
ro-
) r
esp
on
se 
for
 bo
th 
ass
ay
s w
as
 d
ef
in
ed
 a
s a
 4
-fo
ld
 o
r g
re
at
er
 in
cr
ea
se
 in
 a
nt
ib
od
y 
tit
er
 a
fte
r i
m
m
un
iz
at
io
n 
(if
 an
tib
od
y w
as
 d
et
ec
ta
bl
e 
in
 th
e 
pr
e-
im
m
un
iz
at
io
n 
sa
m
pl
e) 
or 
an
 
in
cr
ea
se
 in
 ti
te
r f
ro
m
 <
 1
0 
be
fo
re
 im
m
un
iz
at
io
n 
to
 ≥
 4
0 
af
te
r i
m
m
un
iz
at
io
n.
2 A
 se
rio
us
 a
dv
er
se
 e
v
en
t (
SA
E)
 w
as
 d
ef
in
ed
 a
s a
ny
 u
nt
ow
ar
d 
m
ed
ic
al
 o
cc
ur
re
nc
e 
th
at
 re
su
lte
d 
in
 d
ea
th
, l
ife
-th
re
at
en
in
g 
m
ed
ic
al
 c
on
di
tio
ns
, p
er
sis
te
nt
 o
r s
ub
sta
nt
ia
l d
isa
bi
lit
y 
or
 in
ca
pa
ci
ty
,
 
ad
m
iss
io
n 
to
 
ho
sp
ita
l, 
or
 ex
te
nd
ed
 le
ng
th
 o
f a
n 
ex
ist
in
g 
ho
sp
ita
l a
dm
iss
io
n.
3 S
ub
jec
ts 
wi
th 
pre
-va
cc
in
at
io
n 
he
m
ag
gl
ut
in
at
io
n-
in
hi
bi
tio
n 
(H
I) 
an
tib
od
y t
ite
r w
ere
 ex
cl
ud
ed
 fr
om
 th
e 
an
al
ys
es
.
4 S
er
oc
on
v
er
tio
n:
 P
re
-v
ac
ci
na
tio
n 
he
m
ag
gl
ut
in
at
io
n-
in
hi
bi
tio
n 
(H
I) 
an
tib
od
y t
ite
r <
 1:
10
 an
d p
os
t-v
ac
ci
na
tio
n 
H
I a
nt
ib
od
y 
tit
er
 ≥
 1
:4
0,
 o
r p
re
-v
ac
ci
na
tio
n 
H
I a
nt
ib
od
y 
tit
er
 ≥
 1
:1
0 
an
d 
a 
po
st-
va
cc
in
at
io
n 
in
cr
ea
se
 b
y 
a 
fa
ct
or
 o
f f
ou
r o
r m
or
e.
5 P
ar
tic
ip
an
ts 
w
ith
 p
os
t-v
ac
ci
na
tio
n 
he
m
ag
gl
ut
in
at
io
n-
in
hi
bi
tio
n 
(H
I) 
an
tib
od
y t
ite
r ≥
 1:
40
.
6 A
SO
4 
ad
juv
an
t c
on
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